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Abstract 
HPV is the most common viral infection of reproductive tract, affecting both females 
and males. High-risk oncogenic types are the cause of cervical cancer by the 
expression of E6 and E7 viral oncoproteins. High-risk oncogenic types are also 
responsible for up to 90% of anal and 12 % of oropharyngeal cancers. The well-
characterised interaction of HPV16 E7 is with the cell cycle control protein pRb, 
promoting pRb degradation and resulting in cell cycle misregulation. E7 can interact 
with many other cellular proteins. In this study, RNA aptamers identified against 
HPV16 E7 were used to study E7 interactions further. The aptamers were generated 
previously by an in vitro technique known as the systematic evolution of ligands by 
exponential enrichment (SELEX), in which molecules from a random pool are isolated 
for binding to the target with a high affinity and specificity. Aptamers are single-
stranded oligonucleotides that can form complex structures and bind target molecules 
in a conformation-dependent manner. The E7 aptamers have been stabilised by the 
inclusion of modified pyrimidines. Aptamers have therapeutic potential; examples 
include the aptamer Macugen (also called Pegaptanib). Several HPV16 E7 aptamers 
were able to induce apoptosis in an HPV16-transformed cervical carcinoma cell line 
(SiHa) that actively express both E6 and E7. Of particular interest is the E7 aptamer 
A2. In order to ensure apoptosis is not due to the innate immune response, immune 
stimulatory effects of E7 aptamers were studied by quantitative PCR. Effects of 
aptamers on the steady state levels of E7 and cellular proteins were analysed by 
western blotting. Treatment of cells with A2 resulted in loss of the E7 oncoprotein and 
a rise in cellular pRb levels. We have evidence that some of the HPV16 E7 aptamers 
can also target HPV18 E7. Several inhibitor molecules of protein degradation were 
used to determine the pathway of E7 loss following aptamer transfection in HPV16-
transformed cervical carcinoma cell line, CaSki. Results suggested that aptamer 
transfection did not appear to alter normal degradation pathway of E7, which was 
mainly 26S proteasome-mediated. Co-localisation of aptamers (model aptamers) with 
cellular markers was studied by immunofluorescence. Co-localisation of E7 with 
cellular markers in the presence or absence of HPV16 E7 aptamers suggested the 
accumulation of E7 in the endoplasmic reticulum (ER) in A2 transfected cells, 
suggesting an alternative pathway, leading to a model for E7 degradation. Aptamers 
can be advantageous in terms of developing novel potential therapeutics. In Chapter 
5, model aptamers were shown to internalise into keratinocytes and cervical cancer 
cells without the need for lipofection. This novel ability of aptamers might enable 
topical use of aptamers. The mechanism of aptamer entry was also studied using 
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endocytosis inhibitors for receptor-mediated uptake as well as macropinocytosis. The 
result suggested that reagent-free internalisation can be both energy-dependent 
(receptor-mediated) and passive (macropinocytosis) and that uptake can be 
sequence-dependent. 
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 INTRODUCTION 
1.1 Tumour Virology 
Cancer is characterised by uncontrolled cell proliferation and the ability to invade other 
tissues through the blood and lymph systems. Cancer can be referred to as 
carcinoma, sarcoma, leukaemia, lymphoma and myeloma and central nervous 
system cancer. These are the cancer types that originate from skin, bone, blood-
producing tissues, immune system and brain-spinal cord tissues, respectively. The 
earliest cancers documented are bone cancers seen in 4-million year old fossils and 
nasopharyngeal carcinomas and osteogenic sarcomas seen in ancient Egyptian 
mummies from 3000 BCE, reviewed in (Javier and Butel, 2008). The development of 
microbiology in 19th century led to the proposition of links between cancer and several 
infectious agents such as bacteria, yeasts, fungi and protozoa. Most importantly, 
research which showed a nematode worm as the causative agent of stomach cancer 
in rats was awarded a Nobel Prize in 1926, reviewed in (Javier and Butel, 2008). 
When a new class of infectious agents, viruses, were discovered, studies focussed 
on molecular mechanisms in virus-induced tumours.  The first known tumour virus to 
be identified was from a Plymouth Rock chicken with spindle cell carcinoma and 
named Rous sarcoma virus (RSV); an RNA virus (Rous, 1993). This was followed 
with the discovery of the first DNA tumour virus, cottontail rabbit papillomavirus 
(CRPV) from warts obtained from wild cottontail rabbits (Shope and Hurst, 1933). 
CRPV was then showed to induce the formation of skin carcinomas in domestic 
rabbits (Rous and Beard, 1935). DNA tumour viruses infecting humans were also 
discovered. Human adenovirus was discovered from explants of adenoid and tonsil 
tissues and shown to cause human acute respiratory disease (Hilleman and Werner, 
1954, Rowe et al., 1953). Adenoviruses were also reported to induce tumour 
formation in experimentally infected animals (Trentin et al., 1962). The first human 
tumour virus, Epstein-Barr virus (EBV), was identified and visualised by electron 
microscopy from cell lines derived from Burkitt`s lymphoma (Epstein et al., 1965), 
which is a cancer of antibody producing B-cells. It should however be noted that most 
tumour viruses do not replicate to produce virions in tumour cells, thus making 
electron-microscopy imaging challenging. Studies later suggested that EBV was 
necessary but not sufficient to induce lymphomas; some other cofactors were also 
required such as myc translocation (myc-IgH and myc-IgL) resulting in the abnormal 
expression of myc oncogene (Javier and Butel, 2008). In common with EBV, hepatitis 
B virus (HBV) was shown to be a human tumour virus (Blumberg et al., 1975). It was 
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shown that individuals with chronic HBV infection developed hepatocellular carcinoma 
(HCC) with a 100-fold increase when compared to uninfected individuals (Beasley et 
al., 1981). The first cancer vaccine (offering protection against liver cancer) was 
developed by large-scale purification of HBV surface antigens from the serum of HBV-
positive individuals. However, this vaccine was later replaced by a second generation 
recombinant HBV surface antigen vaccine which was safer due to the production of 
the vaccine in human-plasma free environment with a cost effective way. Later, a non-
A, non-B hepatitis virus, hepatitis C (HCV) was identified and linked to chronic 
hepatitis and HCC (Tan et al., 2008). There were also retroviruses found to be 
associated with human cancer as in the case of human T-lymphotropic virus-I (HTLV-
I) causing adult T-cell leukaemia (ATL). Their association was supported with the facts 
that first ATL was mainly distributed in specific geographic locations where HTLV-I 
infection was disperse, second almost all ATL patients were infected with HTLV-I, 
third in the molecular basis, all leukaemia cells from infected individuals contained 
HTVL-I proviral DNA, and fourth when HTLV-I introduced into healthy T-cells it 
induced transformation (Javier and Butel, 2008). Most animal retroviruses such as 
avian and murine leukaemia viruses lack viral oncogenes, therefore they can cause 
cancer through a mechanism called insertional mutagenesis in which the provirus 
integrates near a cellular proto-oncogene and modify its expression (Butel, 2000). 
Despite being a retrovirus, HTLV-I do not use this mechanism for carcinogenesis. This 
virus behaves more like a DNA virus, and encodes its own oncogene, Tax that is 
required for replication (Matsuoka and Jeang, 2011). This gene can also play roles in 
cellular transformation by e.g. acceleration of transition between G1 and S phase of 
cell cycle, interference with cellular DNA repair mechanisms, and activation of certain 
transcription factors (Matsuoka and Jeang, 2011).  
In 1994, Kaposi`s sarcoma herpesvirus (KSHV) (or human herpesvirus type 8) was 
discovered in 90% of Kaposi`s sarcoma tissues from patients with acquired 
immunodeficiency syndrome (AIDS) by Chang and Moore by representational 
difference analysis (Chang et al., 1994). In this method, fragmented cDNA sequences 
obtained by restriction digestion with an enzyme (e.g. DpnII) from healthy and 
diseased tissues from the same individual can be cross-hybridised and following PCR 
amplification can specifically enrich the DNA obtained from diseased tissue due to the 
presence of additional viral genes (Lisitsyn et al., 1993). The newest member of the 
tumour viruses is Merkel cell carcinoma virus (MCV) discovered in 2008 by 
computational subtraction of cDNA sequence data by digital transcriptome subtraction 
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(Feng et al., 2008). A recent review summarised the key facts including genome 
organisation, virus life-cycle and pathogenesis of MCV (Stakaityte et al., 2014). 
There is a strong selection amongst viruses (tumour and non-tumour viruses) to 
maintain viral genes that have a potential to induce cellular transformation, and the 
products of these viral genes can target similar tumour suppressor pathways. For 
instance, oncoproteins from most of the human tumour viruses destabilise 
retinoblastoma 1 (Rb1) and p53 tumour suppressors using unique mechanisms. 
Other cellular targets of tumour virus oncoproteins include telomerase reverse 
transcriptase (TERT), cytoplasmic PI3K-AKT-mTOR, nuclear factor-κB (NF-κB), β-
catenin and interferon signalling pathways (Moore and Chang, 2010). The KSHV 
LANA1 oncoprotein targets pRb, p53 and interferon signalling and at the same time it 
prevents the virus to progress from latency to lytic replication (Cloutier and Flamand, 
2010, Friborg et al., 1999, Radkov et al., 2000). Human papillomaviruses are small 
DNA tumour viruses and most small DNA tumour viruses encode oncogenes in order 
to function as deregulators of the cell cycle entry and prepare cellular conditions for 
the viral replication (Moore and Chang, 2010). Since, host replication machinery is 
inactive and nucleotide pools are not enough for their replication in the G0 phase of 
the cell cycle of the differentiated host cells. Therefore, these viruses force cells for 
the S-phase transition in order to enrich cellular resources for their genome 
replication. In normal conditions, when cell cycle regulation is disrupted, cell death 
signalling pathways (e.g. p53) become activated. However, in tumour virus infected 
cells, viral oncoproteins inhibit the function of these pathways by targeting these 
tumour suppressor proteins to ensure the export of the progeny viruses (e.g. p53). 
For example, HPV oncoproteins E6 and E7 can maintain infected cells in a 
proliferative state, preventing apoptosis.   
These above described viruses are all linked to tumourigenesis. However, virus 
infection alone is not always sufficient for the development of cancer apart from few 
cases such as KSHV and HPV for Kaposi`s sarcoma and cervical cancer due to the 
fact that these viruses can ubiquitously be found present in the respective tumours 
(Moore and Chang, 2010). Immunity is an important factor in determining if the 
exposure to a tumour virus will result in cancer. Some individuals can have 
propensities for the development of cancer due to defects in immunity. An example of 
this is the signalling lymphocytic activation molecule associated protein (SAP) 
mutations in males that can result in immunodeficiency and X-linked 
lymphoproliferative syndrome following EBV infection (Purtilo et al., 1975). Another 
factor causing immunodeficiency is AIDS caused by HIV infection. A study in USA 
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showed that the incidence of the KSHV-related Kaposi`s sarcoma cases rocketed with 
the increase in HIV infection amongst the population (Engels et al., 2006).  
The evasion of innate immunity can be one of the major elements in viral 
tumourigenesis. Tumour viruses can achieve this with the expression of oncogenes. 
Oncogenes do not only target tumour suppressor proteins but also key effector 
proteins in innate immune signalling. In fact, this key effector proteins such as p53 
and p21 cyclin-dependent kinase inhibitor are shared in both tumour suppressor and 
immune signalling mechanisms. Therefore, while targeting tumour suppressor 
pathways, these viruses also inactivate anti-viral pathways to evade innate immunity. 
This can be one of the crucial steps in the cancerous transformation of infected cells. 
KSHV encodes four interferon regulatory factor (IRF) homologues which play roles in 
the inhibition of interferon signalling and cellular transformation. IRFs are family of 
transcription factors that regulates the induction of interferons, therefore providing a 
host defence mechanism against pathogens.  
Association of papillomavirus infection with cancer was first reported in 1935 by Rous 
and Beard. In this study, CRPV was shown to cause carcinomas in domestic rabbits. 
Since then, research on papillomaviruses had been limited for a certain period of time 
due to the benign nature of skin warts in addition to the lack of tissue culture systems. 
When bovine papillomavirus was shown to induce malignant tumours in animals, 
studies on papillomaviruses and their association with cancer gained importance. 
Harald zur Hausen linked human papillomavirus infection (in particular HPV type 16 
and 18) with cervical cancer by demonstrating the presence of HPV DNA in cervical 
tumours, reviewed by (zur Hausen, 2002). Similar to HBV, there are vaccines 
generated to protect against HPV infection. These vaccines are produced by 
overexpression of HPV structural proteins (VLPs) in recombinant systems and contain 
no oncogenic HPV genome (see section 1.2.6).  
1.2 Human papillomavirus (HPV) and cervical cancer 
1.2.1 Classification of papillomaviruses 
Papillomaviruses have been discovered and studied in many vertebrates including 
human, cattle, dogs, birds, reptiles etc. More than 300 distinct types were classified 
in 37 genera, which makes them one of the largest family of vertebrate viruses. Within 
papillomavirus family, around 170 human and 130 animal different types have been 
sequenced and identified to date (see Papillomavirus Episteme (PaVE) on 
http://pave.niaid.nih.gov/#home).  
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Human papillomaviruses (HPVs) are classified into five genera (Alpha, Beta, Gamma, 
Mu and Nu) based on their L1 capsid DNA sequences. These HPV genera contain 
numerous HPV types with different life-cycle properties and propensities to disease 
conditions. Many HPV types within the cutaneous Beta and Gamma genera do not 
cause symptoms in infected individuals (Doorbar et al., 2012). However, when 
immunosuppressed individuals are infected with these types, cancer e.g. skin cancer 
may result. Cutaneous HPV types in Gamma, Beta and especially Alpha genera are 
more diverse than that in Mu and Nu genera (Doorbar et al., 2012). The Alpha PVs 
contain species that cause cervical cancer as well as benign lesions. The Alpha group 
consists of cutaneous and mucosal HPVs. The mucosal HPVs are further classified 
as high-risk or low-risk types (Bernard et al., 2010). The Alpha types can also include 
low-risk cutaneous species such as HPV2 and 57, causing common warts, and HPV3 
and 10, causing flat warts (Bernard et al., 2010, Hsueh, 2009). Twelve HPVs (alpha 
5, 6,  7 and 9); 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 are defined by the 
World Health Organisation (WHO) as being high-risk types with additional types, 68 
and 73 under investigation. Mucosal high-risk Alpha species that are responsible for 
cervical cancer have been relatively well-studied e.g. in the case of HPV16 infecting 
the ectocervix and cervical transformation zone (zur Hausen, 2009). However, HPV16 
and also other Alpha types at other sites e.g. the anus, endocervix and the penis have 
not been so well studied, reviewed by (Doorbar et al., 2012). Some of the low-risk 
types can also cause cutaneous genital lesions, however infection, mostly, does not 
lead to neoplasia (Middleton et al., 2003). The low-risk Alpha types (alpha 10) i.e. 
HPV6 and 11 can cause genital warts and might also be responsible for a very rare 
condition, juvenile respiratory papillomatosis (RRP) (Major et al., 2005). 
Approximately 5% of children with the persistent infection can later develop lung 
cancer (Derkay, 1995). 
1.2.2 Burden of HPV-associated cancers 
HPV is the most common viral infection of reproductive tract, affecting both females 
and males. High-risk oncogenic types are the main cause of cervical cancer. 
However, all women infected with high-risk HPV do not develop cervical cancer. 
Since, the majority (70% – 90%) of HPV infections with both high and low risk 
genotypes do not cause symptoms and are cleared spontaneously within 1–2 years. 
Squamous cell carcinoma (SCC) and adenocarcinoma are two main histological types 
of cervical cancer. SCC accounts for 90–95% of invasive cancer cases. Only small 
percentage of persistent infections (around ~5–10%) with specific oncogenic types 
(especially type 16 and 18) can result in precancerous lesions and eventually SCC if 
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untreated (Bosch et al., 2002). Persistent infection has been shown by the presence 
of DNA from specific HPV types in biological specimens over a period of time e.g. 6 
months. Progression to invasive carcinoma can take around 10 years or longer upon 
infection with high-risk HPV. This period is dependent on several predisposing 
conditions and risk factors. These include oncogenic potential of the HPV type, the 
immune status of the individual (e.g. HIV infected, treated with immunosuppressant), 
presence of co-infection with other sexually transmitted infections (STI) e.g. herpes 
simplex and/or chlamydia, smoking and childbirth at young age and number of 
childbirths (WHO, 2014).   
HPV types 18 and especially 16 were shown to be the most common types in cervical 
biopsies (Smith et al., 2007). However, the most common high-risk HPV types were 
found to be HPV-16 and HPV-52 amongst men (WHO, 2014). The risk of developing 
cervical cancer is found to be 400 and 250 times higher in HPV16 and HPV18, 
respectively, infected women when compared to that in uninfected women (de 
Sanjose et al., 2010).  HPV infection with low-risk types (HPV6 and 11) may lead to 
anogenital warts (condyloma acuminata) both in females and males, which are 
difficult to treat. These warts, rarely, can progress to become malignant as in the case 
of Buschke-Lowenstein tumours. These low-risk HPV can also result in a rare 
condition termed recurrent respiratory papillomatosis (RRP) mainly in younger 
children (≤5 years old) or people in their 30s (Sinal and Woods, 2005, Humans, 2007). 
This condition can be serious due to the blockage of respiratory tract and larynx where 
warts are formed. HPV infection can also cause (20 – 90%) squamous carcinomas of 
the anus, the oropharynx, the vulva and vagina, and of the penis (Bosch et al., 2002). 
According to the Cancer Research UK statistics, cervical cancer is the twelfth most 
common female cancer in the UK and the third most common gynaecological cancer 
following uterus (womb) and ovary cancers. However, it is the most common female 
cancer of under 35 in the UK. Around 3,100 new cases of cervical cancer were 
diagnosed in 2011 in the UK most of which (more than 75%) were in woman aged 25 
– 64. Around 900 women died from cervical cancer in 2012 in the UK. Main risk factor 
for cervical cancer is the infection with high-risk human papillomavirus (HPV) which 
is linked to the almost 100% of cervical cancer cases in the UK. Other factors leading 
to cervical cancer in the UK include smoking, human immunodeficiency virus (HIV), 
and oral contraceptives.  
The World Health Organisation (WHO) indicated that cervical cancer is the second 
most common cancer in women worldwide, with an estimated 530 000 new cases in 
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2012 (WHO, 2014) with around 270 000 deaths in the same year. Approximately 85% 
of these deaths occurred in developing countries, in Africa, Latin America and 
especially Asia (WHO, 2014). Protection from cervical cancer can be achieved by the 
use of barrier methods and vaccination (see chapter 1.2.6 for more info on HPV 
vaccination). WHO announced that HPV vaccination has been successful in 45 
developed countries (WHO, 2014). However, in order to cure global burden of cervical 
cancer, HPV vaccination needs to be widely introduced in the developing countries 
as part of their national public health service. 
1.2.3 Diagnosis and treatment of HPV  
There is no HPV-specific treatment of cervical lesions or cancer. However, there are 
clinical trials ongoing for T-cell based immunotherapy for cervical cancer e.g. with the 
use of T-cell immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte 
associated protein 4 (anti-CTLA-4) (trial number NCT01693783 in Phase II) and anti-
programmed cell death ligand (anti-PD-L1) (trial number NCT01693562 in Phase I/II) 
targeting antibodies. Current treatment includes surgical removal of affected tissue or 
cryotherapy of precancerous lesions. Diagnosis of HPV infection is based on the 
detection of HPV-DNA on cervical or vaginal swabs by PCR, and of the HPV-induced 
changes (exfoliated cells) in the cervical epithelium by cytology under a microscope, 
known as the Papanicolaou (pap) smear test. Another method used in low-resource 
facilities is the visual inspection using acetic acid. There is an ongoing clinical trial 
testing the efficacy and sensitivity of E6/E7 mRNAs versus HPV DNA for cervical 
cancer screening based on RT-PCR (trial number NCT02116920). An alternative 
detection method for cervical cancer can be developed using aptamer molecules 
recognising E6 and E7 oncoproteins due to the fact that these proteins are 
overexpressed in malignant tissues. 
1.2.4 Genome organisation, life-cycle and pathogenesis of HPV  
Papillomaviruses are double-stranded (ds) DNA viruses from the family of 
Papillomaviridae that also includes polyomavirus, simian vacuolating virus and human 
papillomaviruses (HPVs).  
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Figure 1.1 High-risk HPV 16 genome. Papillomaviruses contain a double-
stranded and circular DNA genome around ~8 kb. Genome consists of three 
major regions; early, late and a long control region (LCR) (or non-coding region 
[NCR]). The LCR region consists of 850 bp and covers around ~10% of the 
papillomavirus genome. It contains regulatory sequences that are important for 
viral replication and transcription. The three regions in papillomaviruses are 
separated by two polyadenylation sites (pA). These are early pA (pAE) and late 
pA (pAL) polyadenylation sites.  Early region cover around ~50% of whole HPV 
genome and encodes non-structural early genes, E1, E2, E4, E5, E6 and E7. The 
expression of these early genes are controlled by p97 promoter in HPV16 and 
31 (p105 in HPV18) prior to productive replication. Late region covers almost 
40% of papillomavirus genome on the downstream of early region. This region 
encodes L1 (major) and L2 (minor) ORFs. The late capsid proteins are 
expressed from p742 in HPV31 (or p670 in HPV16) late promoter during virus 
production. Modified from (Fehrmann and Laimins, 2003).  
These are non-enveloped viruses with icosahedral capsids. They replicate their 
genomes within the nuclei of infected host cells. The HPV genome (~8 kb) contains 
three major regions with an average of 8 open reading frames (ORFs). Gene 
expression occurs from polycistronic mRNAs transcribed from a single DNA strand. 
A non-coding long control region (LCR) with around ~1 kb, ORFs with early genes (3 
kb) E6, E7, E1, E2, E4, E5, regulating viral DNA replication and gene expression. The 
late region encodes two genes responsible for capsid formation; L1, major capsid 
protein and L2, minor capsid protein (Section 1.2.6) 
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Two other ORFs, E3 and E8, were previously thought to be present, however only the 
E8 ORF was shown to encode a protein, a spliced E8^E2C fusion protein functioning 
as a negative regulator of virus replication and transcription, in bovine papillomavirus 
1 (BPV1) and HPV31 (Zheng and Baker, 2006).  The rabbit papillomavirus genome 
also contains an E8 ORF, but it functions as an oncogene similar to the functions of 
E5 oncoprotein (Han et al., 1998).   
 
 
Figure 1.2 The life cycle of high-risk HPVs in infected epithelium. Virus enters 
the basal layer via micro wounds and is maintained as a low copy number 
episome. The E6 and E7 proteins (red nuclei) are expressed from the early 
promoter, p97 in HPV16, in the lower layers of epithelium (red arrow). 
Uninfected cells were represented with dark blue circles. The expression of E4 
and other early proteins (green) occurs from late promoter (p670 in HPV16) 
(green arrow). Their expression will reduce the expressions of E6 and E7. The 
green cells containing red nuclei express both E4 and E7. These cells were 
suggested to possess all the necessary proteins to facilitate genome 
amplification. Once genome amplification is completed, virus capsid proteins 
L1 and L2 are expressed (orange arrow) in cells expressing E4 (green). This 
allows the packaging of the amplified HPV genomes. PAE: Position of the early 
polyadenylation site; PAL: Position of the late polyadenylation site; PE: Early 
promoter (p97); PL: late promoter (p670 or p742 in HPV31). Modified from 
(Doorbar et al., 2012). 
The life cycle of the virus in an infected epithelium is shown schematically above 
(Figure 1.2). Upon infection, virus can complete its reproductive life cycle depending 
on the site and nature of the infection, and presence of other factors including 
hormones and cytokines. The life cycle of HPV is strongly related to the differentiation 
status of keratinocytes. Virus entry is believed to occur in the basal layers of the 
epithelium via micro wounds. Papillomavirus particles can bind many epithelial cell 
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via a conserved receptor region which is called heparan sulphate proteoglycans 
(HSPGs) present on the cell surface (Giroglou et al., 2001). Laminin can possibly help 
virus attachment (Culp et al., 2006). L1 can be one of the major determinants for the 
attachment of virus to the cell surface (Giroglou et al., 2001). Virus entry is believed 
to occur through clathrin-dependent endocytosis (Bousarghin et al., 2003). Upon 
attachment, virus undergoes structural changes including the cleavage of L2 capsid 
protein (Doorbar et al., 2012). This facilitates the interaction with a second receptor 
(e.g. alpha 6 integrin) involved in the internalisation of the virus in cells and 
subsequent transport of the virus genome to the nucleus (Evander et al., 1997). L2 
can function to destabilise the endosomal membrane by e.g. possibly interacting with 
an adaptor protein, sorting nexin 17 (SNX17) (Bergant Marusic et al., 2012). This 
function of L2 is important for the endosomal release of the genome (Kamper et al., 
2006). In addition, L2 can mediate the transport of the viral genome to nucleus. It is 
suggested to contain nuclear localisation signals at the both termini (Fay et al., 2004). 
Whereas, L1 stays in the endosomes and is degraded by lysosomes (Doorbar et al., 
2012).  
The infection is followed by genome amplification. Virus genome is maintained as 
episomes in each cell of undifferentiated basal layer with around 200 
extrachromosomal copies (Doorbar et al., 2012).  The functions of E1 and E2 are 
required for genome amplification and replication of the virus. The E1 protein is 
around 68 kDa in size and expressed in HPV infected cells at low levels. It plays an 
important role in HPV replication by recognizing the AT-rich sequences at the origins 
in the LCR as well as exhibiting ATPase and 3' - 5' helicase activities (Hughes and 
Romanos, 1993, Seo et al., 1993). The E2 protein is a DNA-binding protein with 
approximately 50 kDa. It is active as a dimer and functions as transcriptional regulator 
recruiting the cellular factors, specificity protein-1 (Sp-1), octamer-binding protein-1 
(Oct-1), TATA-binding protein and activator protein-1 (AP-1) to regions in the long 
control region (LCR) in addition to its role in viral DNA replication (Longworth and 
Laimins, 2004). E2 binds the viral origin of replication in the LCR and recruits E1. E1 
protein produces hexamers with a strong affinity for DNA similar to other helicases 
(Sedman and Stenlund, 1998) which then unwinds the viral DNA and recruits cellular 
proteins (such as DNA polymerase) involved in DNA replication. Apart from the 
functions above, E2 was shown to induce apoptosis by p53-independent 
mechanisms. Overexpression of E2 was demonstrated by western blotting to cause 
an accumulation of p53 tumour suppressor protein (Dowhanick et al., 1995, Goodwin 
et al., 2000), leading to apoptosis even with the co-expression of E6 (an HPV 
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oncoprotein targeting p53) (Desaintes et al., 1999). Another study showed by the 
examination of chromatin condensation by epifluorescence microscopy that the 
expression of E2 in several HPV-transformed and non-transformed cells induced 
apoptosis (Webster et al., 2000). Resulting apoptosis was shown to be through p53-
dependent mechanisms due to the fact that co-expression of E2 and a mutant form 
of p53 or expression of E2 in cell lines containing non-functional or mutated p53 such 
as C33A did not appear to induce apoptosis (Webster et al., 2000). Therapeutic 
potential of E2 was also evaluated using a fusion protein expressed in E. coli 
containing VP22 (a protein from herpes simplex virus-1 [HSV-1] that can be 
transferred by mammalian cells) and a mutant E2 (E2p53m) which cannot bind p53 
as efficiently as wild-type (Green et al., 2007). This fusion protein was shown by 
terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assays to 
induce apoptosis in HPV transformed but not non-HPV transformed cells, providing 
cell type specificity for possible therapeutic applications (Green et al., 2007). The 
effects of E2 in transcription levels were also investigated. It was shown by northern 
blotting against E6 and E7 mRNAs that upon introduction of an E2 expression vector 
into HeLa cells, the transcription of E6 and E7 was suppressed, leading to apoptosis 
(Goodwin and DiMaio, 2000). These studies have supported the hypothesis that 
continuous expression of E6 and E7 is required for cancer cells to maintain their 
transformed phenotype (Goodwin and DiMaio, 2000, Wells et al., 2000).  
The expression of E6 and E7 in the upper epithelial layers allows the infected cell to 
re-enter S phase, and subsequently virus copy-number increases. Differentiation 
signals allow the epithelial cell where genome amplification occurs to express several 
differentiation markers such as keratins 1 and 10 (cutaneous epithelia) or 4 and 13 
(mucosa) in addition to the expression of markers involved in cell cycle entry, such as 
mini chromosome maintenance complex (MCM), Ki-67 (a cellular marker for 
proliferation), proliferating cell nuclear antigen (PCNA), Cyclin E and Cyclin A.  
In addition to E1 and E2, E4 and E5 expressions also contributes genome 
amplification and virus release. The E4 from HPV is expressed as a fusion (E1^E4) 
with the first 5 amino acids of E1 (Longworth and Laimins, 2004). This is because E4 
does not have an AUG start codon and uses E1 sequence for the initiation of 
translation (Longworth and Laimins, 2004). The high-risk E1^E4 proteins alters the 
cytoskeleton network associating with keratin intermediate filaments in the host cells 
(Doorbar et al., 1991). In the case of overexpression of this fusion protein in transient-
transfection assays, cells start to collapse, facilitating the virus release. However, 
during the natural course of infection, the amount of collapse is limited. High-risk HPV 
12 
 
E4 can also associate with an RNA helicase, E4-DBD, involved in mRNA splicing, 
transport and translation initiation and acts as a regulator of gene expression 
(Yoshioka et al., 2000). Another study showed that overexpression of HPV11 and 16 
E1^E4 in various cell types induced cell cycle arrest in the G2 phase (Davy et al., 
2002). This can counteract the effects of E7 oncoprotein, a known facilitator of the S-
phase entry. E5 is a hydrophobic transmembrane protein shown to have pore-forming 
capability (Krawczyk et al., 2010, Wetherill et al., 2012). E5 oncoprotein can interfere 
with the intracellular trafficking of endocytotic vesicles (Thomsen et al., 2000). E5 can 
contribute to genome amplification indirectly via its ability to stabilise epidermal growth 
factor (EGF) receptor (EGFR) and enhance EGF signalling and mitogen-activated 
protein (MAP) kinase activity (Doorbar et al., 2012). E5 was also observed by flow 
cytometry staining of E5 expressing cells to downregulate the major histocompatibility 
complex (MHC) class I molecules, playing another role in immune evasion (Campo et 
al., 2010).  
The completion of virus cycle involves the expressions of major and minor capsid 
proteins L1 and L2, respectively from the late promoter p670 in HPV16. Cryoelectron 
microscopy and image reconstruction analysis showed that HPV16 particles contain 
360 molecules of L1 arranged into 72 pentameric capsomeres, and each capsomer 
was observed to be associated with a single L2 protein (Buck et al., 2008). The ability 
of L1 to self-assemble to produce virus-like particles helped to the development of 
vaccines for HPV (see section 1.2.6). Virus maturation occurs on the most upper 
layers of epithelium where cells are dying. The changes in the cellular environment 
(converting from a reducing to an oxidising environment) enables to production of 
extremely stable and infectious viruses through disulphide linkage of L1 proteins. 
Although L1 and L2 capsid proteins are highly immunogenic, their detection by 
immune system is difficult due to the fact that their expression is only activated on the 
upper layer of cells where the immune surveillance is very limited (Badaracco et al., 
2002).  
Replication cycle of the virus, from the infection to the virus release, takes around ~3 
weeks (Stanley et al., 2007). From infection to the appearance of lesions can take 
even longer from weeks to months. Histological detection of cervical and other ano-
genital cancers shows intra-epithelial abnormalities, CIN (cervical intraepithelial 
neoplasia). These abnormalities ranges from low-grade (CIN 1), moderate (CIN 2) 
and high-grade (CIN 3). High- grade lesions (CIN 3) is followed by cervical cancer. 
Around 90% of these lesions were found to contain high-risk HPV (HPV16 mostly and 
18) DNAs (Clifford et al., 2006). 
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Figure 1.3 Classification of cervical cancer with a representative schematic and 
Pap smear images. WHO terminology classifies cervical cancer as mild, 
moderate and severe dysplasia, carcinoma in situ, microinvasive squamous 
carcinoma, invasive squamous carcinoma. Whereas the classification of the 
Bethesda system is either low grade (LG) or high grade (HG) squamous 
intraepithelial lesions (SIL) based on the cytological abnormalities reported in 
a Pap smear. LG-SIL and HG-SIL indicate mild and moderate/severe dysplasia, 
respectively. If an abnormal cytology is observed, it will be followed by a 
colposcopy and/or biopsy, if necessary. Histopathological observations lead to 
classify biopsied lesions based on their location and severity as cervical 
intraepithelial lesions (CIN1, CIN2 and CIN3), carcinoma in situ and invasive 
carcinoma (Hellner and Munger, 2011). Schematic of infected epithelium and 
Pap smear images are modified from www.eurocytology.eu and (Martha Lucía 
et al., 2012). 
Figure 1.3 shows the different methods used for classification of cervical cancer. HPV 
can still complete its life cycle in CIN 1 category lesions and can cause the 
appearance of flat warts. The increase in E6 and E7 expression during high-risk HPV 
infection can result in the development of CIN 2+ where cell starts to accumulate 
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mutations, contributing to cancer progression. CIN 2 and CIN 3+ lesion can also 
facilitate the integration of viral episome in to the host genome. It was suggested that 
here are common fragile sites in the host genome where the integration event occurs 
(Thorland et al., 2003). Integration can often cause the disruption of some of the early 
genes, E1 and E2 with regulatory functions from the LCR region (Yu et al., 2005). E2 
is the key transcription factor that regulates E6 and E7 expression. With the loss of 
E1 and E2 expression upon integration, cells start to aberrantly express E6 and E7 
oncogenes and to accumulate genetic mutations leading to cancer. Malignant 
progression is often correlated with insertion of the viral genome into the host genome. 
Around 70% of HPV16 positive cervical cancers contains integrated HPV genome, 
whereas the genome of HPV18 is almost always found to be integrated to the host 
genome (Doorbar et al., 2012).  
1.2.4.1 E6 oncogene 
E6 is a relatively small protein with around ~150 amino acids and expressed in two 
forms; a full-length form of around ~16 kDa and a smaller form (~8 kDa) containing 
the N-terminal region only (Garnett and Duerksen-Hughes, 2006). E6 contains two 
CXXC-X29-CXXC zinc binding domains (C, cysteine; X, any amino acid). The first 
structural data of the entire HPV16 E6 protein including the structures of these zinc-
binding domains as well as a model structure of the N-terminal domain homodimer 
was obtained by high-resolution NMR spectroscopy (Zanier et al., 2012). Mutagenesis 
of N-terminal homodimer increased the solubility of E6 (Zanier et al., 2012). The 
oncoprotein plays an important role in immortalisation of human keratinocytes 
together with the E7 oncoprotein. One of the major targets of E6 is the tumour 
suppressor p53. In healthy cells, aberrant cell proliferation results in e.g. DNA 
damage, p53 level increases which induces the expression of cell cycle control 
proteins such as cyclin kinase inhibitor, p21. This process leads to cell cycle arrest or 
apoptosis. The E6 protein interacts with E6-associated protein (E6AP), a ubiquitin 
ligase, (Huibregtse et al., 1991) causing the degradation of p53 by the 26S 
proteasome, reducing the half-life of p53 from a few hours to around 20 minutes in 
keratinocytes (Hubbert et al., 1992, Huibregtse et al., 1993). E6 is also involved in 
down-regulation of p53 through its association with a p53 co-activator, p300/CBP4 
(Zimmermann et al., 1999). Interaction of E6 with other proteins such as PDZ proteins 
is also important for its immortalising activity. PDZ protein can localise at cell-cell 
adhesion in epithelial cells. High-risk HPV E6 proteins associates with certain cellular 
proteins with a PSD95/Dlg/ZO-1 (PDZ) domain. These cellular proteins include 
human homologues of Drosophila melanogaster disc large (hDlg) and scribble tumour 
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suppressors (hScrib), post-synaptic density protein 95 (PSD95), multiple PDZ 
domain-containing protein 1 (MUPP1) via formation of complexes with E6AP and E6 
targets them for proteasomal degradation (Longworth and Laimins, 2004). High risk 
E6 protein can bind members of this family proteins through the C-terminus and 
mediate their degradation. This interaction seems to be important. Since, the use 
transgenic mice expressing E6 with no PDZ binding domain resulted in a decrease in 
the proliferation of cells although p53 was still being inactivated (Nguyen et al., 2003).  
E6 oncoprotein can interact with myc and Sp-1 and subsequently induce the 
expression of the catalytic subunit of telomerase, hTERT (human telomerase reverse 
transcriptase) (Oh et al., 2001). Telomerase is an enzyme containing four subunits, 
which incorporates hexamer repeats to the telomeric regions of chromosomes. 
Telomeric ends are shortened following repeated cell divisions due to the absence of 
telomerase activity, resulting in cell death. Other interacting partners of E6 include 
interferon regulatory factor-3 (IRF-3), E6 targeted protein-1 (E6TP1) and 
alternation/deficiency in activation-3 (ADA3) involved in DNA replication, Bak, c-Myc, 
tumour necrosis factor (TNF) receptor 1 involved in apoptosis and immune evasion, 
membrane-associated guanylate kinase (MAGI 1-3) involved in cell-cell adhesion 
(Longworth and Laimins, 2004). 
1.2.4.2 E7 oncogene 
HPV E7 is a highly phosphorylated and acidic polypeptide with approximately 100 
amino acid residues. E7 shares sequence similarities with the adenovirus (Ad) E1A 
protein and the simian vacuolating virus 40 (SV40) large tumour (Large T) antigen 
(McLaughlin-Drubin and Munger, 2009), in particular, in a conserved protein motif, 
LXCXE (L, leucine; C, cysteine; E, glutamate; X, any amino acid) which is required 
for the physical interaction with pRb. A variety of cellular proteins contain the LXCXE 
(or closely related) motifs, including cyclinD1 (Brehm et al., 1998, Ewen et al., 1993), 
histone deacetylase (HDAC) 1-2 (Brehm et al., 1998, Chan et al., 2001) and BRG1 
(Dunaief et al., 1994). The E7 phosphoprotein has two conserved regions: CR1 
(amino acids 2-15), CR2 (amino acids 16-38) and the carboxyl terminal region 
containing a zinc finger domain (amino acids 39-98) (Figure 1.4). 
CR1 and CR2 domains are conserved between HPV E7 proteins from different types 
and connected to each other through non-conserved sequences. The carboxyl 
terminal contains a conserved zinc binding site with two C-X-X-C motifs separated by 
around ~29 amino acid residues. The E6 oncoprotein also consists of these zinc 
binding sequences in common with E7 (Section 1.2.4.1), suggesting that E6 and E7 
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might have evolved from the same ancestors. The 3-dimensional (3D) structures of 
entire HPV45 E7 and C-terminal domain of HPV45  has been demonstrated by 
nuclear magnetic resonance spectroscopy (NMR) and X-ray crystallography, 
respectively (Liu et al., 2006, Ohlenschlager et al., 2006). This study indicated that 
the N-terminus is intrinsically disordered while the C-terminus is highly structured with 
zinc binding pocket involved in dimerisation. E7 was shown to be in dimeric forms 
when expressed in a recombinant system e.g. in Escherichia coli by gel filtration 
column (size-exclusion chromatography [SEC]) and non-denaturing acrylamide gel 
electrophoresis of purified E7 (McIntyre et al., 1993). Although E7 was reported to 
form tetramers (Clements et al., 2000) and higher order oligomers (Alonso et al., 
2004) by sedimentation equilibrium experiments, an analytical ultracentrifugation 
(AUC) method, E7 dimers were suggested as being the dominant forms (Clements et 
al., 2000).  
 
Figure 1.4 A representative schematic of HPV16 E7 oncoprotein with the cellular 
processes interfered. The amino terminus of HPV16 E7 is unstructured with 37 
amino acids and contains two major domains, CR1 (green) and CR2 (red). These 
domains share a sequence similarity with Ad5 E1A protein (blue-identical and 
light red-chemically similar residues). CR2 domain contains pRb binding site, 
LXCXE motif, which is required for pRb degradation and subsequent cellular 
transformation. CR1 is also required for pRB binding. CR2 contains also a 
casein kinase 2 phosphorylation site (CKII) downstream of LXCXE, which is 
conserved in SV40 T, Ad E1A and other alpha virus HPV E7 (Barbosa et al., 
1990). The X-ray crystallography structure of the carboxyl terminus HPV45 E7 
was solved and included here (Ohlenschlager et al., 2006). This region contains 
two zinc binding cysteine motifs (Cys-X-X-Cys) (yellow). The list of cellular 
processes disrupted by E7 was placed on the right hand side of the figure. 
Figure was adapted from (McLaughlin-Drubin and Munger, 2009). 
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The predicted molecular weight of HPV16 E7 is ~11 kDa (Smotkin and Wettstein, 
1987). However, it migrates on SDS polyacrylamide gels with a molecular size of ~17 
kDa (Armstrong and Roman, 1993), possibly due to the high content of acidic, 
negatively charged amino acid residues. When the negative charges were neutralised 
through incorporation of 1-Ethyl-3-[3-dimethyl-aminopropyl] carbodiimide (EDC) to 
free carboxyl groups, HPV16 E7 was observed to migrate with its predicted molecular 
size (11 kDa) (Armstrong and Roman, 1993). The amino terminal CR1 domain is 
suggested to mediate the aberrant migration of E7 on SDS polyacrylamide gels 
(Munger et al., 1991). There are antibodies for the detection of HPV16 E7 some of 
which was used here (see Section 2.3). Another method commonly used for E7 
detection is epitope tagging. Fusing epitopes to the amino terminus of HPV16 E7 
might affect the stability and interaction of E7 with cellular proteins (Huh et al., 2005, 
Reinstein et al., 2000). This can also affect the transforming ability of E7 oncoprotein. 
However, tagging the C-terminus did not seem to alter the functions of E7 (Huh et al., 
2005). HPV16 E7 is known to accumulate in the cytoplasm in addition to nuclear and 
nucleolar localisation. The half-life of E7 was shown to be around ~2 hrs (Smotkin 
and Wettstein, 1987) and the degradation of E7 occurs through a ubiquitin-mediated 
proteasomal mechanism following the conjugation of ubiquitin to the amino terminus 
of E7 (Reinstein et al., 2000). Ubch7 (UBE2L3) and a Cullin 1/Skp2-containing E3 
ubiquitin ligase were also reported as involved in the ubiquitination of HPV16 E7 (Oh 
et al., 2004). Low risk- HPV6 and 11 was shown to be ubiquitinated similar to the high 
risk HPV16 and 18 using oestrogen-receptor (ER) tagged HPV E7 proteins (Roman 
and Munger, 2013). This study, however, showed that E7 from these low risk types 
had a longer half-life than HPV16 and 18. 
HPV16 E7 possess a consensus phosphorylation site for casein kinase 2 (CK2) in the 
CR2 domain (Firzlaff et al., 1989). Phosphorylation occurs on serine residues 
(Smotkin and Wettstein, 1987). CK2, a serine/threonine-selective protein kinase 
involved mainly in cell cycle control and DNA repair pathways, was shown to 
phosphorylate HPV18 E7 two and four times faster when compared to HPV16 E7 and 
HPV6 E7, respectively (Barbosa et al., 1990). There is a cellular complex expressed 
in normal keratinocytes with inhibitory function on CK2, macrophage-inhibitory related 
factor protein (MRP) 8 and 14 (Tugizov et al., 2005). The expression of this complex 
was abolished in HPV-immortalised human keratinocytes with an accompanying rise 
in CK2 activity (Tugizov et al., 2005). The detection of three different isoforms of 
HPV16 E7, E7a1 (17.5 kDa), E7a (17 kDa) and E7b (16 kDa), showing different 
cellular localisation properties is possibly suggesting the presence of other post-
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translational modifications (Valdovinos-Torres et al., 2008). In fact, HPV18, but not 
HPV16 E7, contains glutamine residues (position 87 or 88) that can be polyaminated 
by transglutaminase 2 (TGase 2), a family of enzymes involved in the catalysis of 
protein modification via the incorporation of polyamines in to substrate molecules, in 
the zinc binding region (Jeon et al., 2003). This post-translational modification of 
HPV18 E7 was reported to reduce its pRb binding. The inability of TGase 2 to 
associate and destabilise HPV16 E7 may be one of the explanation of the high 
prevalence of HPV16 over HPV18 in cervical cancer. 
The major functions of E7 ensure that DNA synthesis phase of differentiated cells are 
retained and the viral genome is maintained in undifferentiated cells. E7 interferes 
with various cellular processes e.g. cell cycle entry and apoptosis in order to allow the 
virus to complete its life cycle. In order to study virus life cycle, monolayer human 
primary keratinocytes can be induced to differentiate with calcium and 
methylcellulose. Another method can be the use of in vitro engineered organotypic 
skin rafts. To produce these skin-like structures, keratinocytes are grown at the air-
liquid interface on an artificial dermis. The resulting system has the key features of 
differentiating epithelia, allowing amplification of the viral genome, expression of late 
genes and generation of new virus in the upper differentiated layer. Such system 
adopted previously to study the effects of a mutation in the E6 protein kinase A (PKA) 
recognition motif of HPV18 genome on the virus life cycle (Delury et al., 2013). The 
phosphorylation of the E6 PDZ-binding motif (PBM) by PKA negatively regulates the 
interaction between high-risk E6 protein and their targets containing PDZ domains. 
pRb is a tumour suppressor protein involved in cell cycle control. Defects in pRb can 
be seen in most cancer types. pRb regulates the transition from the G1 to the S phase 
of cell cycle by inhibiting the E2F family proteins: These are transcription factors and 
include E2F1, 2, 3a, 3b, 4, 5, 6, 7a, 7b and 8, upregulating the expression of genes 
involved in the S-phase entry. E2F1-6 can form heterodimer with proteins from a 
related family, DP factors. Hyphophosphorylated pRb binds and inhibits the activity of 
E2F1-3/DP complexes to control the entry to the S-phase (Dyson, 1998). Following 
the phosphorylation of pRb by cdk4 and/or cdk6/cyclin D complexes in the G1, E2F1-
3/DP-pRb complex is disrupted and dissociated E2Fs can subsequently activate the 
transcription of genes required for S-phase entry including cyclin dependent kinase 2 
(cdk2), cyclin A and E and DNA polymerase α. Overexpression of E7 has been 
reported to cause an increase in pRb-E2F1 complexes resulting in the rise of free E2F 
levels (Chellappan et al., 1992, Wu et al., 1993).  
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HDACs are transcriptional co-repressors and responsible for inducing chromatin 
remodelling with acetyl modifications of lysine residues on histones. Histone 
acetylation is responsible for weakening the interaction between histone N-terminal 
region and genomic DNA, opening up the chromatin structure which helps activating 
transcription factors to access to DNA. In normal cells, pRb forms a complex with 
HDAC and associates with the E2F transcription factor in the G1-phase (Garnett and 
Duerksen-Hughes, 2006). This causes the repression of E2F-inducible promoters, 
preventing the activation of genes necessary for proliferation. E7 protein can also bind 
HDAC (independently of its binding to retinoblastoma protein) (Brehm et al., 1999). 
This binding results in the release of the repression on the E2F regulated promoters 
and subsequent activation of E2F-inducible genes, which facilitates the S-phase entry 
and thus cell proliferation.   
The interaction of HPV E7 with the pRb through the conserved LXCXE sequence 
motif within the CR2 domain was reported using co-immunoprecipitation (co-IP) 
assays (Dyson et al., 1989, Munger et al., 1989). The SV40 Tag and the Ad E1A 
proteins were shown by mutational studies to target pRB family proteins through 
LXCXE motifs and retain cells in the S-phase (DeCaprio et al., 1988, Whyte et al., 
1988). High-risk HPV E7 protein binds pRB with an approximately 10-fold greater 
efficiency than low-risk HPV E7 protein. This difference was suggested to result from 
a single amino acid residue present in high-risk but not low-risk HPVs upstream the 
LXCXE motif (e.g. aspartate 21 in HPV16 E7 and glycine 22 in HPV 22 E7) (Barbosa 
et al., 1990, Heck et al., 1992). The HPV16 E7 protein binds hypophosphorylated form 
of pRb (Dyson et al., 1992) and targets this for degradation through interaction with a 
cullin 2 containing ubiquitin ligase complex (Huh et al., 2007). Degradation of pRb 
(caused by HPV E7) was studied using 26S proteasome inhibitor, MG132 (see section 
4.1.2) and reported to be via proteasomal pathways (on a phosphorylation-dependent 
manner) (Boyer et al., 1996, Gonzalez et al., 2001). Since, treatment with MG132 
resulted in the recovery of pRb levels in E7 expressing cells.  
Crystal structure analysis showed that E7 interacts with pRb through a highly 
conserved groove on the β-box, also known as pocket domain where E2F/DP 
interaction takes place through a nine amino acid residue region containing LXCXE 
(Xiao et al., 2003). The role of high risk HPV E7 in pRb degradation is very important 
for transformation of infected cells. HPV E7 can activate cdk2 through interaction with 
cyclin E, cyclin A and cdk inhibitors (CKIs) including p21CIP1 and p27KIP1. These 
interactions can alter cell cycle regulation and result in the blockage of the responses 
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against anti-proliferative signals such as growth factor receptor withdrawal, activation 
of p53 and loss of cellular adhesion (McLaughlin-Drubin and Munger, 2009).  
 
Figure 1.5 A schematic of pRb family proteins, pRb, p107 and p130 with 
homology domains. pRb family of pocket proteins shows a sequence homology 
in the C-terminal region. This region consists of α and β domains separated by 
a spacer region. p107 and p130 contains an additional β domains in addition to 
a cyclin A/Cdk2 and cyclin E/Cdk4 binding sites in between α and β domains. 
P107 and p130 also possess a region with Cdk inhibitor function in the amino 
terminus. 
Other targets of HPV E7 includes pRb family proteins, p107 and p130. pRb family 
proteins show a sequence homology in the C-terminal or pocket region. The pocket 
region of all pRb family members consists of α and β sub-domains which are 
separated by a spacer region. p107 and p130 proteins include an additional region 
where the association with cyclin A/Cdk2 and Cyclin E/Cdk4 occurs (Figure 1.5). 
Pocket proteins, pRb, p107 and p130 are involved in cell cycle control through their 
association with E2F1-3, E2F4 or E2F4-5, respectively (Classon and Dyson, 2001). 
E2F1-3 are transcriptional activators involved in DNA synthesis and S-phase entry, 
whereas E2F4-5 are transcriptional repressors which promotes cell cycle exit/growth 
arrest. p130 is expressed to function as a transcriptional regulator during G0/G1-
phase transition (p130 localises in the nucleus during G0/G1 and is transported to the 
cytoplasm during S-phase for degradation by the 26S proteosome after being 
targeted through a ubiquitin ligase complex (E3) called SCF complexes (Barrow-Laing 
et al., 2010, Deshaies, 1999, Tedesco et al., 2002)), whereas p107 is expressed 
during G1/S-phase transition and in the G2-phase. The interaction of HPV16 E7 with 
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p107 and p130 results in the inhibition of the transcriptional repression of E2F4-5 
promoters, leading to the disruption of pRB/E2F1-3 complexes. This will cause 
consequent expression of transcription factors as mentioned above.  
HPV E7 binds many other proteins besides pRb family proteins and cell cycle control 
proteins mentioned above. This includes proteins involved in transcription regulation 
e.g. TATA box-binding protein (TBP) and the activator protein-1 (AP1) transcription 
factors, and other proteins with different functions e.g. TATA-binding protein-
associated factor-110 (TAF-110), S4 ATPase of 26 proteaseome, interferon (IFN) 
regulatory factor-1 (IRF-1), Insulin-like growth factor binding protein-3 (IGFBP-3), 
protein phosphatase 2A (PP2A) and pyruvate kinase isoenzyme type M2 (M2-PK). 
Interaction partners of E7 along with a list of cellular processes affected were 
reviewed previously (Roman and Munger, 2013). The presence of various E7 
interaction partners can be due to the highly unstructured amino terminus domain 
proving a flexibility to the E7 protein to associate with a variety of cellular proteins and 
even other viral proteins such as HPV E2 and Adeno-associated virus (AAV) Rep78 
protein (Gammoh et al., 2006, Hermonat et al., 2000, Wang et al., 2012). Alternative 
explanation of possessing a large list of interaction partners can be the ability of E7 
to alter its conformation for optimal target binding. For example, the E7 dimer can 
undergo a conformational change when subjected to small changes in the pH (from 
pH 7 to pH 5), increasing the solvent accessibility to hydrophobic surfaces (Alonso et 
al., 2002). 
Apart from the functions of E7 explained above in cell proliferation and virus 
replication, E7 is also involved in apoptosis. By looking at some studies, anti-apoptotic 
actions of E7 can be suggested to be both direct and indirect. E7 was shown to 
upregulate the transcription of cellular inhibitor of apoptosis (c-IAP2), a protein 
involved in apoptosis inhibition, by c-IAP2 promoter-controlled luciferase reporter 
assays and to inhibit tumour necrosis factor (TNF)-mediated apoptosis by caspase 
activity assays and in situ terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) analysis (which measures DNA fragmentation as a result of 
apoptosis) in keratinocytes (Yuan et al., 2005). Another study demonstrated a delay 
in Fas-mediated apoptosis and the inhibition of TNF-mediated apoptosis, based on 
the identification of apoptotic nuclei by bisbenzimide (Hoechst) staining by 
fluorescence microscopy, through a mechanism which involves the suppression of 
caspase-8 activation (analysed by caspase activity assays) (Thompson et al., 2001). 
E7 can also have a pro-apoptotic function. For example, E7 makes mouse lymphoma 
cells (JD3) more sensitive to IFN-alpha induced apoptosis (Thyrell et al., 2005) while 
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overexpression of E7 in genital keratinocytes can make cells sensitive to TNF-
mediated apoptosis (Stoppler et al., 1998). 
1.2.5 Inhibitory molecules targeting E6 and E7 
The current strategies for the treatment of HPV related diseases are primarily anti-
cancer, not anti-viral. In addition to surgical removal of affected lesions, cytotoxic 
agents such as podophyllin and trichloroacetic acid, 5-fluorouracil and arsenic trioxide 
(As2O3), photodynamic therapy (PDT) and immunotherapy (interferons) are available 
as anti-cancer treatment. However, there are propspective HPV-specific treatments 
including therapeutic vaccines, immunotherapies, RNA interference-based therapies 
and anti-virals. Some antivirals such as acyclic nucleoside phosphonate (ANP) and 
Cidofovir [(S)-1-[3-hydroxy-2-phosphonyl methoxy propyl] cytosine 'HPMPC'] 
reported to inhibit the proliferation of HPV-positive cells (Andrei et al., 1998, Johnson 
and Gangemi, 2000). The latter was shown to downregulate E6 and E7 mRNA levels 
with an accompanying increase in p53 and pRb, which radiosensitise HPV-positive 
cells as well as tumours in mice xenografts (Abdulkarim et al., 2002). The abundant 
expression of E6 and E7 in cervical cancer led to the development of inhibitory 
molecules against these proteins. Some of them are aptamers that will be mentioned 
in section 1.3.5.1. Apart from aptamers, siRNAs, single chain antibody fragments 
(scFV) and E6/E7 therapeutic vaccines have been studied. RNA interference 
technology has been used to target HPV E6 and E7 mRNA expression, preferably 
without disturbing the cellular RNA pool. siRNAs specific to E6/E7 mRNA was shown 
to inhibit cellular growth in HPV16 and HPV18 positive cervical cancer cell and 
induced apoptosis via p53-dependent mechanisms (Zhou et al., 2012, Hall and 
Alexander, 2003, Jiang and Milner, 2002). An in vivo xenograft study showed that 
intratumoural injection of siRNAs resulted in the regression of the tumour in mice 
(Chang et al., 2010). The functions of these oncoproteins can also be targeted by 
specific single-chain antibodies (scFV) expressed as intracellular antibodies 
(intrabodies). The successful expression (in endoplasmic reticulum) and anti-
proliferative effects of an MS2D intrabody specific for HPV16 E7 was shown 
previously (Accardi et al., 2011). MS2D inhibited the tumour growth when introduced 
by a retroviral vector into mice models (Accardi et al., 2014). Therapeutic HPV 
vaccines have been developed against HPV16 viral oncogenes E6 and E7 as 
peptide/protein-based or DNA-based vaccines. Aim of these vaccines is to enhance 
T-cell immune response using e.g. a viral vector, a recombinant DNA or 
peptides/proteins derived from HPV oncoproteins. There is an ongoing phase II 
clinical trial testing the safety of a therapeutic HPV vaccine (e.g. the ProCervix, trial 
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number NCT01957878). ProCervix contains recombinant adenylate cyclase (CyaA) 
proteins, CyaA-HPV16 E7 and CyaA-HPV18 E7 in a 1:1 ratio and is being 
administered to the injection sites by Aldara™, a topical cream containing 5% of 
imiquimod (an immune modulator), as a vaccine adjuvant. An example of a 
therapeutic DNA vaccine for HPV is pNGVL4a-Sig/E7(detox)-HSP70, which aims to 
target HPV16 E7. This vaccine contained a mutated non-functional E7 (detox) 
recombinant that was unable to interact with pRb. E7 (detox) was linked to a heat 
shock protein, HSP70 (in order to enhance uptake by antigen presenting cells [APC] 
and MHC class I processing] and a signal sequence (for vaccine to target active APC) 
(Trimble et al., 2009).  This vaccine is currently in a Phase I clinical trial in combination 
with imiquimod (trial number NCT00788164). There are also studies on E6 vaccines 
e.g. an HPV16 E6 related peptide can be promising for vaccine development (Dochez 
et al., 2014).  
1.2.6 HPV vaccination 
Current prophylactic vaccines were generated using recombinant technology based 
on the production of HPV L1 (major capsid protein). Since, HPV is very difficult to 
culture in addition to the presence of three potent oncogenes (E5, E6 and E7). 
Therefore, the production of an inactivated HPV vaccine would have been difficult and 
its human use would be unsafe. In order to express large amounts of L1 protein for 
vaccine production, L1 gene was inserted into a host i.e. baculovirus and yeast.  
These L1 proteins produced virus-like particles, resembling HPV virion in size and 
shape. However, they did not contain viral DNA, therefore did not cause infection or 
cancer, although they are highly immunogenic and protective due to the presence of 
neutralising serum antibodies (Dochez et al., 2014). These antibodies can coat 
virions, preventing their binding to cell surfaces (Dochez et al., 2014). Currently, there 
are two prophylactic vaccines available: CervarixTM and GardasilTM. The bivalent 
vaccine, CervarixTM was expressed in a baculovirus expression system and contained 
HPV16 (20 µg) and 18 (20 µg) VLP antigens in combined with an adjuvant, ASO4 (in 
order to enhance the immune response) and 3-O-desacyl-4 monophosphoryl lipid A 
and aluminium salt. The quadrivalent vaccine, GardasilTM was produced using yeast 
substrate and contained HPV16 (40 µg) and 18 (20 µg), as well as low-risk HPV6 (20 
µg) and 11 (40 µg) in combined with amorphous aluminium hydroxyl-phosphate 
sulphate as an adjuvant. Both vaccines can be administered by intramuscular 
injections in three doses; 0, 1 and 6 months for bivalent vaccine and 0, 2, and 6 
months for quadrivalent vaccine.  Upon 3-dose vaccination, highest immune response 
was observed in girls aged 9-15 years, and high antibody titres maintained for at least 
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8.4 years for the bivalent vaccine with 100% seropositivity and at least 5 years for the 
quadrivalent vaccine with around ~98% seropositivity (Romanowski, 2011). Both 
vaccines showed some cross-protection against non-vaccine HPV types. The 
quadrivalent vaccine was shown to cross-protect against HPV31, while the bivalent 
vaccine was cross-protecting against HPV31, 33 and 45. This was possible owing to 
phylogenetic similarities between L1 genes among HPV types. For example, HPV16 
is phylogenetically related to HPV31, 33, 52 and 58, whereas HPV18 is related to 
HPV45 (Kemp et al., 2011, Malagon et al., 2012). One concern with the HPV 
vaccination is the type replacement. Although, HPV DNA is very stable, preventing 
escape mutations and generation of new HPV types (Dillner et al., 2011, Tota et al., 
2013). There might be a strong natural competition between HPV types which cannot 
be compensated by vaccine cross-protection as mentioned above. It was shown by a 
study performed in the USA that while the prevalence of HPV vaccine types 
decreased in both vaccinated (by 31.8%) and non-vaccinated (by 30.2%) individuals, 
that of non-vaccine types increased by 14% for all individuals (Kahn et al., 2012). 
However, the risk of developing cancer caused by HPV16 or 18 is much greater than 
that by other HPV types (Tota et al., 2013).  
There is another HPV vaccine, nine-valent, which is undergoing clinical trials (trial 
number NCT00943722). Current quadrivalent HPV vaccine (containing HPV6, 11, 16 
and 18 antigens) is suggested to protect against around 70% of all SCC cases, 
whereas this nine-valent vaccine is estimated by mathematical modelling to protect 
against 90% of all SCC worldwide. Since, the nine-valent vaccine (V503) contains 
some other high-risk types, HPV31, 33, 45, 52 and 58 VLPs, in addition to the 
quadrivalent vaccine types (Serrano et al., 2012). Since, women face cervical cancer, 
but not men, HPV studies and HPV vaccination are focussed on women. However, 
HPV-related cancers can also be developed at other sites in men due to the fact that 
high-risk HPVs can cause around ~90%, ~40%, ~12% and ~3% of anal, penile, 
oropharyngeal and oral cancers, respectively (WHO, 2014). Therefore, vaccination of 
males might help to the prevention of these HPV-related cancers. In addition, 
vaccination of men was suggested to aid the protection of women through herd 
immunity (Angelo et al., 2014). However, the reduction of the cervical cancer rates 
through vaccination of men resulting in herd immunity could not be comparable to that 
through broad vaccination of women (Einstein et al., 2009). 
Human papillomaviruses contains mainly L1 in addition to smaller quantities of L2 as 
capsid proteins. L1 protein is highly abundant and strongly stimulates B cells. 
Contrarily, L2 protein is almost invisible for the immune system. Once virus binds to 
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the basement membrane, conformational changes occurs and L2 protein becomes 
more exposed. However, this is still not enough for the induction of an anti-L2 
neutralising antibody response. A small proportion of the L2 capsid protein, especially 
between amino acid 20 and 38, is highly conserved amongst various high-risk HPV 
types and several antibodies against this region can neutralise the activities of various 
papillomaviruses (Karanam et al., 2009). Although poor immunogenicity of L2 
antigens makes them unsuitable candidates for vaccine development, recent studies 
conducted in mice using bacteriophage (Lactobacillus casei) VLPs expressing L2 on 
their surface were promising (Yoon et al., 2012). Oral administration of this vaccine 
candidate triggered the production of IgA, providing a moderate vaginal mucosal 
immunity for at least early phases of the viral infection.  
1.3 Nucleic acid molecules as molecular tools 
Aptamers, antisense oligonucleotides (ASOs), siRNAs and ribozymes each have 
therapeutic potentials. The sequence of an antisense oligonucleotide is 
complementary to a specific mRNA target, and binding the target results in the 
degradation of mRNA or inhibition of translation. siRNAs are short synthetic double-
stranded RNA molecules, leading to the degradation of mRNA target upon binding. 
Ribozymes (catalytic RNAs) are used for site-specific cleavage of target RNA or site-
specific RNA trans-splicing i.e. repair of mutant mRNA molecules causing a genetic 
disease. Antisense oligonucleotides, ribozymes and siRNAs act to inhibit the protein 
expression at the mRNA level through traditional hydrogen bond interactions. 
Aptamers accomplish tight and specific binding to the target ligand taking advantage 
of their three-dimensional (3D) structures. Upon binding, aptamer can become 
encapsulated by the ligand which subsequently becomes a part of the aptamer`s 
intrinsic structure (Huang et al., 2003). Aptamers were used as therapeutic agents for 
the first time in 1990 for a study in which overexpression of TAR (a regulatory RNA 
element in the HIV-1 required for trans-activation of viral promoter and for viral 
replication)-containing sequences (TAR decoys) inhibited human immunodeficiency 
virus type 1 (HIV-1) replication in CEM-SS cells (a human CD4 positive T-cell line) 
(Sullenger et al., 1990). Since then, aptamer studies have raised a considerable 
interest. As far as our knowledge, there are three nucleic acid molecules approved by 
Food and Drug Administration (FDA) to date. Two of those are antisense 
oligonucleotides (ASO), Fomivirsen (Vitravene®) and Mipomersen (Kynamro®) 
approved by FDA in 1998 and 2013, respectively. Fomivirsen is a 21-nucleotide 
phosphorothioate oligonucleotide which is complementary to the mRNA for the major 
immediate-early region proteins of human cytomegalovirus (CMV). The injection of 
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fomivirsen into a human eye can result in the inhibition of CMV retinitis. This is an 
inflammation of the retina of the eye that can lead to blindness. Mipomersen is a 20-
nucleotide second-generation synthetic phosphorothioate oligonucleotide (see 
section 1.3.3.1) with 2'-O-methoxyethyl modifications (2'-MOE) at the 2' moiety of the 
ribose. It mediates the RNase H-mediated degradation of the mRNA for 
apolipoprotein B (apoB), a metabolic precursor of low-density lipoprotein (LDL). This 
antisense oligonucleotide has been used for the treatment of homozygous familial 
hypercholesterolemia which is a genetic disease characterized by high levels of LDL 
in the bloodstream and by early cardiovascular disease. Only one aptamer, termed 
Macugen (Pegaptanib) is approved by the FDA and in clinical use, which will be 
explained in detail in section 1.3.4. 
1.3.1 Aptamers 
Aptamers are short (15-100 nucleotides), chemically synthesised, single stranded (ss) 
RNA or DNA oligonucleotides. They fold into specific three-dimensional (3D) 
structures often with dissociation constants for their targets ranging between pico- 
and nano-molars (Nimjee et al., 2005). In contrast to most oligonucleotide therapies 
which mostly target the translational mechanism on the mRNAs level, aptamers 
directly bind target proteins through structural recognition (similar to antigen-antibody 
interaction) and interfere with functions of target protein by blocking the active site, 
disrupting the interactions with other target protein/DNA/receptor or inhibiting a 
specific protein domain with multiple subunits (Kaur and Roy, 2008). Therefore, 
aptamers are also termed “chemical antibodies”.   
Aptamers have several advantages over antibodies. First, their molecular weight is 
considerably lower (8 – 25 kDa) when compared to antibodies (~ 150 kDa), which 
provides a faster and better target accessibility and more efficient penetration into 
tissues. Second, aptamers are considered non-immunogenic in vivo in contrast to 
antibodies, which are highly immunogenic especially after repeat administration. An 
example is the studies with anti-VEGF aptamer in in vivo models. These clinical 
studies in animal models as well as in humans illustrated no severe adverse effects 
resulting from immune stimulation against the aptamer (Eyetech Study, 2002, 
Eyetech Study, 2003). Third, aptamers are thermally stable, even with treatment at 
95°C. When returned in to the room temperature, they can refold in to their correct 
secondary structures. However, antibodies, with protein properties, are not resistant 
to heat treatment; thus lose their activity. In addition, aptamers can be easily and 
rapidly synthesised in large scales with low costs using a well-established protocol 
27 
 
and in addition they can be modified by a variety of functional groups (Sun et al., 
2014) and reporter molecules such as fluorescent dyes. Most importantly aptamer 
selections can be performed against a wide range of targets, such as metal ions 
(Hofmann et al., 1997, Rajendran and Ellington, 2008), amino acids (Mannironi et al., 
2000), antibiotics (Wallace and Schroeder, 1998), toxins (Huang et al., 2015, Ye et 
al., 2014), peptides (Williams et al., 1997), proteins (Belyaeva et al., 2014, Nicol et 
al., 2013), virus glycoprotein (Liang et al., 2014), bacteria (Park et al., 2014), whole 
cells (Kim et al., 2014, Kunii et al., 2011) and organisms (Lorger et al., 2003) and even 
tissue samples (Noma et al., 2005). There are also some disadvantages including 
their susceptibility to nuclease degradation. However, this can be reduced by 
chemical modifications of nucleotides as further discussed in section 1.3.3.1. Another 
disadvantage is that an aptamer sequence can form several different secondary 
structures with similar ΔG (free energy) (see section 3.2.2). This can cause a 
reduction in the concentration of the desired and effective aptamer structure.  
Aptamers against all these targets are identified through a process called SELEX 
(systematic evolution of ligands by exponential enrichment) which will be explained in 
detail in section below.  This selection process in vitro allows the manipulation of 
specificity, binding affinity and selection conditions. Therefore, aptamers with desired 
properties that can bind to the target of interest at desired conditions i.e. particular 
temperature, pH, salt concentration or other buffer compositions can be generated. 
1.3.2 Generation of aptamers by SELEX (Systematic Evolution of 
Ligands by Exponential Enrichment) 
SELEX, an in vitro selection process, includes two steps; selection and amplification. 
Iterative rounds of SELEX serve to reduce the complexity of nucleic acid library 
(around ~1014  - 1015  molecules) (Tuerk and Gold, 1990).  
As shown in Figure 1.6, technique is based on the incubation of a target of interest 
with a random pool of oligonucleotide library (single-stranded DNA or RNA) at a 
temperature which promotes the formation of most stable structures. The nucleic acid 
library contains a random sequence (30-40 nucleotides) flanked by constant regions 
located at the 5' and 3' ends. Constant regions consists of primer binding sites and 
also a T7 RNA polymerase recognition site (for RNA aptamers only).  
Oligonucleotide–target complex is washed and remaining bound sequences are 
eluted using appropriate buffer compositions. These sequences are then incubated 
with the control target if negative selection is necessary in order to eliminate the 
sequences that could also recognise the control. Recovered sequences are then 
28 
 
amplified by PCR or reverse transcription PCR for the synthesis of DNA and RNA 
aptamers, respectively. In the case of DNA SELEX, double stranded DNA aptamers 
need to be subjected to strand separation (in order obtain the sense strand of PCR 
products for the next round of selection)  by i.e. using biotinylated primers (Bock et 
al., 1992) or fluorophore–labelled forward primers which allows the monitoring of the 
process by affinity separation or flow cytometry, respectively (Pei et al., 2014). 
However, for RNA SELEX, the pool of DNA is used as the template for in vitro 
transcription to produce a new pool of RNAs that goes in to the next round of selection. 
RNAs with a higher affinity for the target out-compete those with a lower affinity which 
are then removed and the whole cycle is repeated. The selection process is repeated 
(~10–20 rounds) to increase the binding affinity of aptamers resulting in Kd (the 
equilibrium dissociation constant) values ranging from nanomolar to picomolar. A 
stringent negative selection is generally included in the selection process in order to 
ensure target specificity. All nucleic acid sequences binding to affinity tags or closely 
related target proteins are discarded and remaining sequences (following 
amplification by PCR or reverse transcriptase PCR) are subjected to the next round 
of positive and negative selection. 
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Figure 1.6 A schematic representation of SELEX process.The RNA or DNA 
aptamer library includes a variable region flanked by two constant regions. 
These constant regions contain primer binding sites for PCR amplification and 
a consensus promoter sequence for the T7-RNA polymerase. SELEX is based 
on incubation of target proteins/cells in a random pool of RNA/DNA, followed 
by washes to remove the unbound sequences. Then, bound RNA/DNA are 
eluted from target protein/cell, and amplified by PCR before moving on to next 
cycle generation. Resulting template pool is cloned into an appropriate plasmid 
and clones are picked and sequenced.  
Aptamers can be identified from DNA or RNA pools. SELEX process for the selection 
of DNA aptamers requires fewer steps that of RNA aptamers which includes an in 
vitro transcription step as mentioned above. Chemical synthesis of RNA aptamers is 
more expensive than that of DNA aptamers, although synthesis of DNA aptamers 
requires an asymmetric PCR using labelled forward primers i.e. with biotin as 
mentioned above. DNAs are more stable and have longer shelf-life when compared 
to their RNA counterparts due to the fact that RNAs are more susceptible to hydrolysis 
than DNAs. This is why manipulation with RNA aptamers requires RNase-free 
conditions, although stability of RNA aptamer can be improved by incorporation of 
several modifications that will be discussed in section 1.3.3.1. In order to maintain the 
Cloning and Sequencing 
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aptamer at an effective concentration, high doses need to be administered in to 
animals or humans with several repeats, due to the issues with nuclease 
susceptibility. However, possibility of genetic encoding of RNA aptamers offers a 
great advantage over DNA aptamers due to the expression of aptamers directly by 
the target cells through vectors bearing sequences of aptamers of interest. In addition, 
base-pairing properties and presence of modified nucleotides (for RNA aptamers) 
within their 3D structures can provide structural diversity and versatility to RNA 
molecules as in the case of riboswitches. These are naturally occurring, non-coding 
and structured RNA sequences found in the 5'-untranslated region of mRNA 
molecules (Santosh and Yadava, 2014). Riboswitches are widespread in prokaryotic 
organisms i.e. bacteria and can recognise specific cellular metabolites (effector 
ligands) through their aptamer binding domain and can subsequently modulate 
metabolic gene expression through their expression platform domain (Santosh and 
Yadava, 2014). Main roles of riboswitches are premature termination of transcription, 
inhibition of translation and cleavage of mRNA itself (acting as ribozymes) when 
metabolite concentrations are sufficient. Similar to 3D RNA molecules found as 
riboswitches, DNA molecules with tertiary structures can also be found in organisms 
especially in telomere and promoter regions (Cogoi and Xodo, 2006, Oganesian and 
Bryan, 2007). They are observed to form G-quadruplex structures which can be 
considered major structural elements of DNA aptamers as in the case of thrombin 
aptamer, NU172 and nucleolin aptamer, AS1411 (section 1.3.4 and 5.2.4). These 
inter- and intramolecular G-quadruplex structures (G-quartets) formed by G-rich 
nucleic acid sequences have unique biophysical and biological properties (Dapic et 
al., 2003). Formation of these structures enhances the binding properties and also 
internalisation of aptamers into cells (Dapic et al., 2003, Reyes-Reyes et al., 2010). 
Based on considerations summarised above, DNA and RNA aptamers have specific 
advantages and disadvantages all of which needs to be taken into account before 
preferring one over the other.   
A variation of traditional in vitro SELEX process is cell-SELEX (cell-based selection 
of aptamers). While traditional SELEX process is achieved by incubating the nucleic 
acid library with purified protein targets, cell-SELEX is performed using whole living 
cells. This protocol can be used even though cell marker proteins are unknown. Cells 
express certain marker proteins on the cellular membrane. Some of these are up-
regulated or modified in a disease condition i.e. cancer or new markers might appear 
on the cell surface.  This approach allows the isolation of RNA aptamers against cell 
surface markers with anti-cancerous, anti-inflammatory and anti-infectious effects for 
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the development of new therapies or biomarker discovery (Cibiel et al., 2012, Mi et 
al., 2010). One of the limitations of this approach is that presence of multiple markers 
on the cell membrane might result in non-specific binding. However, this can be 
overcome by inclusion of a stringent negative selection against negative control cells. 
A modified SELEX protocol, termed cross-over SELEX (if disease markers are known) 
can be used in order to eliminate these non-specific binding events. In this method, 
cell-SELEX are followed by traditional in vitro SELEX using purified cell marker 
proteins as targets. For example, this protocol was utilised to generate aptamers to 
human tenascin C (TN-C), an extracellular matrix protein involved in tumour growth, 
expressing U251 glioblastoma cells (Hicke et al., 2001). Following initial nine rounds 
of cell-SELEX, enriched pools were subjected to incubation with purified TN-C protein 
for two more rounds to identify sequences with higher affinity for the target.  
Tissue-SELEX is another alternative selection process and used to identify aptamers 
against a tissue section i.e. from tumour including a negative selection against healthy 
tissues of the same origin. In this process, aptamers identified are supposed to bind 
several components of the tumour tissue i.e. cellular membranes, extracellular and 
intracellular molecules. In addition, another approach (in vivo SELEX) was described 
for the selection of RNA oligonucleotides that are localising to tumour cells in vivo 
using tumour bearing mice (Mi et al., 2010).  
1.3.3 Challenges of aptamers in therapy 
In vivo administration of aptamers are performed by intravenous (IV), subcutaneous 
(SC), or intravitreal (IVT) injections (Bouchard et al., 2010). However, other routes i.e. 
dermal, mucosal or inhalation can possibly be utilised to administer aptamers. 
Characterisation of aptamers that can internalise into keratinocytes without any 
chemical based introduction might allow topical application of aptamers i.e. to treat 
skin conditions involving inflammation (Doble et al., 2014). Alternative delivery 
mechanisms need to be established as well as subcellular localisation of aptamers 
upon administration. Therapeutic aptamers mostly target cell surface protein, 
abundant in the blood and body fluids. Therefore, aptamers need to remain functional 
and stable in these compartments for longer period of time. However, unmodified 
aptamers are highly unstable and prone to degradation with nucleases (and released 
nucleosides are subjected to purine and pyrimidine metabolism pathways) and rapidly 
eliminated by renal clearance (Sundaram et al., 2013). Aptamers might also result in 
nonspecific immune response in transfected cells which will be discussed below. 
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1.3.3.1 Requirement for modifications for the stabilisation of aptamers 
Nucleic acids consist of base, ribose, and phosphate moieties. Each moiety can 
potentially be modified with various chemical groups in order to increase the half-life 
of unmodified aptamers, which observed to be less than 2 min (Griffin et al., 1993). 
For example, base moiety of pyrimidines and purines are modified at the 5', and 7' 
and 8' positions, respectively; sugar moiety is modified at the 2'  or 4' position; and 
phosphate group is modified by substitution of oxygen with other chemical species 
(Kuwahara and Sugimoto, 2010). Modification of the phosphate group leads to the 
formation of inter-nucleotide phosphodiester linkages. An example of this is 
oligonucleotides synthesised using 5'-α-P-boranonucleotide triphosphates (Lato et 
al., 2002) and α-thio nucleotide triphosphates (phosphorothioate) (Kang et al., 2008) 
in which one of the oxygen atoms of the α-phosphate moiety is replaced by a boron 
atom or sulphur, respectively. Amongst several others, use of nucleotides with fluoro 
(-F), O-Methyl (OCH2) and amino (NH2) substitutions at the 2' OH position of the 
ribose are the most common modifications (Keefe and Cload, 2008). The presence of 
the –OH at the 2' ribose makes RNA more susceptible to nucleophilic attack when 
OH ions are present on the 5' phosphate group (2'–OH group can generate 2'–O ion, 
which attacks the phosphorous atom). This results in the breakage of phosphodiester 
bonds, and 2'-3' cyclic phosphate intermediates are formed. Hydrolysis of cyclic 
nucleotides generates a mixture of 2' and 3' nucleoside monophosphates. Amongst 
other 2' ribose modifications, fluorine is used more often due to its small size and also 
its neither hydrophobic nor hydrophilic nature (Pallan et al., 2011). Therefore, fluorine 
seem to be good mimics of the 2' hydroxyl group. Substitution with fluorine locks the 
ribose in the C3'-endo conformation, which can increase the binding affinity to the 
target (Pallan et al., 2011). The 2'-fluoro modification also reduces non-specific 
immune stimulation by nucleic acid molecules (Deleavey et al., 2010, Yu et al., 2009). 
An alternative position to modify the ribose is the replacement of 4' oxygen atom with 
sulphur compound. SELEX process using these modified 4'-thio UTP and CTPs was 
previously reported (Kato et al., 2005). Uridine or thymidine can also be modified at 
the 5' position (substitution of this position is likely to be ignored by polymerases) i.e. 
5-pentynyl-2'-deoxy uridine (Latham et al., 1994). Mutant T7 RNA polymerase can be 
used in order to incorporate these modifications into aptamers before or after SELEX 
process (Chelliserrykattil and Ellington, 2004, Huang et al., 1997, Sousa and Padilla, 
1995). However, if aptamers are modified after selection, it might be taken into 
consideration that their binding properties might have altered, although this was found 
to be negligible for aptamers selected to the RNA-dependent RNA polymerase 
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(RdRp) of foot-and-mouth disease virus, FMDV (Ellingham et al., 2006, Forrest et al., 
2014). 
Nucleotide capping by incorporation of an inverted nucleotide at the 3'- terminus 
(through 3'-3' phosphodiester bond) is also used to increase the stability of aptamers 
by protecting them from serum nucleases (Beigelman et al., 1995). In this case, 
oligonucleotide contains no 3'-termini, which increase the stability due to the fact that 
3'- exonuclease activity in serum is considerably greater compared to 5'- exonuclease 
activity.  
Locked nucleic acid aptamers and Spiegelmers (containing mirror imaged 
oligonucleotides) are resistant to nucleases with enhanced metabolic stability. Locked 
nucleotides contain a methylene bridge between 2'-O and 4'-C of the ribose group, 
which presents more stable base-pairing structures due to the fact that bridge locks 
the ribose in the 3'-endo (N-type) conformation (Schmidt et al., 2004). Spiegelmers 
are generated by the replacement of D-ribose with L-ribose, resulting in the production 
of unnatural L-nucleotides. These L-nucleotides (mirror images of natural 
oligonucleotides) are subsequently used in the chemical synthesis of L-RNAs 
(Spiegelmers) that are highly resistant to nuclease degradation (Eulberg and 
Klussmann, 2003). Several Spiegelmer aptamers (L-RNA aptamers) are currently 
undergoing clinical trials as presented in Table 1.1. A modified SELEX protocol is 
applied to generate these Spiegelmers owing to the fact that L-ribonucleotide 
triphosphates cannot be recognised by wild-type RNA polymerases that are used 
during selection process i.e. PCR. Therefore, SELEX is performed using the 
enantiomer (mirror image) of the desired protein target (that can be made synthetically 
using L-amino acids) and wild-type RNA sequences. Isolated aptamers are then 
synthesised with L-ribonucleotides and expected to bind to the desired protein target 
(synthesised with D-amino acids) in a similar way.   
1.3.3.2 Conjugation of polymers to enhance the bioavailability of 
aptamers 
Other concern using aptamers as therapeutics is their rapid renal clearance. Although 
low molecular mass (8 – 25 kDa) provides aptamers certain advantages (Section 
1.3.1), this can also be a drawback due to the poor bioavailability of aptamers in 
plasma. As the molecular weight cut-off for the renal glomerulus is 30 – 50 kDa, 
conjugation of aptamers to polymers (30 – 50 kDa) prevents exclusion by renal 
clearance. Cholesterol and mostly polyethylene glycol (PEG) N-hydroxysuccinimide 
polymers are used for this purpose. When 20 kDa or 40 kDa PEG polymer was 
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conjugated to the aptamer, the half-life of the aptamer in circulation was found to be 
increased with reduced distribution to the kidneys (Healy et al., 2004). Use of 2'- 
ribose modified nucleotides i.e. 2'-O-methyl as well as 40kDa PEG conjugation can 
increase the circulation half-life of an aptamer by up to 23 h in mouse models 
(Burmeister et al., 2005) and up to 10 (±4) days in human (Macugen; Pfizer/Eyetech) 
(see clinical pharmacology section on the prescribing information of pegaptanib). PEG 
is conjugated to the protein generally in a random manner through lysine side chains. 
This could lead to heterogeneity (mixed PEGylated and unPEGylated species) and 
also loss of protein`s function. However, taking advantage of being chemically 
synthesised molecules, aptamers can be engineered to contain an additional 
functional moiety (i.e. alkyl amine) that can be used as a conjugation site for further 
modifications i.e. PEG polymer. Conjugation of PEG through an additional moiety 
helps to protect the 3D structure and function of the aptamer.   
1.3.3.3 Potential toxicity due to the activation of innate immunity 
Another challenge using aptamers as therapeutics results from their potential toxicity. 
In fact, there is very limited information available on the activation of innate immunity 
by aptamers unlike viral, bacterial nucleic acids and other DNA or RNA 
oligonucleotides. Host cells present pathogen-recognition receptors (PRRs) in order 
to recognise a pathogen invasion by detecting particular molecules associated with 
the pathogens (Bowie and Unterholzner, 2008). Recognition of viral RNA occurs in 
the endolysosomal compartments by membrane-bound Toll-like receptors (TLRs) 3 
(responds to double-stranded DNA or RNA), mouse TLR7 (human TLR8) (respond to 
single-stranded RNA) and 9 (unmethylated CG motifs (CpG motifs) in DNA) in 
immune cells. However, in nonimmune cells, accumulated foreign nucleic acids are 
recognised in the cytosol by retinoic acid inducible gene 1 (RIG-I) and melanoma 
differentiation associated antigen 5 (MDA5), Nod-like receptors and C-type lectin 
receptors (Akira et al., 2006, Kawamura et al., 2014). RIG-I is a DEXH/D-containing 
RNA helicase which recognises 5' triphosphate moiety of foreign RNA in cytosol 
during the course of infection and subsequently mediates immune responses through 
type I interferons (IFNα/β) (Hwang et al., 2012). Since, cellular mRNA is modified at 
the 5' triphosphate by capping prior to nuclear export. Therefore, only molecules 
containing a 5' triphosphate in cytosol would be foreign, such as viral RNA. RIG-I is 
predominantly expressed in fibroblasts, epithelial cells, hepatocytes, and conventional 
dendritic cells (cDCs) (Kato et al., 2006). RNA molecules that are capable of triggering 
RIG-I response might harbour a recognition sequence or be single-stranded (ss) or 
double-stranded (ds) RNA with 5' triphosphate (Cui et al., 2008, Hornung et al., 2006). 
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However, single-stranded 5' triphosphate oligoribonucleotides were shown to be 
unable to bind or activate RIG-I, unless the complementary strand was added (Schlee 
et al., 2009b). As it was indicated before, activation of MDA5 or RIG-I has been 
observed to be dependent on the length of RNA molecules. While long double-
stranded RNAs (≥ 1 kbp) trigger innate immunity via MDA5, short double-stranded 
RNAs (~70bp – 1kbp) and shorter single-stranded RNA or DNA molecules with a 5' 
triphosphate group activate that through RIG-I (Kato et al., 2008, Schlee et al., 2009a). 
Unmodified RNA is highly sensitive to endogenous nucleases. However, 2'-Fluoro 
modification of ribose reduces unspecific immune responses mediated by TLRs, 
which causes most of the potential adverse effects of aptamers (Yu et al., 2009). 
However, presence of triphosphate moiety at the 5' end of the aptamer can also 
stimulate innate immunity. Aptamers can chemically be synthesised to consist of an 
alternative moiety at the 5' end in order to eliminate immune activation effects of 
triphosphate, if desired. For example, the aptamer bearing -OH instead of a 
triphosphate did not trigger interferon production in cervical cancer cell lines 
(Belyaeva et al., 2014).  
1.3.3.4 Need for efficient delivery systems  
Internalisation of ligands, extracellular molecules, plasma membrane proteins and 
lipids occurs through endocytosis. This can be grouped into these two mechanisms; 
clathrin-dependent and in-dependent as further introduced in section 5.1. 
Endocytosed cargo molecules are first delivered into the early endosomes, then move 
to the late endosomes and lysosomes for degradation, trans-golgi network (TGN) or 
recycling endosomes in order for the cargo to return back to the cell membrane (Grant 
and Donaldson, 2009). Most experimental approaches involve lipid-based 
transfection and electroporation to deliver nucleic acid molecules into the cells (see 
section 5.1.3). It was suggested that cargo was usually delivered into early 
endosomes regardless of the mechanism of internalisation (Grant and Donaldson, 
2009). These cargo molecules accumulate in the endosomal compartments and later 
lysosomes for degradation unless they manage to escape. Such data have been 
mostly derived from siRNAs studies (Barreau et al., 2006, Gonzalez et al., 2007, Lu 
et al., 2009, Menager et al., 2014, Sioud, 2005). A G-rich DNA aptamer, AS1411 were 
shown to enter cancer cells via micropinocytosis, localising in the macropinosomes 
(Reyes-Reyes et al., 2010). Macropinocytosis is a dynamin-independent pathway for 
endocytosis (see section 5.1.4 for endocytosis pathways). Macropinocytosis might be 
an ideal way of delivery due to the fact that they can form large vesicles varying in 
size and shape, mediated by the formation of actin-dependent lamellipodia. Resulting 
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macropinosomes are leaky, giving them an advantage over other endosomal vesicles 
(Wadia et al., 2004). These vesicles are also non-digestive non-acidic in contrast to 
lysosomes (Conner and Schmid, 2003). Macropinocytosis is also thought to be a good 
means of delivery mechanisms of a range of different cargos including peptides, intact 
proteins, bacterial virulence factors and viruses into cells (Reyes-Reyes et al., 2010). 
Macropinocytosis have been shown to be involved in the uptake of siRNAs (Love et 
al., 2010) and also naked DNA plasmids (Basner-Tschakarjan et al., 2004, Fumoto et 
al., 2009, Wittrup et al., 2007). However, there is little data in the literature regarding 
the uptake and localisation of RNA aptamers.  
1.3.4 Aptamers in clinical trials and approved by FDA 
Unlike therapeutic antisense oligonucleotides or siRNAs which target intracellular 
compartments, aptamers can target intracellular (i.e. β-catenin, thyroid transcription 
factor 1 (TTF-1), HPV E6 and E7) and extracellular molecules (i.e. VEGF and 
Tenascin-C) as well as cell surface components (i.e. PSMA, EGFR, Mucin-1 and 
gp120) (Figure 1.7). This broad application of aptamers provides them such 
properties that make their systemic administration feasible i.e. against targets in the 
bloodstream, such as thrombin (NU172), factor IXa (REG1) and von Willebrand factor 
(ARC1779), or on the surface of cells such as growth factor receptors (Table 1.1). 
Aptamers can also access targets inside cells. However, non-toxic delivery methods 
are required for their administration in vivo (section 1.3.3.4). Different types of 
aptamers i.e. agonists and antagonists have been generated and characterised to 
date since they were first discovered. Aptamers with therapeutic potential mostly tend 
to inhibit protein–protein interactions (i.e. receptor–ligand and oncoprotein–cellular 
protein target), functioning as antagonists. However, aptamers have also been 
observed to function as agonists. For instance, aptamers selected against the 
extracellular domain of the human epidermal growth factor receptor 3 (HER3) (or 
known as ERBB3) can promote oligomerisation without affecting its downstream 
phosphorylation (Chen et al., 2003). Therapeutic effects of antagonist aptamers are 
dependent on the binding affinity. If aptamer binds the target molecule with a high 
affinity, its therapeutic use will last longer and be more relevant. However, aptamers 
with higher binding affinity do not necessarily bind their ligands more specifically. 
Binding specificities of RNA aptamers selected against guanosine triphosphate (GTP) 
with Kd values ranging between 8 µM and 9 nM were examined by competition binding 
studies using several chemical analogues of GTP (Carothers et al., 2006). This study 
failed to show that higher affinity binders were more specific for GTP. Thus, potential 
therapeutic aptamers should present strong specificity and high affinity for their 
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targets and be modified in order to increase their nuclease resistance and 
bioavailability (sections 1.3.3.1 and 1.3.3.2). There is currently one aptamer, termed 
“pegaptanib (Macugen; Pfizer/Eyetech)”, previously known as anti-VEGF (vascular 
endothelial growth factor) aptamer “EYE001”, in clinical use that is approved by Food 
and Drug Administration (FDA) in 2004 (Table 1.1). VEGF regulates the pathological 
angiogenesis in cancer, ocular and inflammatory diseases (Keefe et al., 2010). 
Pegaptanib is a modified RNA aptamer (truncated to 27, originally ~70 nucleotides) 
selected against VEGF and used to treat age-related macular degeneration (AMD), a 
disease leading to vision loss of elderly caused by enhanced expression of VEGF, 
damaging the retina. Modification was accomplished by the incorporation of 2'- fluoro 
pyrimidines and 2'-O-Methyl purines to the RNA transcript and also capping the 3' end 
with an inverted deoxythymidine (dT) (for alternative modifications see section 1.3.3.1 
and 1.3.3.2)  (Ng and Adamis, 2006). In addition, bioavailability of this aptamer was 
enhanced by a 40 kDa polyethylene glycol (PEG) conjugation to the 5' position.   
 
Figure 1.7 Aptamers have been selected against a wide range of target 
molecules. Modified from (Que-Gewirth and Sullenger, 2007, Santosh and 
Yadava, 2014).  
Apart from their therapeutic potential, aptamers possess a wide range of applications 
such as in disease diagnosis (Barfod et al., 2009, Wan et al., 2010), as imaging tools 
(Kim et al., 2010) and in biomarker discovery (Mi et al., 2010). Moreover, aptamers 
generated against cell surface receptor proteins found an alternative utility on the 
delivery of therapeutic and diagnostic substances including small siRNAs, drugs, 
toxins, enzymes, photodynamic molecules and nanoparticles into target cells as 
“escort molecules” (Hicke and Stephens, 2000). Aptamers selected against cell 
surface receptors may be internalised along with target receptors themselves, 
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carrying the cargo inside the cells. To ensure the selective delivery of aptamers into 
the target cells (but not healthy cells), the receptor protein should be overexpressed 
only in the disease condition i.e. cancer which can be considered as a tumour 
biomarker. Examples will be given in the below section. Aptamers targeting proteins 
that are cancer- or virus- related, of interest, will be further introduced in the following 
section.   
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Name 
(Company) 
 Composition Target Medical 
indication 
Current phase 
(Trial 
registration 
number) 
Ref 
Pegaptanib 
sodium/ 
Macugen/ 
EYE001 
(Pfizer/ 
Eyetech) 
2' -O-methyl purine/2′-
fluoro pyrimidine with 
two 2' -ribo purines 
conjugated to 40 kDa 
PEG, 3'inverted dT 
Vascular 
endothelial 
growth 
factor 
Age-related 
macular 
degeneration 
 
Approved in the 
US and the EU 
 
(Ng et al., 
2006) 
AS1411/ 
AGRO001 
(Antisoma) 
G-rich DNA Nucleolin Acute Myeloid 
Leukemia, 
Metastatic 
Renal Cell 
Carcinoma 
Phase II completed 
(NCT00512083) 
Phase II status 
unknown 
(NCT00740441) 
(Bates et 
al., 2009, 
Teng et al., 
2007) 
REG1/RB006 
plus RB007 
(Regado 
Biosciences) 
2' -ribo purine/2' -fluoro 
pyrimidine (RB006)/40 
kDa  PEG plus 2'-O-
methyl antidote (RB007) 
Coagulatio
n factor IXa 
Coronary 
artery disease 
Phase III 
(NCT00715455) 
(Becker 
and Chan, 
2009) 
ARC1779 
(Archemix) 
DNA and 2'-O-methyl 
with a single 
phosphorothioate 
linkage conjugated to 
20kDa PEG, 3' inverted 
dT 
A1 domain 
of von 
Willebrand 
factor 
Thrombotic 
microangiopath
y 
 
Phase II closed 
(NCT00726544) 
(Diener et 
al., 2009, 
Gilbert et 
al., 2007) 
ARC19499 
(Baxter 
Healthcare) 
2'-ribocytidine/2'-O-
methyl 
Adenine/Guanine/Uracil 
conjugated to 40 
kDa PEG, 3' inverted dT 
TFPI Hemophilia Phase I closed 
(NCT01191372) 
(Waters et 
al., 2011) 
NU172 (ARCA 
biopharma) 
 
Unmodified DNA 
aptamer 
Thrombin Cardio-
pulmonary 
bypass to 
maintain 
steady state of 
anticoagulation 
Phase II status 
unknown 
(NCT00808964) 
(Gomez-
Outes et 
al., 2011) 
ARC1905 
(Ophthotech) 
 
2'-ribo purine/2'-fluoro 
pyrimidine conjugated to 
40 
kDa PEG, 3' inverted dT 
 
Compleme
nt 
component 
5 
 
Dry age-related 
macular 
degeneration 
 
Phase I completed 
(NCT00950638) 
(Biesecker 
et al., 1999) 
E10030 
(Ophthotech) 
 
DNA and 2'-O-methyl 
5'-conjugated to 40 kDa 
PEG, 3' inverted dT 
Platelet-
derived 
growth 
factor 
 
Wet age-
related macular 
degeneration 
 
Phase III recruiting 
participants 
(NCT01089517) 
(Green et 
al., 1996) 
NOX-A12 
(NOXXON 
Pharma) 
 
L-RNA with 3'-PEG CXCL12 Chronic 
Lymphocytic 
Leukemia 
(CLL), Multiple 
Myeloma (MM)  
Phase IIa ongoing 
(NCT01486797), 
(NCT01521533) 
(Sayyed et 
al., 2009) 
NOX-E36 
(NOXXON 
Pharma) 
L-RNA with 3'-PEG CCL2 Type 2 
diabetes and 
albuminuria, 
diabetic 
nephropathy 
 
Phase IIa 
completed 
(NCT01547897), 
(NCT01372124) 
(Kulkarni et 
al., 2009, 
Kulkarni et 
al., 2007, 
Maasch et 
al., 2008) 
NOX-H94 
(NOXXON 
Pharma) 
L-RNA with 3'-PEG Hepcidin Anemia of 
chronic 
disease 
Phase II completed 
(NCT01691040) 
(NCT02079896) 
(NCT01372137) 
(Schwoebel 
et al., 2013) 
Table 1.1 The list of aptamers undergoing clinical trials updated from (Keefe et 
al., 2010, Sun et al., 2014). CXCL12, chemokine (C-X-C motif) ligand 12 (or SDF-
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1α); CCL2, chemokine (C-C motif) ligand 2 (or MCP1); EU, European Union; US, 
United States; PEG, polyethylene glycol; TFPI, tissue factor pathway inhibitor. 
1.3.5 Aptamers in cancer and virology 
Some of the best characterised aptamers (in particular for targeted delivery) are the 
aptamers identified against prostate specific membrane antigen (PSMA). PSMA is a 
transmembrane glycoprotein that is aberrantly expressed in human prostate cancer 
cells and vascular endothelium. PSMA plays a major role in the internalisation of 
certain ligands and in the enzymatic processes i.e. glutamate carboxypeptidase (Pei 
et al., 2014). It can be used as a potential cell surface target for prostate cancer cells. 
In 2002, 2'-fluoropyrimidine RNA aptamers, A9 and A10, against extracellular domain 
of PSMA were generated and shown to inhibit the enzymatic activity of PSMA (Lupold 
et al., 2002). These aptamers have been utilised as tools to deliver nanoparticles, 
toxins, therapeutics and siRNAs in cells. Cell-type specific delivery of siRNAs is the 
main problem in their therapeutic applications. This can potentially be accomplished 
by creating chimeras with aptamers. PSMA specific aptamer-siRNA chimeras were 
constructed to consist of the aptamer sequence, A10,  and a siRNA against cell 
survival factors polo-like kinase 1 (Plk-1) or B-cell lymphoma 2 (Bcl-2) (McNamara et 
al., 2006). Both are anti-apoptotic oncoproteins overexpressed in cancer.  In order to 
generate these chimeras, the sense strand of the siRNA was covalently linked to the 
3` end of the aptamer. Subsequently, complementary anti-sense strand was annealed 
to generate double-stranded siRNA molecules. An alternative approach to create 
chimeras is the non-covalent conjugation of siRNAs and aptamers, that are both 
biotinylated, through a streptavidin linker (Chu et al., 2006). Upon intratumoural 
injection, these chimeras were reported to induce apoptosis in PSMA-expressing cells 
and reduce the prostate tumour size in a xenograft model (McNamara et al., 2006). 
PSMA aptamer-siRNA chimeras were also used to increase tumour immunity. 
Aptamer A10 was used to deliver siRNAs against Upf2 and Smg1, which are involved 
in nonsense-mediated mRNA decay (NMD) pathway, in to PSMA expressing tumour 
cells (Pastor et al., 2010). NMD pathway is a post-transcriptional RNA surveillance 
process that eliminates mRNAs with premature termination codons. Interference with 
this pathway results in the production of antigens, leading to the stimulation of the 
immune system. It was shown that Upf2 or Smg1 siRNA-A10 chimeras (siRNA was 
conjugated to the 3' end of the aptamer) inhibited the tumour cell growth in in vivo 
xenograft models as well as in cultured cells (Pastor et al., 2010). Another example 
was that a short hairpin RNA (shRNA) was linked to the 3' end of the truncated PSMA-
targeted aptamer and used to enhance the radio-sensitivity of prostate cancer cells 
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(but not neighbouring tissues) to ionizing radiation (IR) therapy (Ni et al., 2011). This 
aptamer-shRNA chimera was selectively targeting the catalytic subunit of the DNA 
protein kinase (DNAPK) in cancer cells, resulting in the attenuation of DNA repair 
mechanisms leading to reduced cancer cell survival following ionising radiation 
treatment. 
Cell surface specific aptamers can also be conjugated to the surface of nanoparticles, 
formulated with poly D,L-lactic-co-glycolic acid poly ethylene glycol (PLGA-bPEG) 
copolymer, containing chemotherapeutics (Farokhzad et al., 2006). A truncation of 
PSMA aptamer A10 (A10-3) conjugated to these nanoparticles containing docetaxel 
(Dtxl), an anti-mitotic chemotherapy drug, was shown to deliver the drug into PSMA-
expressing tumour cells and reduce the tumour volume following intratumoural 
injection in mouse models of prostate cancer (Farokhzad et al., 2006). The targeted 
uptake of these nanoparticles modified with PSMA aptamer into PSMA-expressing 
prostate cancer cells can reduce the side-effects and toxicity of chemotherapy drugs 
such as docetaxel.  
NOX-A12, a Spiegelmer and AS1411 aptamer are the only aptamers in clinical trials 
for cancer treatment (Table 1.1). AS1411 is a 26-mer guanosine-rich DNA 
oligonucleotide (GRO) that can form G-quadruplex structures. G-quadruplex-forming 
sequences have been identified in the genome for example in telomeric repeats and 
promoter regions of some oncogenes in addition to DNA and RNA aptamers (Cogoi 
and Xodo, 2006, Oganesian and Bryan, 2007, Reyes-Reyes et al., 2010, Huang et 
al., 2014). AS1411 (AGRO100) was discovered while several G-rich oligonucleotides 
were being tested in numerous cancer cell lines for anti-proliferative activity (Bates et 
al., 1999). In this study, radiolabelled oligonucleotides were incubated with cancer cell 
extracts, resulting protein complexes were analysed by electrophoretic mobility shift 
assays (EMSAs). One of the protein complexes was hypothesised to be nucleolin due 
to its apparent molecular weight of around ~110 kDa (Bates et al., 1999). Nucleolin 
was later confirmed as the major interacting protein for AS1411 by western blotting 
(using biotinylated aptamer to pull-down interacting proteins thorough streptavidin 
magnetic beads from cell extracts or whole cells) and mass spectrometry 
fingerprinting (Girvan et al., 2006, Teng et al., 2007). Nucleolin is a Bcl-2 mRNA-
binding protein that is overexpressed on the surface of cancer cells. In vitro and in 
vivo studies showed that AS1411 aptamer causes apoptosis in several cancer cell 
lines and a reduction in tumour size, respectively (Mongelard and Bouvet, 2010). The 
induction of apoptosis and the S-phase arrest by AS1411 was shown to be through 
interference with DNA replication and stabilisation of Bcl-2 mRNA (an apoptosis 
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inhibitor), respectively (Ireson and Kelland, 2006, Soundararajan et al., 2008). A 
phase II clinical trial with AS1411 in combination with cytarabine to treat acute myeloid 
leukemia (AML) was completed (Table 1.1); and response rate in patients was found 
to be considerably higher (21%) when compared to the treatment with cytarabine 
alone (5%) (Mongelard and Bouvet, 2010). Another phase II trial with AS1411 was 
performed in metastatic renal cell carcinoma (Table 1.1), however, only 1 out of 35 
patients responded the treatment (Rosenberg et al., 2014). The current status of this 
trial is unknown.  
Recently, AS1411 was utilised for targeted delivery of therapeutic molecules into 
cancer cells overexpressing nucleolin on the cell surface. Targeted delivery of drugs 
and siRNAs was accomplished using liposome-aptamer conjugates in MCF-7 breast 
cancer (Cao et al., 2009) and A375 melanoma cells (Li et al., 2014), respectively. 
Moreover, same aptamer was also used for the labelling of cancer cells. U87MG 
glioblastoma cells was efficiently labelled using cadmium telluride (CdTe) quantum 
dot-AS1411 conjugates (Alibolandi et al., 2014). 
NOX-A12 is a 45-nucleotide L-RNA aptamer or Spiegelmer (section 1.3.3.1), binds 
stromal cell-derived factor-1 (SDF-1) also known as chemokine (C-X-C motif) ligand 
12 (CXCL12) with an affinity of less than 1 nM (Keefe et al., 2010). This aptamer does 
not contain any further modifications apart from being made using L-nucleotides and 
conjugated to a PEG polymer. Inhibition of the chemokine, involved in tissue 
generation, angiogenesis, tumour metastasis and cell homing, by NOX-A12 aptamer 
can be useful to treat some cancers. NOX-A12 is currently in a phase II clinical trial 
for the treatment of multiple myeloma and chronic lymphocytic leukemia (CLL) (Table 
1.1) in combination with bortezomib and dexamethasone; and bendamustine and 
Rituximab, respectively.  
There are several more therapeutic and diagnostic aptamers selected against cancer-
related proteins or biomarkers.  For example, an aptamer (SQ-2) identified by cell-
based selection to specifically recognise pancreatic cancer cells (Dua et al., 2013). 
The target of this aptamer was shown to the alkaline phosphatase placental-like 2 
(ALPPL-2) protein by pull down assays and also genome-wide microarrays (to identify 
target mRNAs in the aptamer transfected or untransfected cells) (Dua et al., 2013). 
Further characterisation of this protein showed tumour-associated functions such as 
inhibiton of cell proliferation and invasion in pancreatic cells (Dua et al., 2013).  
As described above, many aptamers have been identified with anti-tumour activity 
(Figure 1.7). However, there are aptamers used to inhibit virus replication, viral entry, 
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transcription and translation. 2'-fluoro-pyrimidine modified aptamers were selected 
against R5-strain of HIV-1 glycoprotein 120 (gp120), an envelope glycoprotein 
involved in the attachment of HIV to cell surface receptor CD4 (Khati et al., 2003). 
This aptamer competes with highly conserved N-terminus region of HIV co-receptor, 
CCR5 for binding to gp120 and prevents the entry of the virus into helper T-cells (Dey 
et al., 2005a, Dey et al., 2005b), reducing the infectivity of HIV-1 as well as some 
other R5 viruses (Khati et al., 2003) The minimal region of the aptamer involved in 
binding to gp120 were identified by RNAase footprinting analysis (nuclease protection 
mapping) and mutagenesis (Dey et al., 2005a). Although clinical trials were not 
pursued, gp120 aptamer was used for the development of aptamer-siRNA chimeras. 
These chimeras, generated by base-pairing of one strand of a 27-mer anti-tat/rev 
siRNA that is covalently attached to the 3' end of the aptamer to the complemetry 
strand, dual-function to inhibit virus replication (aptamer) and downregulate the 
expression of the target gene (siRNA) (Zhou et al., 2008). Same group was later 
coupled the siRNA and anti-gp120 aptamer through packaging RNA (pRNA), one of 
the components of the bacteriophage phi29 DNA-packaging motor, and used it as 
potential HIV-1 inhibitor as well as a vehicle for cell-type specific delivery of siRNAs 
(Zhou et al., 2011).  
Influenza virus entry was also targeted using DNA aptamers, A22, generated against 
H3 type haemagglutinin (HA) which mediates the attachment of the virus to target 
cells via the sialic acid-containing oligosaccharide receptors (Jeon et al., 2004). A22 
was shown to prevent binding of virus to host cells, therefore reducing virus titres 
(Jeon et al., 2004). However, this aptamer was cross-reacting with H1N1, H3N2 and 
H2N2 strains. Subtype specific RNA aptamers were generated against influenza virus 
H3N3 HA (Gopinath et al., 2006). These aptamers were shown to recognise the target 
virus, A/Panama/2007/99 and also A/Wyoming/3/2003 by surface plasmon resonance 
(SPR) analysis at 20 and 50 nM, concentrations, however fail to bind other closely 
related H3 strains even at higher concentrations (500 nM). Moreover, the selected 
aptamer showed higher binding affinity to HA (15-fold) than currently available 
monoclonal antibodies. These studies showed the possibility of using aptamers as 
biosensors for rapid genotyping of influenza virus strains and also for the development 
of diagnostic tools for influenza infection.  
Aptamers can interfere with the assembly of the viral nucleocapsid (NC). An aptamer 
generated against HIV NC inhibited the proper packaging of the viral genome by 
competing with the HIV-1 packaging signal, psi sequence (Kim et al., 2002). Another 
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NC aptamer against HIV-1 Gag protein reduced the replication of HIV in cells by 
downregulating the Gag protein or mRNA (Ramalingam et al., 2011).  
Viral polymerases are some of the earliest targets for aptamer selection. HIV reverse 
transcriptase (RT) produces double stranded DNA (dsDNA) from single stranded 
RNA genome (ssRNA). RNA aptamers were identified against HIV-RT, inhibiting 
cDNA synthesis (Tuerk et al., 1992). These aptamers were only effective against RT 
of HIV but no other retroviruses. HIV RT is a heterodimeric and multifunctional 
enzyme with an RNase H activity, mediating the cleavage of replication intermediates, 
DNA/RNA hybrids. Therefore, its RNAse activity was also targeted with aptamers 
(Andreola et al., 2001). Some of these selected aptamers, with G-quadruplex 
structures, were shown to inhibit both RNase H and DNA polymerase activities, 
therefore HIV infection with an IC50 values of 10 nM in a tat transactivation reporter 
assay when applied on the cells without transfection. Another virus polymerase to be 
a target for aptamer studies was RNA-dependent RNA polymerase (RdRp) of 
hepatitis C virus (HCV), non-structural protein 5B (NS5B). Both DNA and RNA 
aptamers were generated against NS5B, inhibiting its polymerase activity (Bellecave 
et al., 2008, Biroccio et al., 2002). The RNA aptamer, B.2 was shown to bind to NS5B 
with a Kd value of 1.5±0.2 nM by filter-binding assays (Biroccio et al., 2002). The use 
of point mutagenesis of deletion mutants of the aptamer indicated the requirement of 
a GC bulge and a stem loop for aptamer binding to NS5B (Biroccio et al., 2002). 
Aptamers were also identified against the RdRp of FMDV termed, 3Dpol as introduced 
above (Ellingham et al., 2006). Some of these aptamers, 47tr and 52tr, with 2'-fluoro 
Cy3 modifications were recently shown to inhibit the replication of FMDV sub-genomic 
replicon, monitoring green fluorescent protein (GFP) reporter expression over time 
(Forrest et al., 2014). Same study also showed that aptamers had an effect on 
replication but not translation (through binding to 5' untranslated region, UTR) by 
luciferase reporter assays using reporter genes under the control of either cap- or 
IRES dependent translation. IRES is an internal ribosome entry site located in the 5' 
UTR of the mRNA. This structured region mediates the attachment to the ribosome 
and initiates the cap-independent (IRES-dependent) translation. There are aptamers 
targeting IRES such as HCV anti-IRES aptamers inhibiting IRES-dependent 
translation (Kikuchi et al., 2005). These aptamers have a potential therapeutic value 
with reduced side effects. Since, aptamers recognises the secondary structures in the 
viral mRNA which does not exist in the host mRNA. These anti-IRES aptamers are 
also modified with conjugation to other aptamers targeting different regions in the 
IRES in order to enhance the inhibitory activities of aptamers (Kikuchi et al., 2009). 
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1.3.5.1 Aptamers against HPV proteins 
There are few studies explained the identification and characterisation of aptamers 
against HPV proteins. High level expression of high-risk HPV E6 and E7 oncoproteins 
in cervical cancer tumours led to the development of aptamers for potential diagnostic 
and therapeutic applications (Belyaeva et al., 2014, Gourronc et al., 2013, Graham 
and Zarbl, 2012, Nicol et al., 2011, Nicol et al., 2013, Toscano-Garibay et al., 2011). 
HPV16 E7 aptamers described by (Toscano-Garibay et al., 2011) was shown, using 
deletion mutants of E7, to bind first on the N-terminus CR1 and then CR3 in a two-
step mechanism through a stem-loop structure on the aptamer. However, these 
aptamers were not tested in terms of their function and effects in cells or in vivo. 
However, an HPV16 E7 aptamer used in this study, possibly binding the LXCXE motif 
in the CR2 of E7 where pRb binding occurs, was shown to induce apoptosis in HPV 
positive cervical cancer cells (Nicol et al., 2013). This was suggested to probably be 
due to the loss of E7 and accompanying recovery of pRb following aptamer 
transfection. Another study described aptamers against HPV L1 virus-like particles 
produced in a baculovirus expression system (Leija-Montoya et al., 2014). HPV L1 
aptamers may help the development of an effective diagnostic tool for the diagnosis 
of the HPV infection. There are examples of aptamers that can be used for early 
detection of virus infected cells. For example, a fluorescently labelled aptamer HBs-
A22, selected against the Hepatitis B virus (HBV) surface antigen (HBsAg) which 
locates on the cell surface of HBV-infected hepatocytes, was used to discriminate 
HBsAg positive cells (HepG2.2.15) from HBsAg negative cells (HepG2) by 
fluorescence microscopy (Liu et al., 2010).  
In the work described here, HPV16 E7 aptamers were used for further 
characterisation. These aptamers were selected using GST-E7 by SELEX. Negative 
selection was performed to eliminate GST-binding aptamers (Nicol et al., 2011). 
Negative selection against closely related targets or affinity tags can both reduce 
cross-reactivity and increase target specificity. RNA aptamers synthesised by in vitro 
transcription using 2'-Fluoro modified (CTP and UTP) and unmodified (GTP and ATP) 
nucleotides by a mutant T7 RNA polymerase in an “optimised” reaction conditions. A 
mutation (Y639F) in T7 RNA polymerase was identified to cause an approximately 
20- fold decrease in the ability of enzyme to discriminate between rNTPs and dNTPs, 
retaining its wild type activity (Padilla and Sousa, 1999).  
The sequence alignment using ClustalW2 multiple sequence alignment tool (EMBL-
EBI) of identified monoclonal HPV16 E7 aptamers after 10 rounds of SELEX was 
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published previously (Nicol et al., 2011). While some of these aptamers were grouped 
into families i.e. A, B, C, D and E, some others were outliers F1, G1, H1, I1 and J1. 
Apparent binding affinities (KDapp) of HPV16 E7 aptamers were determined as the 
concentration of GST-E7 at which 50% binding by aptamer was observed by a bead-
binding assay through scintillation counting (Nicol et al., 2011). Values for A-series 
aptamers were also published (Nicol et al., 2011). After 10 rounds of SELEX process, 
the KDapp for the naïve pool was shown to be decreased from 333 nM to 58 nM. 
Amongst A-series aptamers, A3 (KDapp = 251 nM) differs from A2 (KDapp = 107 nM) by 
1 nucleotide and from A1 (KDapp = 87 nM) by 2 nucleotide deletions. These few 
nucleotide changes were shown to affect binding affinities of aptamers as indicated 
in brackets, above. A-series aptamers especially A2 were the focus for this study.  
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1.4 Aims of the project 
One of the aims of this project was to characterise previously selected aptamers to 
HPV16 E7. These aptamers were used to analyse their effects on the steady state 
levels of E7 and also in the induction of apoptosis in HPV positive cells. There were 
several questions. Are these aptamers cross-reacting with E7 from other HPV types? 
Does the 5' triphosphate group of the aptamer trigger an interferon response and if 
so, could this be partly responsible for the induction of apoptosis in cervical cancer 
cells?  
If E7 is lost from the cells after aptamer treatment, is this degraded? If so, how does 
E7 degradation occur? Was this through general protein degradation pathways or 
were there some other mechanisms also involved?  
Did aptamer transfection alter the localisation of E7 in cells? 
For an aptamer to be used as a therapeutic reagent, an efficient delivery system 
needs to be generated. For this, several questions were asked. Can we deliver 
aptamers into cells without the need for transfection? If so, can we block this by using 
endocytosis inhibitors? Can we analyse the efficiency of the uptake? Do the 
molecules enter cells through passive or active internalisation? Which endosomal 
compartments do aptamers localise? Can we use alternative delivery methods such 
as nanoparticles to introduce aptamers into cells? 
The outcome of this study should therefore aid to the further characterisation of 
HPV16 E7 aptamers and also to understand internalisation and localisation of 
aptamers in cells.  
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 MATERIALS AND METHODS 
2.1 General Buffers, Media and Reagents 
2.1.1 Luria-Bertani (LB) broth 
10 g NaCl 
10 g Tryptone 
5 g Yeast extract 
1 L dH2O 
For LB agar, add 1 g Bactoagar 
2.1.2 10xTBE (Tris-borate-EDTA) buffer pH 8.3 
100 g Tris base 
55 g Boric acid 
9.3 g Na4EDTA 
1L dH2O 
For 1x TBE buffer, dilute 100 ml in 1L dH2O 
2.1.3 6x DNA loading buffer 
0.03% bromophenol blue 
0.03% xylene cyanol FF 
30% glycerol 
10 mM Tris-HCL (pH 7.5) 
50 mM EDTA (pH 8.0) 
2.1.4 Protein extraction buffer 
20 mM Tris-HCl (pH 7.5) 
250 mM NaCl 
0.5% Nonidet P40 (NP40) 
2.1.5 SDS-PAGE resolving gel 
0.4 M Tris-HCl (pH 8.8) 
8, 10, 12 or 15% 29:1 Acrylamide: bisacrylamide 
10% SDS 
10% Ammonium persulphate (APS) 
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1% NNNN-tetramethyl-ethane-1, 2-diamine (TEMED) 
2.1.6 SDS-PAGE stacking gel 
0.2 mM Tris-HCl (pH 6.8) 
5% 29:1 Acrylamide: bisacrylamide 
10% SDS 
10% APS 
1% TEMED 
2.1.7 Laemmli SDS-PAGE loading buffer 
4% SDS 
20% glycerol 
10% 2-mercaptoethanol 
0.004% bromphenol blue 
25 mM Tris-HCl (pH 6.8) 
2.1.8 10x SDS-PAGE running buffer 
10 g SDS 
30.3 g Tris-HCl 
144.1 g Glycine 
1L dH2O 
For 1x SDS-PAGE running buffer, dilute 100 ml in 1L dH2O 
2.1.9 Coomassie blue protein stain 
2.5 g Coomassie brilliant blue 
300 ml methanol 
100 ml acetic acid 
400 ml dH20 
Mix and adjust to 1L with dH2O 
2.1.10  Coomassie destain solution 
300 ml methanol 
100 ml acetic acid 
400 ml dH20 
Mix and adjust to 1L with dH2O 
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2.1.11  10x PBS 
1.4 M NaCl 
27 mM KCl 
100 mM Na2HPO4 
18 mM KH2PO4 
For 1 x PBS, dilute 100 ml in 1L dH2O 
2.1.12 TE buffer 
10 mM Tris-HCl (pH 7.5) 
1 mM Ethylenediamine tetra-acetic acid (EDTA) 
2.1.13 Eukaryotic cell growth medium 
Dulbecco`s Modified Eagle`s Medium (DMEM) 
10% (v/v) Foetal bovine serum 
100 units/ml penicillin 
0.1 mg/ml streptomycin 
1% (w/v) glutamine 
2.1.14 Propidium iodide (PI) stain 
50 µg/ml PI 
50 units/ml RNase A 
Diluted in PBS 
2.1.15 10 x Annexin V buffer 
100 mM HEPES (pH 7.4) 
1.4 M NaCl 
25 mM CaCl2 
For 1x Annexin V buffer, dilute 1 ml in 10 ml dH2O 
2.1.16  Radio-immunoprecipitation assay (RIPA) buffer 
50 mM Tris-HCl (pH 8.0) 
150 mM NaCl 
1% (v/v) Nonidet P-40 
0.5% (w/v) Sodium deoxycholate 
0.1% (w/v) SDS 
51 
 
2.1.17  10x Transfer buffer 
30.3 g Tris-base 
144.1 g Glycine 
1L dH2O 
For 1 x transfer buffer, dilute 100 ml in 200 ml methanol and 700 ml dH2O 
2.1.18  10x TBS-T 
500 mM Tris-HCl (pH 7.5) 
1.5 M NaCl 
1% (v/v) Tween-20 
For 1x TBS-T, dilute 100 ml in 1L dH2O 
2.1.19  Chemiluminescence reagent 
Solution 1: 
2.5 mM luminol 
400 µM p-coumaric acid 
100 mM Tris-HCl (pH 8.5) 
Solution 2: 
0.018% (v/v) H2O2 
100 mM Tris-HCl (pH 8.5) 
Immediately prior to use, mix solution 1 and 2 in a 1:1 ratio 
2.1.20  10x T7 RNA polymerase buffer 
10 x Tris-acetate buffer 
400 mM Tris-acetate 
10 mM EDTA 
100 mM MgAc 
5 mM MnCl2 
Titrate with 5M NaOH to pH 8.0 
Sterilise by autoclaving 
To make 10 x T7 polymerase buffer, take 100 ml of 10 x Tris-acetate buffer and add 
80 mM spermidine. 
Titrate again with 5 M NaOH to pH 8.0 
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Filter sterilise and keep at -20°C 
2.1.21  Acidic wash buffer 
0.2 M Glycine 
0.15 M NaCl 
Adjust to pH 3.0 with HCl 
2.2 Oligonucleotides 
Cy3 – Apt21-2 (2' F-U and C)  
5' Cy3 – GGUCUAGCCGGAGGAGUCAGUAAUCGGUAGACC – 3' 
 
Cy5 – Apt21-2 – Cy3 (2' F-U and C)  
5' Cy5 – GGUCUAGCCGGAGGAGUCAGUAAUCGGUAGACC – Cy3 3' 
 
Cy3 – 47tr (2' F-C) 
5' Cy3 – GGGUUAACAGAAAACCUCAGUUGCUGGGUUGU – 3' 
 
Control aptamer SF1 template DNA sequence: 
5' – GGGAATGGATCCACATCTACGAATTCGGCTCAAAAATACGTCCGC 
ACCATACATTCACTGCAGACTTGACGAAGCTT – 3' 
 
HPV16 E7 aptamer template DNA sequences: 
A1: 
5' – GGGAATGGATCCACATCTACGAATTCCCTTCATTAACCCGTCCACGC 
GCTTCACTGCAGACTTGACGAAGCTT – 3' 
A2: 
5' – GGGAATGGATCCACATCTACGAATCCCTTCATTAACCCGTCCACGC 
GCTTCACTGCAGACTTGACGAAGCTT – 3' 
A3: 
5' – GGGAATGGATCCACATCTACGAATCCTTCATTAACCCGTCCACGC 
GCTTCACTGCAGACTTGACGAAGCTT – 3' 
J1: 
5' – GGGAATGGATCCACATCTACGAATCACGTTGAGGCCGTCGGGCTG 
TTCGGAGCACCCTTCACTGCAGACTTGACAGAAGCTT – 3' 
 
 
HPV18 E7 forward primer 
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5' – TATATAGGATCCATGCATGGACCTAAGGC – 3'   
HPV18 E7 reverse primer 
5' – TATATAGAATTCTTACTGCTGGGATGC – 3' 
 
HPV11 E7 forward primer 
5' – TATATAGGATCCATGCATGGAAGAC – 3' 
HPV11 E7 reverse primer 
5' – TATATAGAATTCTGGTTTTGGTGCGC – 3' 
 
pGEX sequencing primers: 
pGEX5' (Forward) 
5' – GGGCTGGCAAGCCACGTTTGGTG – 3' 
pGEX3' (Reverse) 
5' – CCGGGAGCTGCATGTGTCAGAGG – 3' 
 
Aptamer template primers: 
N30P1 (Forward)    
5' – TGATAATACGACTCACTATAGGGAATGGATCCACATCTACGAAT – 3′ 
N30P2 (Reverse) 
5' – AAGCTTCGTCAAGTCTGCAGTGAA – 3' 
U6 qPCR primer sequences 
Forward (5' – 3') CTCGCTTCGGCAGCACA  
Reverse (5' – 3') GCAAATTCGTGAAGCGTT 
2.3 Antibodies 
Mouse monoclonal HPV16 anti-E7; clone NM2, Santa Cruz Biotechnology, Inc., USA 
(1:200) 
Mouse monoclonal HPV16 anti-E7; clone 289-17013, AbCam, UK (1:2000) 
Mouse monoclonal HPV18 anti-E7; clone 8E2, AbCam, UK (1:2000) 
Rabbit anti-GAPDH, Sigma-Aldrich, USA (1:6000) 
Mouse monoclonal anti-pRb, clone 1F8, AbCam, UK (1:2000) 
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Rabbit polyclonal anti-pRb, Clone Ab-2, Calbiochem, Merck Millipore, USA (1:1000) 
Mouse monoclonal anti-Rb2, clone 10/Rb2, BD Biosciences, USA (1:1000) 
Alexaluor 568 F (ab`) 2 fraqment of goat anti-mouse IgG (H+L), Invitrogen (Life 
Technologies), UK (1:500) 
Alexafluor 488 chicken anti-mouse IgG (H+L), Invitrogen (Life Technologies), UK 
(1:500) 
Alexafluor 488 goat anti-rabbit IgG (H+L), Invitrogen (Life Technologies), UK (1:500) 
Alexafluor 488 donkey anti-goat IgG (H+L), Invitrogen (Life Technologies), UK (1:500) 
Rabbit polyclonal anti-EEA1, Millipore, USA (1:500) 
Rabbit polyclonal anti-LAMP-1 (CD107a), Millipore, USA (1:500) 
Sheep anti-TGN46 (1/500), a gift from Dr Vas Ponnambalam, University of Leeds, 
Leeds, UK 
Donkey anti-sheep 488, Invitrogen (Life Technologies), UK (1:500) 
Goat anti-mouse IgG peroxidase conjugate, Sigma, USA (1:2000) 
Goat anti- rabbit IgG peroxidase, Sigma, USA (1:1000) 
Mouse monoclonal acetylated anti-tubulin (6-11B-1), Sigma-Aldrich, USA (1:500) 
Mouse purified anti-GST, BioLegend, Inc., USA (1:1000) 
Rabbit monoclonal anti-calreticulin (D3E6), Cell Signalling, USA (1:200) 
Rabbit polyclonal anti-LC3, (1:2000) was provided by Prof Mark Harris, University of 
Leeds, Leeds, UK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
2.4 Enzymes 
Terminal deoxynucleoside transferase, stored at – 20°C (New England Biolabs 
(NEB), USA)  
Yeast inorganic pyrophosphatase, stored at – 20°C (YIP, Sigma Aldrich, USA) 
T7 RNA polymerase (Y639F), stored at – 20°C (Padilla and Sousa, 1999) (a kind gift 
from Dr David Bunka, University of Leeds) 
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RNaseOut, stored at – 20°C (Invitrogen [Life Technologies], UK)  
pfu DNA polymerase, stored at – 20°C (Promega, USA) 
Taq DNA polymerase, stored at – 20°C (New England Biolabs, USA) 
DNase, stored at – 20°C (Promega, USA) 
DNase I, stored at – 20°C (Thermo Scientific, USA) 
2.5 Cell lines 
SiHa (ATCC No. HTB-35), derived from a human squamous cell carcinoma of the 
cervix, contains 1 copy of the HPV16 genome integrated into chromosome 13 (Baker 
et al., 1987, el Awady et al., 1987). 
 
CaSki (ATCC No. CRL-1550), derived from a human epidermoid carcinoma of the 
cervix, contains approximately 600 copies of the HPV16 genome arranged as tandem 
repeats distributed across 11 chromosomes (Baker et al., 1987, Mincheva et al., 
1987). 
 
HaCaT, spontaneously immortalised human keratinocyte cell line (Boukamp et al., 
1988). 
 
HaCaT HPV16 and HPV18 E6/E7 expressing stable cell lines were generated by Kat 
Richards (University of Leeds, Leeds, UK) (Richards et al., 2014). 
 
HeLa (ATCC No. CCL-2), derived from a human adenocarcinoma of the cervix, 
contains approximately 10-50 copies of HPV18 genome (Scherer et al., 1953). 
 
C33A (ATCC No. HTB-31), derived from a human epidermoid carcinoma of the cervix, 
expresses abnormal size retinoblastoma protein (pRb) and elevated levels of p53 with 
a point mutation at codon 273 resulting in an Arg to Cys substitution. These cells are 
negative for HPV DNA (Yee et al., 1985).  
 
HEK293T (CTCC no. CRL-3216) (formerly known as 293tsA1609neo), a derivative of 
human embryonic kidney 293 cells. It contains the SV40 T-antigen and is highly 
transfectable. 
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SaOS-2(ATCC No. HTB-85), derived from primary osteosarcoma (Fogh et al., 1977, 
Rodan et al., 1987).  
2.6 Electrophoresis methods 
2.6.1 Agarose gel electrophoresis  
DNA samples were mixed with 6 x DNA loading buffer (Promega, USA) and resolved 
by using agarose gels with the concentrations of 0.8 (≥1kb DNA) – 2 (≤300bp DNA)% 
(w/v) depending on the sizes of DNA fragments. 1 x TBE buffer and 1xSYBR safe 
(Invitrogen, Life Technologies) were used as running buffer and DNA stain, 
respectively.  Current was applied to electrophoresis unit at 8 – 10 V/cm for 45 min 
until the blue dye reaches the bottom of the gel. DNA was visualised under UV light 
using a GeneDoc system (Syngene). 
2.6.2 RNA gel electrophoresis 
RNA samples were electrophoresed using 12% (w/v) 19:1 acrylamide/bis-acrylamide 
gel containing 7M urea in 1X TBE (Severn Biotech, UK). RNA samples and marker 
(RiboRuler, Fermentas, Thermo Fisher Scientific, USA) were denatured in RNA 
loading buffer containing 95% (v/v) formamide, 0.025% (w/v) SDS, 0.025% (w/v) 
bromophenol blue, 0.025% (w/v) xylene cyanol FF, 0.025% (w/v) ethidium bromide 
and 0.5 mM EDTA (Fermentas,Thermo Fisher Scientific) at 95° C for 10 min. Gel was 
preheated at 12 W for at least 30 min before loading the samples. Electrophoresis 
was performed at 10 W for between 30-45 min. Gel was stained in 1 x SYBR safe/TBE 
for 15 min to allow visualisation of RNA.  
2.6.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were analysed on 8, 10, 12 or 15% (w/v) 29:1 acrylamide/bisacrylamide gels 
(Severn Biotech, UK) containing 375 mM Tris (pH 8.8) and 0.1% (w/v) SDS with a 5% 
(w/v) acrylamide stacking layer containing 187.5 mM Tris (pH 6.8) and 0.1% (w/v) 
SDS. Samples were denatured by incubation in Laemmli SDS-PAGE loading buffer 
(Sigma, USA) at 95°C for 5 min.  Electrophoresis was performed in 1 x SDS-PAGE 
running buffer at 150-200 V.  Proteins were visualized by staining in InstantBlue 
(Expedeon, Inc., USA) or Coomasie blue stain for 15 min – 1 h.  
2.6.4 Western blotting 
SDS-PAGE gels were soaked in 1 x ice-cold transfer buffer for 5 min before assembly 
in a vertical rig for transfer to nitrocellulose membrane (Whatman) or PVDF (Millipore, 
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USA).  Vertical electrophoretic transfer was performed at 30 V at room temperature 
for 1.5-2 hrs.  Membranes were washed in 1 x TBS-T and blocked in 5% (w/v) 
milk/TBS-T for at least 1 h prior to incubation with primary antibodies diluted in 5% 
(w/v) milk/TBS-T overnight at 4°C.  Membranes were washed for 4 x 15 min in 1 x 
TBST prior to incubation with secondary antibodies diluted in 5% (w/v) milk/TBS-T for 
1 h at room temperature.  Membranes were again washed for 4 x 15 min in 1 x TBS-
T. Membranes were incubated with ECL (Thermo Scientific, USA) for 1 min and 
exposed to X-ray films (Hyperfilm ECL, GE Healthcare, USA) and developed manually 
or automatically (Konica film processor, Srx-101A). Densitometry analysis of western 
blots was perfomed using Aida image analyser software (Raytest) and levels of 
protein expressions were normalised against the level of housekeeping protein 
GAPDH.  
2.7 Preparation of plasmid DNA 
The HPV16 E7 open reading frame (ORF) had previously been cloned from a plasmid 
containing the HPV16 ORFs, pEF3.99 (obtained from Dr P. Lambert, University of 
Wisconsin-Madison, GenBank Accession Number AF125673) into the BamHI and 
EcoRI restriction sites of pGEX-2T expression vector (GE Healthcare, USA).  
Resulting pGEX-2T-E7 plasmid was transformed into E. coli (DH5α) and (BL21) 
(Invitrogen, Life Technologies, UK) cells and sequence analysis was performed using 
the pGEX 5' and 3' standard sequencing primers. Sequencing analysis was performed 
by DNA sequencing unit of Beckman Coultier Genomics. PCR amplification of HPV 
11 and 18 E7 fragments were performed from pBabepuro constructs containing whole 
HPV11 or 18 genomes (kindly provided by Dr Andrew Macdonald, University of 
Leeds, Leeds). HPV11 and 18E7 were amplified from these plasmid templates using 
specific primers by Pfu DNA polymerase (NEB, USA).  pGEX-6P-1 plasmid were 
double digested with EcoRI (NEB, USA) and BamHI (NEB, USA) restriction enzymes 
at 37°C for 2 h. PCR products and linearised vector were analysed on agarose gels 
and gel purification was performed to recover the DNA. Ligation reaction was 
performed 3:1 vector: insert molar ratios using T4 DNA ligase 1 h at room 
temperature.  E. coli DH5α cells were transformed with ligation reactions and spread 
on LB/amp (100 µg/ml ampicillin) plates. Following overnight incubation at 37°C, 
several colonies were picked to perform colony PCR and diagnostic digestion. 
Positive clones were sent for sequencing to confirm the presence of inserts. 
Sequencing primers were pGEX 5' and 3' (section 2.2). 
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2.8 Transformation of competent cells 
Stocks of transformation competent E. Coli DH5a were produced using calcium 
chloride (CaCl2) in the lab (by research technicians; Susan Matthews and Rajni 
Bhardwaj). Transformation of plasmid DNA into E. coli DH5α was performed using 
heat shock method. 650 µl LB was added onto the transformants and incubated at 
37°C with shaking. Serial dilutions (50 µl, 100 µl and 200 µl) were spread onto LB/Amp 
plates (100 µg/ml ampicillin) and plates were left overnight at 37°C. A colony was 
picked from plates and inoculated into LB/amp broth (100 µg/ml ampicillin) to grow 
overnight. Next day, glycerol stocks of BL21 (DE3)-pGEX-2T-16E7, pGEX-6P-1-11E7 
and pGEX-6P-1-18E7 were prepared by mixing equal volumes of 80% glycerol and 
cell suspension, and stored at – 70°C. 
2.9 Recombinant protein expression 
2.9.1  Expression in E. coli BL21 (DE3) cells 
pGEX-2T-16E7, pGEX-6P-1-11 and pGEX-6P-1-18E7 transformed E. coli BL21 
(DE3) from glycerol stocks were inoculated into 20 ml LB broth supplemented with 
100 µg/ml ampicillin and incubated with shaking at 37°C overnight. 5 ml of this starter 
culture was used to inoculate 500 ml LB broth supplemented with 100 µg/ml ampicillin 
and incubated with shaking at 37°C until OD600 reached 0.6 – 0.7. GST-11E7, GST-
16E7 and GST-18E7 expressions were induced by the addition of 1mM isopropyl β-
D-1-thiogalactopyranoside (IPTG) (Fisher Scientific, USA) overnight at 16°C, 3 hrs at 
37°C and 6 hrs at 30°C, respectively. Cells were pelleted by centrifugation at 18,600 
x g (Avanti® J-26xp centrifuge), 4°C for 20 min and re-suspended in 20 ml protein 
extraction buffer containing 1 mg/ml lysozyme (Calbiochem [Merck Millipore], USA) 
and 5 µg/ml DNase I (Thermo Scientific, UK, stored at – 20°C). Cells were lysed on 
ice by sonication for 6 x 20 seconds with 30 seconds intervals (Soniprep 150, Sanyo). 
The soluble protein fraction was obtained by centrifugation at 16,100 x g at 4°C for 2 
min (Centrifuge 5415 R, Eppendorf). A 20 µl aliquot of the soluble fraction and 2 ml 
pellet (as insoluble fraction) was reserved for SDS-PAGE analysis. 
2.9.2  Purification of GST-E7 via a glutathione sepharose column 
A few millilitres of Glutathione sepharose 4b (GE Healthcare, USA) was placed into a 
column followed by a wash with 1 x PBS. Supernatant of the cell lysate obtained by 
centrifugation after sonication was filtered using 0.22 µm filters and applied to the 
glutathione column. Column was then washed with 0.5% Triton X-100/PBS. Proteins 
were eluted from glutathione beads with 50 mM reduced glutathione, pH 8.0. Proteins 
59 
 
in the flow through, wash and elution fractions were analysed by SDS-PAGE. Protein 
samples might be stored in 10% glycerol at – 20°C.  
2.9.3  Buffer exchange by dialysis of protein  
Appropriate length of dialysis membrane (Spectrum Laboratories, Inc., UK) with a 
molecular weight cut-off (MWCO) of 6-8 kDa was left in the dialysis buffer (e.g. 1 x 
phosphate buffered saline) for 10 – 15 min. Elution fractions was collected in the 
membrane and stirred in the dialysis buffer overnight at 4°C. PBS buffer was changed 
twice in order to remove the elution buffer from protein solution.  
2.9.4  Binding of GST-E7 protein to glutathione sepharose beads 
To bind GST-E7 to glutathione sepharose (GE Healthcare, USA) beads, sepharose 
first washed with 1 x PBS three times. Dialysed protein was then mixed with 
glutathione sepharose and incubated for 1 hour at 4°C on a mixing platform. 
Glutathione sepharose beads were recovered via centrifugation, supernatant was 
also used for SDS-PAGE analysis. Beads were then washed with 1 x PBS, washes 
were also used for SDS-PAGE analysis.  
2.10  Methods used in cell culture 
2.10.1 Maintenance of the cell culture  
Maintenance of HEK293T, SaOS-2, CaSki, HeLa, C33A and HaCat cells was 
managed in DMEM containing 1% L-glutamine (GE Healthcare, USA) supplemented 
with 10% foetal bovine serum (FBS) (PAA, Austria), 100 units/ml penicillin (Lonza, 
Slough, UK), 0.1 mg/ ml streptomycin (Lonza, Slough UK) in T-25 flasks. Cells were 
observed using a light microscope. Cell passages were performed every 3 – 4 days 
before they became 80 – 90% confluent. Old medium was removed from the flask 
and the cells were washed with 1 x PBS before addition of 2 x Trypsin. When cells 
were detached from the surface of the flask, they were transferred into sterile falcon 
tubes. 1/10th of the cell suspension were transferred back into the flask to maintain 
the cell culture. Growth medium (maximum 15 ml for T-25 flasks) was added onto 
cells. Flasks were then placed in the horizontal position in the humidified incubator 
(37°C; 5% CO2). HaCat stable cells expressing HPV 16 and HPV 18 E7 (provided by 
Dr Kat Richards, University of Leeds, Leeds) were maintained as described above 
with the addition of 0.5 µg/ml puromycin. Generally, 0.4 x 106 cells/well were seeded 
in 6-well plates 24-hour prior to transfection to be used in experiments. Cells were 
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counted using a Neubauer hemocytometer (Assistant, Germany). Tryptan blue 
solution (0.4 %) (Sigma, USA) was used to screen out dead cells.  
2.10.2  Culture of primary keratinocytes  
Human primary keratinocytes (HPK) were cultured in Keratinocyte Growth Media 
(KGM) Kit II (PromoCell, Heidelberg, Germany). Culture medium was changed every 
second to third day. On stimulation keratinocytes were placed in Keratinocyte Growth 
Media with all supplements apart from epidermal growth factor and hydrocortisone. 
When the HPK cells reached 60-70% confluency the cells were passaged. Cells were 
washed with sterile phosphate buffered saline (PBS) (Gibco, Life technologies, UK) 
and then EDTA (Versen) 1% (Pan Biotech, Germany) for 2 min at 37°C, 5% CO2. 
Trypsin (170.000U/L)-EDTA (200mg/ml) (Lonza, Slough, UK) was added and placed 
in the incubator for 2 minutes at 37°C, 5% CO2. An equal amount of trypsin 
neutralising solution (Lonza, Slough, UK) was added to the trypsinised cells in order 
to neutralise the enzyme. The cells were then centrifuged at 230 x g and then re-
seeded. Cells were cultured at 37°C with 5% CO2.  
2.10.3  Bringing up frozen cells 
A vial of cells from liquid nitrogen or – 70°C freezer was removed and thawed quickly 
in a water bath. Cells were then mixed with 5 ml DMEM (GE Healtcare, USA) and 
centrifuge in order to remove DMSO (Sigma, USA). Pellet was re-suspended in 
appropriate amount of media and placed in a T-25 flask in a total volume of 5 ml 
growth medium. Flask was maintained in a CO2 cabinet at 37°C. Media was changed 
in 24 hours with the fresh medium. 
2.10.4  Preparation of freezer stocks  
Cells were collected from the flask and transferred into a 15 ml falcon tube. The falcon 
tube was then centrifuged at 230 x g for 5 min to pellet the cells.  Media was removed 
and cells were re-suspended in 1 ml of freezing mixture (10% DMSO, 90% FBS). 
Cells were frozen gradually with 1°C per minute in isopropanol at – 70°C.  
2.10.5  Transfection of cells  
2.10.5.1 Polyethylenimine (PEI) transfection 
2 – 3 µg of plasmids was diluted in 200 µl of serum-free media (DMEM, GE Healtcare, 
USA) and mixed by vortexing. 10 µl of PEI (1 µg/µl) reagent was added to plasmid 
suspension, and incubated at room temperature for 10 – 15 min. PEI-plasmid mixture 
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was applied onto HEK293T cells in a drop wise manner and cells were allowed to 
express proteins in the humidified CO2 incubator at 37°C for 24 hrs.  
2.10.5.2 Introducing aptamers into cells by Oligofectamine 
Cells were transfected with aptamers to a final RNA concentration of 100 nM using 
Oligofectamine (Invitrogen, Life Technologies, UK). 3 µl of Oligofectamine and 12 µl 
of serum-free medium (DMEM, GE Healtcare, USA) were mixed and incubated at 
room temperature for 5 min. 100 nM of RNA was diluted in 185 µl serum free DMEM. 
Oligofectamine (15 µl) and RNA diluents (185 µl) were mixed and incubated for 20 
min at room temperature. Meantime, cells were removed from the incubator, old 
medium was aspirated and they were washed with 1 x PBS. 800 µl of serum free 
DMEM was added onto 70% confluent cells. Oligofectamine – RNA mixture was then 
added onto cells in a drop wise manner and plates were placed in the humidified CO2 
incubator (37°C) for 4 hrs. When this period is over, cells were returned to 10% serum-
media by adding 500 µl of 30% FBS/DMEM, and left to grow overnight. 
2.10.5.3  Introducing aptamers into cell by HappyFect (Nanocin)TM 
Cells were transfected with aptamers to a final RNA concentration of 100 nM using 
HappyFectTM (Nanocin) (Tecrea, UK). Aptamer was diluted in 50 µl serum-free media 
(DMEM, GE Healthcare). 4 µl of nanocin was added into the aptamer mixture and 
incubated for 15 min at room temperature. Meantime, cells were removed from 
incubator, old medium was aspirated and cells were washed with 1 x PBS. 450 µl of 
serum free DMEM was added onto 70% confluent cells in a 12-well plate. HappyFect 
– RNA mixture was then added onto cells in a drop wise manner and plates were 
placed in the humidified CO2 incubator (37°C) for 4 hours. When this period is over, 
cells were returned to 10% serum-media by adding 250 µl of 30% FBS/DMEM, and 
left to grow overnight. 
2.10.6  Collection of cells and protein extraction 
Media was removed into 15 ml tubes and cells were collected after 2 x trypsin 
treatment for 5 – 10 min. Tubes were centrifuged to obtain the pellet.  Cells were 
washed with 1 x PBS and transferred into 1.5 ml Eppendorf tubes. Cell suspension 
was then centrifuged again in the chilled centrifuge at 4°C at 16,100 x g for 2 min. Cell 
pellet was re-suspended in appropriate volume of RIPA buffer containing EDTA free 
protease inhibitor tablet (Roche, Penzberg, Germany) (1 tablet for 10 ml buffer), 
DNase (5 µg/ ml) and 10 mM MgCl2, and incubated on ice for 30 min, vortexing every 
10 min. Protein sample was mixed with 2 x Laemmli buffer and boiled to denature at 
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95°C for 5 min. Protein samples were loaded in the SDS-acrylamide gel for separation 
after 1 min centrifugation at 16,100 x g.  
2.11  Generation and labelling of 2’-fluoro-modified RNA 
molecules 
A library for templates of RNA aptamers selected against GST-E7 is available (Nicol 
et al., 2011). Sequences of some of the aptamers are listed in Section 2.2.  
2.11.1  PCR amplification of DNA template for in in vitro transcription 
DNA template below which harbours a T7 recognition site at the 5' – end was utilized 
to generate RNA aptamers by in vitro transcription. T7 enzyme recognises the 
sequence below underlined in order to initiate RNA synthesis starting from 
nucleotides, GGG. N30 region is specific to each aptamer molecules while constant 
region is shared between different aptamers to enable primer binding to initiate the 
PCR amplification.   
 
 
Amplification of double stranded DNA template was achieved using N30P1 (Forward) 
and N30P2 (Reverse) primers. Pfu DNA polymerase (2.5 U) (Promega, USA) and 10 
x Pfu DNA polymerase buffer (Promega, USA) [200mM Tris-HCl (pH 8.8), 100mM 
KCl, 100mM (NH4)2SO4, 20mM MgSO4, 1mg/ml nuclease-free BSA and 1% Triton® 
X-100], 0.2 mM of each dNTPs, 0.5 µM each primers (N30P1 and N30P2) and 20-40 
ng aptamer DNA template were used for 50 µl of PCR reaction. 
PCR was performed in the conditions below:  
1 cycle 
Initial denaturation  95°C for 5 min 
25 cycles 
Denaturation     95°C for 30 sec 
Primer annealing   52°C for 30 sec 
Extention   72°C for 1 min 
1 cycle 
TGATAATACGACTCACTATAGGGAATGGATCCACATACTACGAAT 
-N30-TTCACTGCAGACTTGACGAAGCTT 
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Final extension  72°C for 5 min 
PCR fragments were then recovered from an agarose gel using gel purification kit 
(Qiagen, USA). Another PCR reaction was performed using templates obtained from 
gel purification step. Resulting PCR product was cleaned up by using PCR purification 
kit (Qiagen, USA).  
2.11.2  In vitro transcription of 2`-fluoro-modified RNA 
In vitro transcription was achieved using 1 µg of template DNA, 20 units of mutant T7 
RNA polymerase, 10 x T7 RNA polymerase buffer, 10 mM dithiothreitol (DTT), 2 units 
of yeast inorganic pyrophosphatase (YIP, Sigma Aldrich, USA), 0.2 mM ATP and 0.2 
mM GTP (Fermentas [Thermo Fisher Scientific], USA), 0.2 mM 2'-fluoro-UTP and 0.2 
mM 2'-fluoro-CTP (TriLink Biotechnologies, USA) for 3 hrs at 37°C. After incubation, 
DNA template was removed by 5 units of RNase free DNase (Promega, USA) 
treatment for 30 min at 37°C. This enzyme was inactivated by incubating at 65°C for 
10 min, alternatively EDTA to 1 mM would stop the reaction. Excess nucleotides were 
removed using a spin column (NucAway spin column, Ambion Inc., Life Technologies, 
UK) which retains free nucleotides while eluting the RNA into the solution. Neutral 
phenol: chloroform extraction was performed to purify RNA from proteins. An equal 
volume of cold phenol: chloroform: isoamyl alcohol (25: 24: 1) was added to the RNA 
sample and mixed by vortexing followed by centrifugation at top speed for 2 min to 
separate the phases, the aqueous phase was removed and this step was repeated 
three times. Additional step was performed in chloroform only to remove phenol. The 
aqueous phase was removed and 1/10 volume of 3M sodium acetate and 2.5 volume 
of ice cold 100% ethanol were added into the tube.  The sample was left at – 20°C to 
precipitate for 1 h or overnight followed by centrifugation at 16,100 x g for 20 min. 
RNA pellet was then mixed with 70% ice cold ethanol and centrifuged to the pellet at 
16,100 x g for 10 min. Ethanol was removed, and the pellet was left to dry for 5 min 
at room temperature prior to re-suspending in RNase-free dH2O (Severn Biotech, 
UK).  
2.11.3  Quantitation of aptamers 
Following removal of excess nucleotides using a NucAway column, aptamers were 
quantified by NanoDrop (Thermo Scientific, USA).  An A260 value of 1 was estimated 
to be equivalent to 40 µg/ml RNA. The A260/A280 ratio around ~2.0 was indicative of 
purified RNA (low contamination by proteins, phenol and other contaminants).  
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2.11.4  De-phosphorylation of aptamers 
De-phosphorylation of in vitro transcribed A2 and SF1 RNA (section 2.11.2) was 
performed using 4 µM of aptamer, 10 x reaction buffer, 20 units of RNaseOut 
(Invitrogen, Life technologies, UK) and 10 units of Antarctic phosphatase (New 
England BioLabs, UK) for 45 min at 37°C. Reaction was inactivated at 70°C for 10 
min. Mixture was phenol: chloroform extracted and ethanol precipitated overnight. 
RNA was eluted in nuclease-free dH2O to obtain 10 µM aptamer solutions.  
2.11.5  Fluorescent labelling of aptamer 
In order to label 5' end of aptamers with fluorescein maleimide, aptamer RNAs were 
de-phosphorylated, phenol: chloroform extracted and ethanol precipitated before 
labelling performed. All were performed according to the manufacturer`s instructions 
by Vector Laboratories. Up to around ~10 µg RNA (0.6 nmols of 5' ends) was 
incubated with 1 µl universal reaction buffer and 1 µl alkaline phosphatase (Vector 
Laboratories, USA) in a total reaction volume of 10 µl (with dH2O). Reaction was 
incubated for 30 min at 37°C. The entire dephosphorylation reaction mixture were 
then treated with 2 µl universal reaction buffer, 1 µl ATPγS, 2 µl T4 polynucleotide 
kinase in a total reaction volume of 20 µl (with dH2O). Mixture was incubated for 30 
min at 37°C. Then 10 µl (135 µg) of thiol-reactive label [Fluorescein Maleimide, 
(C27H18N2O8)] (Vector Laboratories, USA) was added in to the reaction mixture for 
additional 30 min at 65°C in order to allow labelling of 5' end of RNA. The RNA was 
again phenol: chloroform extracted and ethanol precipitated to remove excess label 
(Section 2.11.2). 
2.12  RNA extraction, cDNA synthesis and Quantitative PCR 
(qPCR) 
SiHa and C33A cells were transfected with 100 nM A2, SF1 or 21-2 and de-
phosphorylated A2 and SF1 along with mock transfection and Poly I:C (InvivoGen, 
France) incubations as negative and positive controls, respectively.  Poly I:C was 
used at 1 µg/ml from the stock of 1 mg/ml. Cells were maintained at 37°C for 24 h. 
Cells were harvested and RNA was extracted using Quick RNA Mini-prep kit (Zymo 
Research, USA) according to the manufacturer`s instructions.  RNA was eluted in 35 
µl of dH2O.  cDNA synthesis were performed using First-strand cDNA synthesis kit 
(Thermo Fisher Scientific, UK), following manufacturer`s instructions. Around ~1 µg 
of RNA (~10 µl) was pre-incubated with 0.5 µg (1 µl) oligo (dT)18 for 5 min at 65°C. 
Then, reaction buffer, 20 units of RiboLock RNAase inhibitor, 2 mM dNTP mix, 20 
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units of M-MuLV Reverse Transcriptase were added for 60 min at 42°C. Enzyme was 
inactivated by incubating at 70°C for 10 min. Quantitative real-time PCR (qPCR) was 
performed using the Quantifast SYBR Green PCR kit (Qiagen, Germany) by a Corbett 
Rotor-Gene 6000 (Qiagen, Germany). Around ~ 80 ng of cDNA, 1 µM from forward 
and reverse primers and 2 x Quantifast SYBR Green PCR master mix were combined 
in a 25 µl of total reaction. Primers utilised were MX1, IFNβ, which were purchased 
from Qiagen. U6 forward and reverse primers were purchased from Sigma and 
sequences were as listed in Section 2.2. Conditions for PCR reactions were as 
follows: initial activation step and two-step cycle of denaturation, for 5 min at 95°C 
and 10 sec at 95°C, respectively, followed by 40 x repeats of combined annealing and 
extension steps for 30 sec at 60°C. A melting curve from 60°C to 95°C with 5 sec at 
every 1°C interval was performed at the end of last cycle. Data was analysed 
according to the ΔΔ Ct method described previously (Livak and Schmittgen, 2001) 
using the Rotor-Gene 6000 software.  
2.13  Analysis of apoptosis by flow cytometry using Annexin 
V  
Cells were transfected with up to 200 nM of aptamer RNA (section 2.10.5.2) and 
maintained at 37°C for 24 h. Cells were washed with 1 x PBS and incubated with 
trypsin (section 2.10.6). Cells were collected in 5 ml flow cytometry tubes and pelleted 
by centrifugation at 230 x g. Pellets were washed 3 times with 1 x PBS and re-
suspended in 100 µl ice cold Annexin V buffer. 3 µl of FITC – conjugated Annexin V 
(BD Biosciences) was added and incubated on ice for 15 min. Cells were co-stained 
with 5 µl of 50 µg/ml propidium iodide/PBS.  Analysis was performed using the 
FACSCalibur (Becton Dickinson) software. Cells were treated with staurosporine (Cell 
Signalling, USA) at 1 µM for 24 hrs as a positive control for apoptosis.   
2.14  Immunostaining of cells 
Cells on coverslips were washed three times with 1 x PBS for 5 min each. Cells were 
fixed with 4% (v/v) formaldehyde/PBS for 10 min at room temperature.  Cells were 
washed 3 x with PBS in order to remove formaldehyde. Permeabilisation of cells was 
performed by incubation in 0.1% (v/v) TritonX-100/PBS for 10 min.  Cells were again 
washed with 1 x PBS, and incubated in blocking solution [1% BSA/Triton X-100 in 1 
x PBS (w/v)] for 1 h at room temperature.  Primary antibodies were added onto cells 
with appropriate dilutions and incubated overnight at 4°C on a rotating platform. Cells 
were washed three times with 1 x PBS for 5 min each and incubated with flurochrome-
conjugated secondary antibodies at a dilution of 1/500 in 1% BSA/Triton X-100 for 2 
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h at room temperature and kept in dark.  Cells were washed in 1 x PBS three times 
and mounted on microscope slides in Vectashield containing DAPI stain (Vector 
laboratories, USA). Cells were imaged on the Zeiss LSM 510 upright or LSM 700 
inverted confocal microscopes. In order to image fluoro labelled aptamers per se, 
above was performed until permeabilisation step. Then glass coverslips were 
mounted on microscope slides and imaged as described above. 
2.15  GST- pull down assay 
HaCat cells were used as a pRb source for pull down assays. Cells were lysed in 
radio-immunoprecipitation assay (RIPA) buffer.  Lysates were pre-cleared by 
incubation with GST coated magnetic beads for 30 min at 4°C on a rotating platform. 
10 µg of GST-E7 bound to sepharose (Section 2.9.4) was pre-incubated with aptamer 
RNA in 100 µl 1 x PBS at 4°C for 30 min with mixing.  600 µg of protein from the pre-
cleared HaCat cell lysate was then added and incubated at 4°C for 1 h with mixing.  
Sepharose was recovered by centrifugation at 1200 x g and washed 3 times in RIPA 
buffer.  Beads were re-suspended in 2 x Laemmli sample buffer, boiled at 95°C for 5 
min and analysed by SDS-PAGE and Western blot (sections 2.6.3 and 2.6.4). 
2.16  Use of Inhibitors to investigate the mode of protein 
degradation 
In order to analyse the pathway of E7 degradation in the presence or absence of 
aptamers, inhibitors of the 26S proteasome/lysosome (MG132), 20S and 26S 
proteasome (lactacystin), lysosomal degradation pathway (chloroquine), HDAC6 
mediated misfolded protein degradation pathway (tubacin) and ER-associated protein 
degradation pathway (eeyarestatin I) were utilised for treatment of CaSki cells. 
MG132 (Cayman Chemicals, USA), lactacystin (Tocris Bioscience, Bristol, UK), 
chloroquine (Sigma Aldrich, USA), tubacin (Sigma, USA) and eeyarestatin I 
(Calbiochem, Merck Millipore, USA) were used at concentrations of 100 µM,  20 µM, 
30 µM, 25 µM and 8 µM for up to 6 h.  
2.17  Detection of transfection efficiency by Flow Cytometry 
Primary or SiHa cells were incubated with up to 100 nM of cy5 labelled aptamer 21-2 
or transfected using oligofectamine or HappyFect-] (Nanocin) (section 2.10.5.2 and 
2.10.5.3) with the aptamer. Cells were maintained at 37°C for 5 hrs and then washed 
with 1 x PBS and incubated with 2 x trypsin (Sections 2.10.1 and 2.10.6). Cells were 
collected in 5 ml flow cytometry tubes and pelleted by centrifugation at 230 x g. Pellets 
were washed 3 times with 1 x PBS and once with an acidic wash buffer (Section 
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2.1.21) (Kameyama et al., 2007), and re-suspended in 100 µl of 1 x PBS. Cells were 
stained with 5 µl of 50 µg/ml propidium iodide/PBS for 5 min. 10, 000 cells were 
counted for each sample. Analysis on flow cytometer was performed using APC 
(allophycocyanin) (Excitation at 633 nm, emission at 660 nm) and PI (Propidium 
Iodide) (Excitation at 488 nm, emission at 617 nm) channels by counting 10, 000 cells. 
Results were represented as percentage of cells that are positive for cy5. Data was 
analysed using the FACSCalibur (Becton Dickinson) software. 
2.18  Treatment of cells with endocytosis inhibitors 
In order to determine the pathway of uptake of aptamers, inhibitors of dynamin-
mediated uptake (dynasore) and macropinocytosis (amiloride) were used in SiHa 
cells. Dynasore (Sigma, USA) and amiloride (Sigma, USA) were used at 
concentrations of 80 µM and 75 µM, respectively for up to 2 hrs treatments. 
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 EFFECTS OF APTAMERS IN CELLS 
3.1 Introduction 
Cervical cancer is the second most common cancer in women worldwide. Nearly all 
cases have been linked to persistent infection with one of the approximately 15 
genotypes of high risk human papillomavirus (HPVs) (Cogliano et al., 2005). Each 
HPV genotype could result in an independent infection. Current knowledge in the field 
aided the development of strategies for prevention of the disease, such as screening 
tests and vaccines as well as clinical management for cancer patients. High-risk 
HPV16 and 18 are known to be the most carcinogenic HPV genotypes, responsible 
for more than 70% of cervical carcinoma and almost 50% of cervical intraepithelial 
neoplasia (CIN) grade 3 (CIN3), whereas low-risk HPV6 and 11 have been shown to 
be the cause of approximately 90% of genital warts (Smith et al., 2007). The HPV 
genome encodes only eight genes, with E6 and E7 the major transforming HPV 
oncoproteins. These oncoproteins have a variety of cellular target proteins, most 
importantly retinoblastoma tumour suppressor protein (pRb) for E7, and p53 for E6. 
These interactions result in cell cycle progression and inhibiton of apoptosis, 
respectively, leading the transformation of infected cells. As well as pRb, E7 also 
target the other members of pocket protein family, p107 and p130 for degradation 
(Helt and Galloway, 2003, Jones and Wells, 2006). C-terminal region are highly 
conserved amongst all pRb family members, which is known as “pocket domain”. This 
region is where E2F transcription factors bind. However, E7 could also bind tightly 
this pocket region in order to abrogate their association with cellular targets 
(Chellappan et al., 1992, Liu et al., 2006). The major function of pRb is to interact with 
the E2F family transcription factors in order to stop cells entering into the S-phase of 
the cell cycle by acting as transcriptional co-repressor. Therefore inactivation and 
degradation of pRb by E7 leads to disruption of pRb tumour suppressor activity, 
causing uncontrolled division of cells (Bartek et al., 1997, Dyson, 1998).  
A library of HPV16 E7 aptamers which were selected previously by a process called 
systematic evolution of ligands by exponential enrichment (SELEX) was available 
(Nicol et al., 2011). This technology has been widely used for the isolation of RNA 
and DNA molecules that bind a specific target with a high affinity and strong specificity 
from a large pool (approximately 1014 molecules) of random nucleotide sequences. 
Sequence similarity of HPV16 E7 aptamers were analysed by multiple alignment of 
random regions (each aptamer also contains constant region harbouring T7 
polymerase and primer binding sites) and classified in to the groups that were named 
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A, B, C, D and E (Nicol et al., 2011). There were also other molecules that could not 
be grouped together due to sharing less than 65% similarity. Therefore, these outlier 
molecules were classified into F, G, H, I and J families. Sequence similarity of 
aptamers in the random region that were grouped into A and D families were 82.4% - 
96.9% (Nicol et al., 2011). Although the A-family of aptamers only differed in 1-2 
nucleotides, they had quite different effects on the pRb-E7 interaction as well as 
steady state levels of E7. It was shown previously by bead binding assays that from 
the A-family, only A2 disrupted the pRb-E7 interaction probably due to tertiary 
structures of the aptamers especially when in a complex with the target protein, E7 
(Nicol et al., 2011). Bead binding assays using several mutant forms of E7 and radio-
labelled A2 also suggested that disruption of pRb-E7 interaction could possibly be 
due to the fact that A2 might also be binding a region around LXCXE motif of E7 
where pRb binding occurs (Nicol et al., 2013). SF1, selected against an unrelated 
protein, RNA-dependent RNA polymerase (3Dpol) of foot-and-mouth disease virus 
(FMDV) was included in all experiments as a control aptamer (Nicol et al., 2013). In 
addition, SF1 is similar to E7 aptamers in their length and constant regions (2.2). 
These aptamers were used in cancer cells/HPV16 E7 positive cells in order to 
determine their apoptotic potentials as well as the abilty to degrade E7 oncoprotein. 
HPV16 E7 aptamer synthesis was performed by in vitro transcription using chemically 
modified 2'-fluoro pyrimidines (U and C) and natural purine nucleotides (A and G). 
Modification of ribose groups with 2'-fluoro increases the stability of aptamers in cells 
(Kong and Byun, 2013). 
Two main immune receptors, RIG-I and MDA5, have been shown to detect viral RNA 
in the cytosol. RIG-I like receptors (RLRs) play an important role in the inflammatory 
response against infection. RIG-I recognises short double stranded RNA ligands or 
single stranded RNA with 5' triphosphate moiety. Whereas, longer genomic RNA and 
replication intermediates are recognised by MDA5 (Reikine et al., 2014). When 
aptamers are introduced into cells, being foreign nucleic acid molecules harbouring 5' 
triphosphate moiety, they are recognised by host cell innate immunity through 
canonical pattern recognition receptors, mostly RIG-I. Some viruses such as influenza 
A virus and vesicular stomatitis virus (VSV) single-stranded RNA are not capped and 
contain a 5' triphosphate, therefore they are likely to be recognised by RIG-I receptors. 
Treatment of these viruses with calf intestinal phosphatase was shown to stop their 
stimulatory effects (Pichlmair et al., 2006). In addition, influenza virus A non-
structured NS1 protein was found in a complex with RIG-I following infection, resulting 
in abrogation of RIG-I recognition (Pichlmair et al., 2006). In addition, some viruses 
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which bear 5' triphosphate such as encephalomyocarditis virus (EMCV) from the 
picornavirus family escapes RIG-I recognition with a different mechanism by the 
linkage of viral RNA to the small viral protein VPg (Gitlin et al., 2006, Kato et al., 2006, 
Pichlmair et al., 2006). 
Non-self nucleic acids with 5' triphosphate could therefore result in the production of 
interferons and pro-inflammatory cytokines by downstream activation of IRF and 
NFκB transcription families (Chi and Flavell, 2008). There was a possibility that 
HPV16 E7 aptamers were triggering these responses in transfected cells, leading to 
apoptosis due to the presence of triphosphate on the 5' end of the aptamer following 
their in vitro transcription. Therefore, this was also investigated here.   
Another objective of this chapter was to determine the cross-specificity of HPV16 E7 
aptamers with E7 from other HPV types such as high-risk HPV18 and low-risk HPV11. 
E7 oncoproteins share a sequence similarity amongst several HPV types, such as 
some conserved motifs like LXCXE in CR 1 and CXXC in the C-terminal zinc finger 
(McLaughlin-Drubin and Munger, 2009). Aptamers are known to be highly specific to 
their target molecules. For instance, in a recent study, an aptamer that can specifically 
bind to avian influenza virus (AIV) H5N1 was utilised for the detection of AIV H5N1 in 
chicken swab samples with no interference detected from other AIV subtypes, such 
as H5N9, H7N2, H2N2, H9N2 and H1N1 (Wang et al., 2013). However, there are 
some other cases in the literature where an aptamer selected against a specific 
molecules were also shown to be targeting closely related species. One example of 
this is the aptamer selected against 40-residue form of Aβ (Aβ40) oligomers (Rahimi 
et al., 2009). This aptamer was also observed to recognise fibrils of Aβ40, Aβ42, and 
several other amyloidogenic proteins. Another example is the single-stranded DNA 
aptamer RT1t49 selected against reverse transcriptase (RT) of a subtype B strain of 
HIV-1 (Kissel et al., 2007). This aptamer was also demonstrated to inhibit the 
recombinant RT clones amongst various members of lentivirus family such as HIV-2 
and SIV RTs.  
In order to determine cross-specificity of HPV16 E7 aptamers in vitro with HPV11 and 
18 E7, GST-tagged E7 constructs were generated and expressed in E. coli BL21 cells. 
Recombinant proteins were utilised in GST-pull down experiment to analyse whether 
HPV11 or 18 E7 – pRb interactions were affected in the presence of some of the 
HPV16 aptamers. In addition, some of the HPV16 aptamers were transfected in to 
HPV18 positive HeLa cell in order to determine and quantitate the steady state levels 
of 18E7, observing any degradation following addition of aptamers.  
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3.2 Effects of aptamers on HPV E7 levels 
3.2.1 Steady state levels of E7, pRb and p130 in CaSki, SiHa and HeLa 
cells 
p130 and pRb are cellular proteins, whereas E7 is expressed only in HPV transformed 
cell lines. In the first instance the steady state levels of p130, pRb and E7 expression 
in the cervical cancer cell lines CaSki, SiHa and HeLa cells was analysed. The 
cervical cancer cell lines studied here have different copy numbers of HPV DNA per 
cell (CaSki with 600 copies of HPV 16 and some HPV18 related sequences, SiHa 
with 1 – 2 copies of HPV 16, HeLa with 10 – 50 copies of HPV 18 (Chardonnet et al., 
1995). Human Embryonic Kidney 293T (HEK293T) cells were used as a positive 
control for p130 and pRb; and a negative control for proteins related to HPV such as 
E7. The HEK293T cell line was generated from embryonic tissue by transformation 
with sheared adenovirus 5 DNA as well as transformation with the simian virus 40 
(SV40) large T antigen. This cell line could be easily and efficiently transfected with 
plasmid DNA and therefore it has been widely used for transient protein expression. 
Therefore, we decided to determine the level of expression of E7 oncoprotein as well 
as that of pRb and p130 in cervical cancer cell lines and HEK293T cells. As shown in 
Figure 3.1 CaSki cells expressed the highest amounts of HPV16 E7 oncoprotein even 
when quite small number of cells was used (3 x 105). SiHa cells were also found to 
express HPV16 E7, however to be able to detect this, at least 6 x 105 cells were 
needed to be lysed for analysis. Likewise, HPV18 E7 was also well expressed in HeLa 
cells. pRb (key target for E7 oncoprotein) was well expressed in all cervical cancer 
cell lines. The expression of pRb in HEK293T cells seemed to be greater than cervical 
cancer cells. HEK293T cell contains large T antigen, ~100 kDa oncoprotein derived 
from polyomavirus SV40, which inhibits the functions of p53 and Rb-family tumour 
suppressor proteins, resulting in the cellular transformation (Ahuja et al., 2005). 
Another finding was that levels of p130 detected in CaSki and SiHa cells were quite 
low compared to that in HEK293T cells even in the case when a large number of cells 
were utilised for analysis.  
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Figure 3.1 Steady state level expression of p130, pRb, E7 in cervical cell lines 
CaSki, SiHa (both HPV16+), HeLa (HPV18+) and HEK293T cells (HPV negative, 
pRb and p130+). 3 and 6 x 105 cells from each cell line were analysed by SDS-
PAGE and western blotting. A housekeeping protein, GAPDH was used as a 
loading control for E7. Separation of p130 and pRb was performed using a 10% 
acrylamide gel whereas that of E7 and GAPDH was using a 15% acrylamide gel. 
Membranes were blocked in 5% milk/TBS-T solution for at least 1 h prior to 
primary antibody incubations overnight. Anti-p130, anti-pRb, anti-HPV16E7, 
anti-HPV18E7 and anti-GAPDH were used as primary antibodies). Image shown 
is representative of two independent experiments (n = 2).  
3.2.2 Effects of HPV16 E7 aptamers on the steady state levels of E7, pRb 
and p130 in CaSki cells.  
Here, we have examined the levels of E7 oncoprotein as well as some of its major 
cellular targets, pRb and p130 in the presence and absence of HPV16 E7 aptamers. 
For this experiment, CaSki cells were utilised due to the fact that their E7 expression 
was considerably higher and easily detectable in small number of cells by 
immunoblotting in comparison with SiHa cells. CaSki cells were transfected with A-
series aptamers A1, A2 and A3 as well as an outlier E7 aptamer J1 (see Figure 3.3 
for Mfold structures and section 2.2 for aptamer sequences) for 24 hrs. SF1, selected 
against an unrelated protein, was used as a control. Levels of E7, pRb and p130 were 
then analysed by immunoblotting. Relative levels of protein expression were 
quantified by densitometry analysis (Figure 3.2A and C). Results were normalised 
against the level of GAPDH from at least three independent experiment and 
represented as graphs with standard errors (Figure 3.2B and D). Looking at the data 
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obtained at Section 3.2.1, 3 x 105 cells were seeded on to experimental plates 24-
hours prior to transfection with aptamers.  
 
 
 
Figure 3.2 Effects of HPV16 E7 aptamers on the steady state levels of HPV16 E7 
(A, B) and pRb and p130 (C, D) in HPV16 positive CaSki cells. Cells were mock 
transfected or transfected with 100 nM A1, A2, A3, SF1 and J1 for 24 hrs using 
oligofectamine transfection reagent (A, C). Cells were lysed in RIPA and 
Laemmli buffer. Immunoblot analysis was then performed to detect HPV16 E7, 
pRb, p130 and GAPDH. (B) Graph shows the data from eight independent 
experiments (n = 8), with E7 levels shown as % mock together with standard 
errors (*p = 0.05, **p = 0.008). Significance was calculated over SF1 transfection. 
(D) Graph shows the data from four independent experiments (n = 4) for pRb 
and two independent experiments for p130 (n = 2), with pRb and p130 levels 
shown as % mock in blue, together with standard errors (*p = 0.039, **p 
=4.5991E-05). Significance was calculated over mock treatment.  
 
Figure 3.2 showed that A2 (Lane 3) caused a considerable amount of decrease in the 
levels of E7 in CaSki cells. In addition, some other aptamers also affected E7 levels 
especially A1 and J1, but not A3. Aptamer A1, A2 and A3 differ only by 1-2 nucleotide 
change, whereas aptamer J1 is one of the HPV16 aptamers classified as an outlier 
(Nicol et al., 2011). Although the sequences of the A-series aptamers are almost 
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identical, a single nucleotide change is the cause for the prediction of different 
secondary structures of these aptamers by Mfold (Figure 3.3). pRb levels, however, 
seemed to increase slightly following A1, A2 and J1 transfections but not control 
aptamer SF1 or other E7 aptamer A3. p130 levels were observed to be unaffected by 
aptamers.  
When E7 levels were analysed by densitometry analysis from three independent 
experiments and presented as a percentage relative to mock treatment Figure 3.2B, 
A1, A2 and J1 resulted in a significant decrease in the levels of HPV 16 E7 (33.5 ± 
2.20%, 48.3 ± 3.37% and 50.3 ± 3.87%, respectively). In addition, reduction in the E7 
levels was significant over mock transfection with corresponding p values of 0.05, 
0.008 and 0.0083. However, only 31.15 ± 3.58% and 16.32 ± 3.24% decrease in E7 
levels following A3 and SF1 transfections, respectively, were observed.  
Levels of pRb and p130 tumour suppressor proteins following aptamer transfections 
were also quantitated by densitometry analysis. It was shown in Figure 3.2D that there 
was a 53.42 ± 3.31% increase in pRb in A2 transfected cells. Although recovery of 
pRb with A2 transfection did not seem significant over that of SF1, pRb levels were 
significantly increased over mock transfection with **p = 4.5991E-05. Similarly A1, A3 
and J1 transfections also resulted in a similar increase in the levels of pRb. However, 
p130 as demonstrated by western blot (Figure 3.2C), seemed unaffected by 
aptamers. 
Computational RNA folding secondary structures of some of the HPV16 E7 aptamers 
were determined using the RNA mFold web server (Zuker, 2003). This software 
performs the prediction of RNA secondary structures according to the free energy 
(ΔG) minimisation and based on a dynamic programming algorithm using several 
energy parameters for example from Watson-Crick and GU base pairing, loop 
structures and mismatching or unpaired nucleotides (Mathews et al., 1999). However, 
it does not take in to account the 3D interactions and protein-RNA interactions, which 
could make suboptimal folding favourable. In addition, it does not always represent 
accurate folding of RNA in the biological environment. 
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Figure 3.3 Predicted secondary structures of aptamers, A1, A2, A3 and J1. ΔG 
values for these aptamers are as indicated in brackets [structure 1 (ΔG = -13.00) 
and  2 (ΔG = -12.60)], A2 [ structure 1 (ΔG = -11.9), 2 (ΔG = -12.6) and 3 (ΔG = -
7.73)  ], A3 [ structure 1 (ΔG = -6.84) and 2 (ΔG = 6.83)] and J1 (ΔG = -19.7) using 
Mfold (Zuker, 2003). 
 
77 
 
Mfold predicted two different lowest energy secondary structures for aptamers A1, A2 
and A3 with the lowest –ΔG structure being more stable and more likely to be formed. 
Although A1, A2 and A3 are almost identical in RNA sequence with only 2 nucleotide 
difference (Nicol et al., 2011), slightly different structures were predicted. A2 was 
previously shown to have an effect on E7 steady state level in CaSki cells (Nicol et 
al., 2013). Predictions for A1 and A2 were similar but the predicted structures for A3 
were quite different, possibly reflecting the differences in the effects of aptamers on 
E7 levels observed here. Interestingly, there was only one structure predicted for J1 
with a quite low ΔG (-19.7), indicating a very stable RNA structure. However, it should 
be noted that some parameters during the course of in vitro transcription such as pH, 
temperature and the local composition bias of RNA as well as intracellular conditions 
when RNA was delivered in cells are also important in determining the secondary 
structures.  
3.2.3 Dose dependence and time course for effect of A2 in CaSki cells 
HPV16 E7 aptamer A2 has been shown to cause a reduction in the levels of E7 
oncoprotein when used at 100 nM (Figure 3.2). Here a dose-dependence experiment 
was performed in order to determine the effects of A2 transfections in CaSki cell when 
used at lower and higher concentrations. Figure 3.4 shows that loss of E7 was 
dramatic even at lowest concentrations. In contrast control aptamer SF1 (at 100 and 
200 nM) was shown not to have an effect on the levels of E7. In addition, Following 
A2 transfections, pRb levels seemed to recover, whereas pRb levels were not affected 
by SF1 transfections similar to that of mock treatment. Finally, an increase in p130 
expression was also shown if cells were transfected with A2 at concentrations of 200 
nM or higher. However, the result was inconclusive due to the detection of the 
recovery of p130 in SF1 transfected cells.  
 
 
78 
 
 
Figure 3.4 Dose-dependence of A2 in CaSki cells. CaSki cells were seeded on 
to 6-well plates and incubated 24 hrs prior to the aptamer transfection. An 
increasing concentration of A2 and control aptamer SF1 (from 25 to 400 nM) 
was used for transfections. Transfections were performed in a serum-free 
medium for 4 hrs, followed by returning the cells into the media containing 10% 
of foetal bovine serum. Proteins were analysed by SDS-PAGE and Western 
blotting. Anti-p130, anti-pRb, and anti-HPV16E7 and anti-GAPDH were used as 
primary antibodies. A housekeeping protein, GAPDH was used as a loading 
control for E7. A representative blot was shown (n = 2).  
 
In order to understand better and determine the time point when A2 starts affecting 
the E7 levels, a time course experiment was employed. Following 100 nM A2 
transfections, cells were collected at different time points; 6, 14 and 20 hrs post-
transfection. Figure 3.5 shows that A2 caused a considerable reduction in E7 levels 
as early as 14 hrs post-transfection. However, no difference was detected in the levels 
of pRb during 20 hrs time course. 
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Figure 3.5 Effects of A2 transfections on E7 and pRb levels in CaSki cells. Cells 
were transfected with 100 nM A2 for 6, 14 and 20 hrs, collected and lysed prior 
to analysis by SDS-PAGE and Western blotting in order to determine the levels 
of E7 and pRb. GAPDH was used as a loading control for E7. A representative 
blot was shown (n = 2). 
 
3.3 Cross-specificity of HPV16 E7 aptamers with other HPV 
E7 proteins 
3.3.1 Using several HPV E7 types in in vitro assays 
3.3.1.1 Cloning and E.coli expressions of GST-tagged HPV11 and 18 E7 
The aim of this section was to design GST – tagged expression vectors of several 
high- and low- risk HPV E7 oncoproteins for use with the existing aptamers. PCR 
fragments were obtained from plasmids containing HPV11 and 18 open reading 
frames (ORFs) (see methods section 2.7). HPV11 and 18 E7 fragments were cloned 
into the BamHI/EcoRI restriction sites of the pGEX-6P-1 expression vector. The 
integrity of the plasmids was analysed by sequencing and the data indicated that E7 
ORFs were in-frame downstream of the GST ORFs. Vectors were transformed into 
E. coli BL21 (DE3) Rosetta-competent cells. BL21 cells are deficient in the expression 
of Ion proteases and outer membrane protease, ompT in order to prevent the 
degradation of heterologous proteins. These cells contain a T7 RNA promoter and 
Lambda DE3 phage for expression of T7 RNA polymerase under the control of a 
lacUV5 promoter. IPTG was used to induce the expression of recombinant proteins 
cloned downstream of the T7 RNA promoter in these BL21 (DE3) cells. Rosetta™ 
host strains have been designed to enhance the expression of eukaryotic proteins 
that contain codons rarely used in E. coli. Expression of GST- 11E7 and 18 E7 was 
optimised (20, 30 and 37°C for 3, 6hrs or overnight) and conducted at 20°C overnight 
and 30°C for 6 hrs, respectively following 1 mM IPTG inductions. The results of the 
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successful expression using conditions of 30°C for 6 hrs for GST-18E7 and 37° 
overnight for GST-11E7 are shown in Figure 3.6 and 3.7, respectively. The predicted 
molecular weights (MW) of GST, 11E7 and 18E7 are 26.62 kDa, 11 and 12 kDa, 
respectively. However, MW of GST-11 and 18E7 were detected to be around ~40 kDa 
as oppose to calculated predicted molecular weights of 37.6 and 38.6 kDa, 
respectively.  
 
Figure 3.6 GST- HPV18 E7 was successfully expressed in E. coli BL21 (DE3) 
Rosetta cells and purified on glutathione sepharose (GS) beads. Protein 
expression was performed at 30° C for 6 h with 220 rpm shaking following 1 mM 
IPTG induction. Samples were kept before and after induction for gel analysis. 
Cells were pelleted by centrifugation and lysed in protein extraction buffer 
containing DNase (5 µg/ml) and lysosyme (1 mg/ml) by sonication. Protein was 
purified from soluble fraction of the cell lysate on the glutathione sepharose 
column by gravity flow.  Insoluble protein fraction, column flow through and 
wash were all kept for gel electrophoresis. Elution fractions were collected in 
50 mM glutathione/PBS pH 8.0. Samples from each purification steps were 
analysed on a 12% SDS-PAGE. Gel stained with Coomassie blue [M: marker 
(Precision Plus Protein™ Dual Colour, BioRad), 1: Un-induced, 2: Induced, 3: 
Soluble, 4: Insoluble, 5: Flow Through, 6: Wash, 7-13: Elution Fractions 1-7]. A 
representative blot is shown from three independent protein expression (n = 3).   
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Figure 3.7 GST- HPV11 E7 was successfully expressed in E. coli BL21 (DE3) 
Rosetta cells and purified on Glutathione sepharose (GS) beads. Protein 
expression was performed at 20°C overnight with 220 rpm shaking following 1 
mM IPTG induction. Cells were pelleted by centrifugation and lysed in protein 
extraction buffer containing DNase (5 µg/ml) and lysosyme (1 mg/ml) by 
sonication. Protein was purified from soluble fraction of the cell lysate on the 
glutathione sepharose column by gravity flow.  Elution fractions were collected 
in 50 mM glutathione/PBS pH 8.0. Samples were analysed on a 12% SDS-PAGE. 
Gel stained with Coomassie blue (1: Flow Through, 2: Wash, 3-10: Elution 
Fractions 1-8). Molecular weight was as indicated. A representative blot is 
shown from two independent protein expression (n = 2).   
 
Following the expression and purifications of GST- tagged 11 and 18 E7, recombinant 
GST-E7 was successfully bound to GS-beads (Figures 3.8 and 3.9). Binding of the 
protein to beads was performed at 4°C for 1 h. Almost all of the protein was observed 
to bind an equal volume of GS-beads, since levels of GST-11 and 18E7 level detected 
from samples of unbound and several washes were quite low. Molecular weights of 
these recombinant proteins were around ~43 kDa (26 kDa GST + 17 kDa E7). GST 
alone as well as some degradation products were also detected by SDS-PAGE seen 
as bands between molecular weights of 43 – 26 kDa. These proteins bound to GS-
beads were subsequently used in GST – pull down experiments where pRb and E7 
interactions were studied in vitro in the presence and absence of HPV16 E7 aptamers 
in order to determine their cross-specificity for E7 from other HPV types (section 
3.3.1.2).  
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Figure 3.8 GST-18 E7 was bound to glutathione sepharose beads. The input and 
unbound lanes shows the amount of protein incubated with beads and the 
amount of protein did not bound to the beads, respectively. Bound beads were 
than washed with 0.5% Triton-X100/PBS three times. The last lane is the amount 
of protein bound an equal amount of glutathione sepharose beads. M= marker 
(Precision Plus Protein™ Dual Colour, BioRad). 20 µl of each sample was 
loaded on to the each well. Gel was Coomassie stained.  
 
 
Figure 3.9 GST-11 E7 was bound to glutathione sepharose beads. The input and 
unbound lanes shows the amount of protein incubated with beads and the 
amount of protein did not bound to the beads, respectively. Bound beads were 
than washed with 0.5% Triton-X100/PBS three times. The last lane is the amount 
of protein bound an equal amount glutathione sepharose beads. M= marker 
(Precision Plus Protein™ Dual Colour, BioRad). 20 µl of each sample was 
loaded on to the each well. Gel was Coomassie stained. 
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3.3.1.2 GST-pull down experiments 
GST-pull down experiments were designed in order to study the effects of HPV16 E7 
aptamers on E7 – pRb binding using E7 from other HPV types. HaCaT cell 
(immortalised keratinocytes) lysate was used as a source for pRb and p130. GST-E7 
(from HPV11, 16 or 18) immobilised onto GS-beads (from 3.3.1.1) was incubated with 
600 µg protein from HaCaT cell lysate. GST-immobilised GS-beads and GS-beads 
alone were also incubated with the lysate as controls. Figure 3.10 shows that pRb 
and p130 were precipitated by GST11, 16 and 18 E7. However, there was some 
nonspecific binding of the beads to pRb and p130. Several washes and different 
washing buffers were used to optimise the conditions for pull-down. However, 
attempts to remove nonspecific binding were unsuccessful. Therefore, aptamers 
could not be included in the experiments to investigate if these HPV16 E7 aptamers 
were also effective in disrupting pRb interaction with HPV 11 and 18 E7.  
 
Figure 3.10 GST pull-down assay in order to study interaction of pRb and p130 
with E7 from HPV11, 16 and 18. 10 µg of GST-E7 bound to GM-beads was 
incubated with 600 µg of protein from a HaCaT cell lysate (as a source of pRb) 
for 1 hour at 4°C. Bead-bound GST was also incubated with cell lysate. GST 
proteins and interacting proteins were isolated from the reaction and analysed 
by immunoblotting using antibodies to pRb, p130 and GST. A representative 
blot was shown (n = 2). 
84 
 
3.3.2 Effects of HPV16 E7 aptamers on the steady state levels of 18 E7 
in HPV18 positive HeLa cells 
In order to determine if HPV16 E7 aptamers had an effect on 18 E7 as well as 16 E7, 
HeLa cells were transfected with these aptamers for 24 hrs followed by 
immunoblotting. As it was seen from the Figure 3.11A, some of the aptamers were 
likely to be active against HPV18 E7, possibly due to amino acid conservation around 
the pRb binding site (as discussed in section 3.2).  
Observations in CaSki cells (Figure 3.2) indicated that A2 was the most effective 
aptamer in the reduction of E7 levels of those tested. However, in HeLa cells A1 and 
J1 resulted in the largest reductions of E7 levels (Figure 3.11). In addition, A2 also 
seemed to cause a moderate decrease in the levels of 18 E7 oncoprotein in HeLa 
cells (Figure 3.11). Several independent experiments were conducted and 
densitometry analysis using Aida image analyser was performed from each 
transfections. Mean E7 levels from three different experiments were then showed as 
a percentage relative to mock treatment Figure 3.11B. Transfections with A1, A2 and 
J1 resulted in a significant decrease in the levels of HPV 18 E7 (to 54.78 ± 5.44%, 
72.18 ± 6.22% and 48.33 ± 6.5%, respectively). In addition, reduction in the E7 levels 
were significant over mock transfection with p = 0.034 for A2 and p = 0.003 for A1 and 
J1 transfections. However, transfections with A3 and SF1 caused only approximately 
20% decrease in 18 E7 which was smaller than that observed for the other aptamers 
tested.  
As well as determining the effects of aptamers on E7 levels in HeLa cell, steady state 
levels of pRb was also examined following aptamer transfections. According to Figure 
3.11C and D, transfection with aptamers resulted in an increase in pRb levels when 
compared to mock treatment. pRb levels following A1, A2, A3, SF1 and J1 
transfection presented as percentage of mock, indicated a 35, 57, 69, 51 and 39% 
increase, respectively (Nicol et al., 2013).  Further aptamers were also tested in HeLa 
cells (B1, C4 and D1) (data not shown), however E7 levels did not seem to be affected 
by transfection with these aptamers.  
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Figure 3.11 Effects of HPV16 E7 aptamers on the steady state levels of HPV18 
E7 and pRb in HPV18 positive HeLa cells. (A, C) HeLa cells were transfected 
with 100 nM A1, A2, A3, SF1 and J1 for 24 hrs using oligofectamine transfection 
reagent. Cells were lysed in RIPA then Laemmli buffer. Immunoblot analysis 
was then performed to detect HPV18 E7, pRb and GAPDH. (B) Graph shows the 
data from six independent experiments (n = 6), with E7 levels shown as % mock, 
together with standard errors. *p = 0.034, **p = 0.003. (C). Graph shows the data 
from three independent experiment (n = 3), with pRb levels shown as % mock. 
 
3.4 Effects of 5` tri or monophosphate aptamers on the 
induction of apoptosis and interferon response 
3.4.1 Effect of in vitro transcribed HPV16 E7 aptamers on apoptosis  
3.4.1.1 Annexin V apoptosis assays in SiHa, HeLa and C33A cervical 
cancer cell lines 
It could be proposed that reduction of E7 levels in the cervical cancer cell lines should 
result in an induction of apoptosis. To detect apoptotic cells followed by aptamer 
transfection, Annexin V apoptosis assays were utilised. This assay is sensitive, easy 
to perform and offers the possibility of detection of early stages of apoptosis. The 
method is based on the detection of apoptotic cells via Annexin V-phosphatidyl serine 
(PS) interaction on the cell membrane. During apoptosis PS translocates to the outer 
layer of membrane from the inner layer. When Ca2+ is present in the environment, 
Annexin V can bind negatively charged phospholipids such as PS. Therefore, Annexin 
V with a flurorescent tag has been widely used for the detection of apoptosis by flow 
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cytometry. This protocol should be performed with extra care to avoid damaging the 
plasma membrane integrity which might result in the false positive Annexin V 
readings. Another dye such as PI is included in the assay to assess the integrity of 
plasma membrane to detect necrotic and dead cells.  
SiHa, C33A and HeLa cells were used in apoptosis experiments. Information about 
the cell lines has already given at sections 2.5 and 3.2.1. C33A and HeLa cells were 
used as controls in order to determine any cross-specificity of the HPV16 E7 aptamer 
A2.  These cell lines were transfected with up to 200 nM A2 and also SF1 as a control 
against non-specific effects of transfection with aptamers. Staurosporine was used as 
a positive control since it is a known inducer of apoptosis possibly via activation of 
caspase-3 (Feng and Kaplowitz, 2002) (Chae et al., 2000) in addition to caspase-
independent mechanisms (Belmokhtar et al., 2001, Zhang et al., 2004). 
To perform the assay, samples were dual-stained with fluorescein isothiocyanate 
(FITC)-labelled Annexin V (green fluorescence) and propidium iodide (PI) (red 
fluorescence) (Vermes et al., 1995) and analysed by flow cytometry.  The staining 
pattern indicates if cells are intact/healthy (FITC-/PI-), early apoptotic (FITC+/PI-), late 
apoptotic (necrotic) (FITC+/PI+) or dead (FITC-/PI+). Results were presented as % of 
early and late apoptosis in the three different cervical cancer cell lines. Figure 3.12 
shows that A2 induced apoptosis in SiHa cells but not in the control cells, C33A and 
HeLa. Total (combined early and late) apoptosis was found to be increased in SiHa 
cells (Figure 3.12A) transfected with 50, 100 and 200 nM of A2 with 30.6 ± 1.64%, 
18.01 ± 1.28% and 23.67 ± 0.63% apoptosis, respectively, over mock transfected 
cells (3.34 ± 0.176%). The effect of A2 transfection on the induction of apoptosis was 
significant over that of SF1 transfections. 50, 100 and 200 nM of SF1 transfections 
resulted in 17.73 ± 0.42%, 5.22 ± 0.93% and 11.15 ± 1.01% , which was significantly 
lower compared to A2 transfections with p = 0.006, p = 0.03 and p = 0. 0005, 
respectively. Staurosporine treatment caused an increase up to 34.16 ± 1.45% 
apoptosis. The percentage of early (FITC+/PI-) and late apoptotic cells (FITC+/PI+), 
were analysed separately in Figure 3.12. The percentage of early: late apoptotic cells 
following 100 and 200 nM A2 transfections were 11%: 9% and 14%: 12%, 
respectively.  
In C33A cells (Figure 3.12B), although apoptosis was increased by A2 6.4 ± 1.2%, 5 
± 1.2% and 6.5 ± 1.2% for 50, 100 and 200 nM, respectively) and by transfection with 
SF1 (9.36 ± 0.83%, 5.3 ±  1.2% and 5.2 ±  0.58%, respectively) over mock-transfection 
(2.16 ± 0.62%), the level of apoptosis caused by control aptamer was similar to the 
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E7 aptamer A2. There was no significant difference between aptamer transfections. 
Staurosporine, as a positive control, found to increase the percentage of apoptosis 
up to 32.9 ± 6.77%. When the effect of A2 was compared between SiHa and C33A 
cells, induction of apoptosis in SiHa cells with 100 and 200 nM of A2 were significantly 
greater than that of C33A cells with p values of 0.022 and 0.0002, respectively. 
Therefore, we suggest that A2 induces apoptosis in HPV16 positive SiHa cells but not 
HPV negative control cell line, C33A (Nicol et al., 2013).  
HeLa cells were also utilised to check if there was any cross-specificity of HPV16 E7 
aptamers on a HPV18 positive cell line (Figure 3.12C). These cells were also 
transfected with 50, 100 and 200 nM of A2, which resulted in 6.26 ± 1.05%, 7.6 ± 
0.29% and 8.03 ± 1.25% of apoptosis, respectively, and SF1, which resulted in 6.26 
± 0.82%, 6.23 ± 0.86% and 7.46 ± 0.83% of apoptosis, respectively (Nicol et al., 2013). 
Although A2 and SF1 transfections enhanced the percentage of apoptosis in HeLa 
cells over mock transfection (2.23 ± 0.18%), there was no significant difference 
observed between A2 and SF1 transfection. 
 
 
 
 
 
 
 
88 
 
 
Figure 3.12 HPV16 E7 aptamer A2 is inducing apoptosis in HPV16 positive 
cervical carcinoma derived cell line (SiHa), however not in control cell lines 
which are derived from HPV negative and HPV18 positive cervical carcinomas. 
SiHa (A), C33A (B) and HeLa (C) cells were seeded on to 12-well plates at 1.5 x 
105 cells/ ml per well and incubated for 24 hrs at 37°C with 5% CO2. Cells were 
mock transfected or transfected with in vitro transcribed aptamer A2 and SF1 
up to 200 nM. Staurosporine was also used as a positive control due to its high 
potency of causing apoptosis. Cells were analysed for apoptosis 24 hrs later. 
Cells were collected and washed several times with PBS. Cell pellets were dual-
stained with FITC-conjugated annexin V and propidium iodide followed by 
analysis on the flow cytometer. Graph shows early and late apoptosis data from 
seven independent experiments for SiHa (n = 6) and three independent 
experiments from HeLa and C33A (n = 3), together with standard errors. P 
values (by student`s t-test) were calculated to determine the significance of A2 
treatments over that of control aptamer SF1 within SiHa cells as well as the 
significance of A2 treatments in comparison to control cell lines, C33A and 
HeLa. 
A1, A2 and A3 are quite similar in sequence, differing only by a single nucleotide 
change (Nicol et al., 2011). Therefore, the effects of these aptamers were tested in 
SiHa cells as well as C33A cells as a negative control (Figure 3.13). It seemed as if 
all of these aptamers induced apoptosis in SiHa cells. The total percentage (early and 
late) of apoptosis caused by A1, A2 and A3 was 26.22 (± 0.59), 24.41 (± 0.53) and 
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24.11 (± 0.51)%, respectively. These aptamers caused apoptosis in SiHa cells which 
was significantly higher than that observed for C33A cells with corresponding p values 
of 0.0001, 3.01E-05 and 8.39E-06, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Induction of apoptosis by HPV16 E7 aptamers A1, A2 and A3, which 
differs only one nucleotide in sequences. 100 nM aptamer was used for 
transfections of SiHa (A) and C33A (B) cells for 24 hrs prior to the assay using 
Annexin V/Propidium iodide. Staurosporine was used as a positive control. 
Percentages of early and late apoptotic cells induced by aptamers were 
presented in the graphs from three independent experiments (n = 3), together 
with standard errors.  
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3.4.1.2 Annexin V apoptosis assays in HaCaT, HaCaT 16 and 18E7 
stable cells 
HPV16 E7 aptamer A2 as well as control aptamer SF1 was also used for transfection 
of HaCaT, HaCaT HPV16 E7 and HaCaT HPV18 E7 stable cell lines to detemine the 
apoptotic effects of aptamers. HaCaT cells are from an immortalised (>140 
passages), long-term primary culture of human adult skin keratinocytes (Boukamp et 
al., 1988). HaCaT E7 stable cell lines were generated by Kat Richards (University of 
Leeds, Leeds, UK). Figure 3.14 shows that percentage of apoptosis with 50, 100 and 
200 nM A2 was 10.86 (± 1.43), 14.63 (± 1.05) and 14.33 (± 1.0), respectively in HaCaT 
cells; and  18.8 (± 0.41), 19.93 (± 0.66) and 17.03 (± 1.04), respectively, in HaCaT 16 
E7 stable cell line. Therefore, transfection with 50 and 100 nM A2 was significantly 
induced apoptosis in HaCaT 16 E7 expressing cells compared to HaCaT cells (p = 
0.0185 and p = 0.034, respectively). Staurosporine treatment of both cell lines 
resulted in a similar level of apoptosis [for HaCat 30.23 (± 2.39)% and for HaCaT 16 
E7 stable cells 32.03 (± 3.24)%]. However, SF1 seemed to be apoptotic in the HaCaT 
16 E7 expressing cell, therefore only significant difference between A2 and SF1 
transfection was detected when 100 nM of aptamer was used (p = 0.02). There was 
no significant difference in apoptosis between A2 and SF1 transfection in HaCaT 18 
E7 stable cells. However, apoptosis was increased significantly by A2 in HaCaT 18 
E7 stable cells when compared to that in HaCaT cells.  
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Figure 3.14 Effects of HPV16 E7 aptamer A2 and a control aptamer SF1 on 
inducing apoptosis in the immortalised human keratinocyte HaCat cells and as 
well as HaCat cells stably expressing HPV16 and 18E7. HaCaT stable cells were 
maintained in the regular DMEM plus 0.5 µg/ ml puromycin. Cells were seeded 
on to 12-well plates at 1.5 x 105 cells/ ml per well and incubated for 24 hrs at 
37°C with 5% CO2. Cells were mock transfected or transfected with in vitro 
transcribed aptamer A2 and SF1 up to 200 nM. Staurosporine was also used as 
a positive control. Cells were analysed for apoptosis 24 hrs later. Cells were 
collected and washed several times with PBS. Cell pellets were dual-stained 
with FITC-conjugated annexin V and propidium iodide followed by analysis on 
the flow cytometer. Graph shows the total percentage of apoptosis, analysed 
from three independent experiments (n = 3), together with standard errors. P* = 
0.02. 
3.4.2 Use of 5` triphosphate and monophosphate (dephosphorylated) 
aptamers in apoptosis assays and quantitative real-time PCR 
(qPCR) for detection of expression of interferon responsive 
genes 
3.4.2.1 Introduction 
Since the recognition of ds/ss RNA is mostly dependent on the presence of 5' 
triphosphate, aptamers such as HPV16 E7 aptamer A2 could also activate innate 
immunity by triggering RIG-I, resulting in the expressions of interferon genes. 
Although E7 aptamers are single-stranded without extensive double-stranded 
regions, they are able to form secondary structures with complementary base-pairing. 
These lowest energy secondary structures could be predicted by Mfold software 
(section 3.2.2). Hence, we hypothesised that although these aptamers will probably 
not have enough double-stranded regions, they have 5' triphosphate moiety which 
could induce RIG-I. One could consider this as a non-specific effect of an aptamer. 
However, this property of aptamer can also provide potential advantages as 
discussed in section 1.3.4 especially for induction of apoptosis by interferon 
stimulation in HPV-transformed cancer cells. Since, some toll-like receptors and 
interferon stimulating genes (ISGs) were reported as being down-regulated in HPV 
positive cervical cancer cells with different oncogenic types (CaSki and HeLa) rather 
than HPV negative cervical cancer cells (C33A), subsequently leading to the reduced 
interferon levels (Yu et al., 2012). There is little data on the effects of aptamers, 
however, siRNA molecules modified with 5' triphosphate group in the RIG-I activation 
have been studied (Chen et al., 2013, Poeck et al., 2008). For example, use of an 5' 
triphosphate siRNA for anti-apoptotic gene Bcl2 (B-cell lymphoma 2) was shown to 
simultanously knock down Bcl2, resulting in an increased susceptibility to apoptosis 
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and activate RIG-I, leading to type I interferon response with anti-tumour activity in 
B16 melanoma cells (Poeck et al., 2008). 
3.4.2.2 Interferon response to mono or tri-phosphate aptamers 
HPV negative C33A and HPV16 positive SiHa cells were utilised to determine if 
aptamers were triggering expression of interferon response genes, MX1 and IFNβ 
and also how dephosphorylation of aptamers would affect this response. After 24 hrs 
incubation with aptamers, RNA levels for MX1 and IFNβ were analysed by 
quantitative real-time PCR (qPCR) following RNA extraction and cDNA synthesis 
(Figure 3.15). Resulting data was analysed according to the ΔΔ Ct method by Corbett 
Rotor-Gene 6000 software (Livak and Schmittgen, 2001). The level of gene 
expression in A2 and SF1, dephosphorylated A2 and SF1, 21-2 and Poly I:C 
transfection was compared with that of the mock transfection after normalization of 
the expression level to the small nuclear RNA (snRNA), U6. Poly I:C was used as a 
positive control, since has been shown to increase the expression of interferon 
response genes (Magee and Griffith, 1972, Manetti et al., 1995). 21-2 is a 33 
nucleotide oligomer, chemically synthesised aptamer selected against human IL-17A 
(Ishiguro A., 2011).  This aptamer has a 5' OH group instead of triphosphate, therefore 
could be used as a good control to study 5' immune stimulatory effects of aptamers 
in cells. 
First, effect of aptamers in the upregulation of some interferon response genes was 
determined in SiHa cells (Figure 3.15A). MX1 and IFNβ gene expressions were 
enhanced following Poly I:C treatment by up to 87.69 (± 16.13) and 265.75 (± 229.59) 
fold, respectively. A2 transfection resulted in the up-regulation of MX1 and IFNβ gene 
expressions with 111.47 (± 46.80) and 628.62 (± 475.0) fold, respectively. De-
phosphorylation of A2 resulted in decreased levels of corresponding gene expression 
by 35 (± 12.48) and 204.52 (± 170.22) fold, respectively. However, a student`s t-test 
did not show a significant difference between 5' triphosphate and de-phosphorylated 
(5' monophosphate) A2 transfections in the up-regulation of interferon response 
genes. When aptamer 21-2, which has 5' OH instead of 5' triphosphate, was used for 
transfection of SiHa cells, up-regulation of MX1 and IFNβ was relatively low with (4.28 
(± 1.46) and 1.78 (± 0.54) fold, respectively, compared to A2 and SF1 transfection. 5' 
triphosphate and de-phosphorylated SF1 were also used to determine the interferon 
response. MX1 and IFNβ gene expression were observed as being enhanced in SiHa 
cells by up to 115.32 (± 40.09) and 1602.69 (± 1440) fold by 5' triphosphate SF1 
transfection and 51.85 (± 15.23) and 435.75 (± 366.19) fold, respectively, by de-
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phosphorylated SF1 transfection (Belyaeva et al., 2014). There was no significant 
difference between 5' triphosphate and de-phosphorylated SF1 both in MX1 and IFNβ 
gene expression (Belyaeva et al., 2014).  
Secondly, quantitative real-time PCR (qPCR) technique was also employed in a HPV-
negative cervical cancer cell line, C33A (Figure 3.15B). This allowed investigation of 
the changes in interferon gene expression followed by aptamer transfection +/- de-
phosphorylation, as a result of non-specific innate immune sensing. It was shown that 
MX1 and IFNβ expressions were up-regulated by the Poly IC treatments by 1645.01 
(± 762.04) and 2923.28 (± 237.51) fold, respectively. Similar to the results presented 
above for SiHa cells, 21-2 did not seem to enhance the expressions of MX1 and IFNβ 
genes [1.41 (± 0.18) and 2.85 (± 0.53) fold, respectively]. Whereas, expression of 
those genes were up-regulated by 14.33 (± 3.29) and 39.01 (± 2.30) fold, respectively, 
by transfections with 5' triphosphate A2, and a 3.56 (± 1.48) and 3.23 (± 0.54) fold 
increase, respectively, by de-phosphorylated A2. Likewise, transfection with 5' 
triphosphate and de-phosphorylated SF1 resulted in 50.00 (± 21.52) and 7.34 (± 3.37) 
fold increase, respectively, in MX1; and a 20.23 (± 2.38) and 4.16 (± 0.65) fold 
increase in IFNβ gene expression (Belyaeva et al., 2014). With reference to the p 
values calculated by student t-tests, it was indicated that 5' triphosphate A2 and 5' 
triphosphate SF1 enhanced the expression of IFNβ in C33A cells. Furthermore, it was 
seemed to be significant compared to the corresponding de-phosphorylated aptamers 
(p = 0.0005 and p = 0.01, respectively). It should also be noted that transfections with 
5' triphosphate A2 seemed to cause an up-regulation of IFNβ gene significantly higher 
than that with 5' triphosphate SF1 (p = 0.015).    
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Figure 3.15 Effects of the 5' de-phosphorylation of the RNA on the expressions 
of interferone response genes; MX1 and IFNβ. SiHa (A) and C33A (B) cells were 
transfected with either 5' triphosphate or de-phosphorylated A2 and SF1 
aptamers. Mock transfections and Poly IC incubations were also included as 
negative and positive controls, respectively. Aptamer 21-2 was also included as 
a control due to the presence of –OH groups (a chemically synthesised 
aptamer) at the 5' end instead of a triphosphate. Cells were incubated at 37°C 
for 24 hrs, followed by RNA extraction and cDNA synthesis according to the 
manufacturer`s instructions. Quantitative real-time PCR (qPCR) was performed 
using Quantifast SYBR Green PCR mix, synthesised cDNA from each 
transfections and primers (MX1, IFNβ and U6. Gene expression was measured 
by Corbett Rotor-Gene 6000. Resulting data was analysed according to the ΔΔ 
Ct method by Corbett Rotor-Gene 6000 software. The level of gene expression 
in A2 and SF1, dephosphorylated A2 and SF1, 21-2 and Poly IC transfected wells 
was compared with that of the mock transfected (control) after normalization of 
the expression level to U6. The data was obtained from three independent 
experiments (n = 3), shown together with standard errors. p* = 0.015, p** = 0.01, 
p*** = 0.0005 (student`s t-test). Only significant values were represented in the 
graph.   
Some of the effects on apoptosis could be due to non-specific effects of the 5' 
triphosphate. To investigate this, apoptosis assays was repeated by using de-
phosphorylated aptamers in SiHa cells (section 3.4.2.3). 
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3.4.2.3 Effects of de-phosphorylation of aptamers on apoptosis in SiHa 
cells 
In order to study whether the 5' triphosphate groups of aptamers were involved in the 
induction of apoptosis in SiHa cells, in vitro transcribed aptamers as well as de-
phosphorylated aptamers were utilised. SiHa cells were transfected with A2 and SF1 
+/- de-phosphorylation as well as 21-2 (Figure 3.16). Transfection of SiHa cells with 
50, 100 and 200 nM A2 resulted in an induction of apoptosis by up to 26.7 (± 3.09)%, 
29.3 (± 1.33)% and 30.3 (± 1.51)%, respectively. The corresponding percentage of 
apoptosis with dephosphorylated A2 was 16.26 (± 0.98)%, 16.96 (± 2.66)% and 18.06 
(± 1.79)%, respectively. When A2 was de-phosphorylated, apoptosis was found to be 
decreased with p = 0.0162, p = 0.00735 and p = 0.003221 for 50, 100 and 200 nM of 
aptamer, respectively. Transfection with control aptamer SF1 +/- de-phosphorylation 
was also shown to induce apoptosis in SiHa cells. Apoptosis was found to be 16.6 (± 
0.45)%, 19.8 (± 2.47)% and 18.4 (±1.97)% for 5' triphosphate SF1 and 11.86 (± 
0.33)%, 12.83 (± 0.82)% and 14.3 (± 0.65)% for de-phosphorylated SF1, respectively, 
when SiHa cells were transfected with 50, 100 and 200 nM of the aptamer. 5' OH 
aptamer 21-2 and mock treatment were similar in the apoptosis ratio with 5.66 (± 
0.35)% and 5.1 (± 0.92)%, respectively, whereas staurosporine treatment, as a 
positive control, induced apoptosis by up to 55.23 (± 10.62)% in SiHa cells. The 
significance between 5' triphosphate and dephosphorylated SF1 was p = 0.000573, 
p = 0.0275 and p = 0.058 for 50, 100 and 200 nM aptamer transfections, respectively. 
Although, there was a decrease in apoptosis following de-phosphorylation of both A2 
and control aptamer SF1, induction of apoptosis was significantly enhanced in cells 
transfected with 50 nM de-phosphorylated A2 compared to that of SF1 with p = 
0.0066. 5' triphosphate A2, as shown in section 3.4.1.1, induced apoptosis in SiHa 
cells and it was significant over SF1 transfection with p values of 0.016, 0.014 and 
0.004 for 50, 100 and 200 nM aptamer transfection, respectively.  
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Figure 3.16 Effects of de-phosphorylation on the total apoptosis (early+late) 
triggered by aptamers. Aptamer A2 and SF1 (4 µM each) were de-
phosphorylated using 10 u of Antarctic phosphatase, reaction buffer and 20 u 
RNase for 45 min at 37°C, followed by enzyme inactivation at 70°C for 10 min. 
After phenol: chloroform extraction and ethanol precipitations, aptamers were 
re-suspended in nuclease-free dH2O to obtain 10 µM solutions. SiHa cells were 
seeded on to 12-well plates at 1.5 x 105 cells/ ml per well and incubated for 24 
hrs at 37°C with 5% CO2. Cells were mock transfected or transfected up to 200 
nM with either tri-phosphate (in vitro transcribed) or de-phosphorylated 
aptamers as well as 21-2 (5' OH) as a control. Staurosporine was also used as 
a positive control due to its high potency of causing apoptosis. Cells were 
analysed for apoptosis 24 hours later. Cells were collected and washed several 
times with PBS. Cell pellets were dual-stained with FITC-conjugated annexin V 
and propidium iodide followed by analysis on the flow cytometer. Graph shows 
the total percentage of apoptosis, analysed from three independent 
experiments (n = 3), together with standard errors. P values were calculated for 
each concentrations in the same aptamer, tri-phosphate or de-phosphorylated. 
p* <0.05, p** <0.01 and p*** <0.001. 
3.5 Chapter Discussion 
Tumour formation in HPV positive cervical cancers is initiated by uncontrolled 
proliferation of cells due to abrogation of cell cycle control by HPV oncoproteins. pRb 
and its related proteins, p107 and p130 are major tumour suppressor proteins that 
prevents uncontrolled proliferation by preventing cells to enter S-phase of cell cycle 
(Nevins, 2001). pRb is a key target for inactivation by the viral oncoproteins E1A, E7 
and T-antigen from adenovirus, HPV and simian 40 (SV40), respectively (Felsani et 
al., 2006) E7 from other high- and low- risk HPVs are able to target these tumour 
98 
 
suppressor proteins for degradation, resulting in the release of E2Fs therefore leading 
to transcription of downstream S-phase genes (Davies et al., 1993, Felsani et al., 
2006, Zhang et al., 2006). In this chapter, the levels of E7 and pRb expression in three 
different cervical cancer cell lines; CasKi, SiHa and HeLa cells were studied and 
compared to levels in HEK293T cells. 16E7 from CaSki and SiHa cells and 18E7 from 
HeLa cells were detected, however levels were higher in CaSki cells (Figure 3.1). pRb 
expression levels in SiHa and HeLa cells were higher than in CaSki cells which is 
consistent with having lower levels of E7 present in these cells. Both phosphorylated 
and unphosphorylated forms of p130 from CaSki and SiHa cells were also detected 
despite the fact that their levels were also reduced in comparison to 293T cells 
possibly due to E7 oncoprotein expression. Attempts in order to detect p130 from 
HeLa cells were not successful. Due to the high level of E7 expression, CaSki cells 
were selected for further experiments.  
 
The effects of HPV16 E7 aptamers especially A2 on pRb and E7 levels was then 
investigated (Figure 3.2). Following the transfection of CaSki cells with A2, steady 
state levels of E7 decreased with an accompanied increase in pRb levels (Nicol et al., 
2013). This was consistent with the hypothesis that A2 was binding to LXCXE motif 
of E7, therefore preventing its binding to pRb (Nicol et al., 2011, Nicol et al., 2013). 
Recovery of pRb, especially the hypophosphorylated active form, might lead to cell 
cycle arrest and apoptosis of cervical cancer cells, since, it was shown that expression 
of constitutively active ectopic pRb alleles (PSM-Rb) suppress cell proliferation by 
arresting the cell cycle (Angus et al., 2002). Depletion of E7 following A2 treatment in 
SiHa cells might have resulted in the reactivation of mechanisms that are involved in 
the cell cycle control, indicating that although HPV positive cells are highly 
transformed they are still very much dependent on the functions of E7 for cell viability 
(Goodwin and DiMaio, 2000, Magaldi et al., 2012). Elevated levels of active pRb might 
have also been the trigger for apoptosis that was observed in HaCaT-HPV16 E7 
stable cells (Figure 3.14B). However, some pRb-independent mechanisms could also 
result in cell proliferation in cervical cancer cells. Some antibodies that were identified 
against E7 were shown to bind to the amino terminus but not pRb binding site by 
epitope mapping and inhibit cell proliferation in SiHa cells possibly via pRb-
independent mechanisms (Accardi et al., 2011). The region upstream of the LXCXE 
pocket of E7 at the amino terminus was also shown to be involved in the degradation 
of pRb and its related proteins although it does not play a role in E7-pRb binding 
(Gonzalez et al., 2001). Non-pRb targets of E7 have also been studied and 
demonstrated to be important in development of invasive cervical  carcinoma (Balsitis 
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et al., 2003). In addition, E7 could also destabilise pRb via other cellular proteins (Huh 
et al., 2005).  
 
Rb is the first gene from Rb family, however, subsequently two other related proteins 
from same family were identified as p130 (Rb2) and p107 (Rbl2) (Felsani et al., 2006).  
These family of proteins share a considerable structural and functional homology, 
primarily at the level of the 'pocket' domain (see section 1.2.4.2) (Felsani et al., 2006). 
HPV16 E7 and other  DNA tumour viruses such as polyomavirus Large T antigen and 
adenovirus E1A, which contains an LXCXE motif could also bind other Rb related-
proteins, p107 and p130 (DeCaprio, 2014). Therefore, steady state level of p130 was 
also investigated in the presence and absence of aptamers (Figure 3.2C). Levels of 
p130, however, seemed unaffected following aptamer transfection with A2 (Figure 
3.2D). In addition to A2, transfection with A1 and J1 seemed to slightly decrease E7 
levels. Mfold software predicts a very similar, and quite stable secondary structures 
for aptamers A1 and A2, having a stemloop containing a CCAC motif (Figure 3.3). 
However, both secondary structures predicted for A3 by Mfold were less stable than 
for other A-series aptamers although there is only 1-2 nucleotide difference in 
sequence. This structure prediction seemed to be consisted with data presented here 
where A1 and A2 had an effect on E7 degradation but not A3 (Figure 3.2A, B). One 
reason for this could be the lower affinity binding of  A3 (KDapp = 251 nM),  to GST-E7 
in comparison with A1 and A2 (KDapp = 87 and 107 nM, respectively) (Nicol et al., 
2011). J1 was also demonstrated as being effective on E7 oncoprotein degradation 
(Figure 3.2A, B). 
 
The amino terminus of E7 is “intrinsically disordered” or “natively unfolded” which may 
present conformational plasticity to E7 in order to optimise their binding to multiple 
cellular components by conformational change (α-helix and β-sheet transition) 
depending on the conditions of intracellular environment such as pH (Garcia-Alai et 
al., 2007, Uversky et al., 2006). Therefore, we could hypothesise that an HPV16 E7 
aptamer, especially A2 binding to amino terminus, could result in a conformational 
shift of the E7 oncoprotein, preventing its interactions with other cellular target 
proteins as well as pRb. Therefore, in addition to preventing pRb binding via 
occupying LXCXE pocket with aptamers, A2 could affect E7 conformational change, 
therefore effecting other interactions leading to unstability and subsequently 
degradation of E7. E7 is a highly unstable protein with a half-life of around ~30 min 
(Smotkin and Wettstein, 1987). Prevention of E7 oncoprotein binding pRb by A2 could 
therefore be resulting in the gradual depletion of E7 from CaSki cells.  
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The model above predicts that E7 loss could be accompanied by apoptosis. This was 
investigated in SiHa cells (HPV16 positive) as well as HeLa and C33A cells (HPV18 
positive and HPV negative, respectively) (Figure 3.12). Apoptosis assays indicated 
that HPV16 E7 aptamer A2 induced apoptosis in SiHa cells but not in HeLa or C33A 
cells. It was not possible to demonstrate the same experiments in CaSki cell cells due 
to higher levels of E7 expression. In addition, it was not possible to increase the 
amount of transfected RNA (Nicol et al., 2013, personal communication). It was shown 
that CaSki cells were highly resistant to the overexpression or recovery of pRb 
compared to SiHa and HeLa cells (Bourgo et al., 2009). One explanation could be 
that CaSki cells could also bear additional mutations preventing responses to ectopic 
expressions or recovery of pRb. 
Apoptosis induced by A2 was significantly higher than that by control aptamer SF1 in 
HPV positive SiHa cells (Figure 3.12A). Other A-series aptamers A1 and A3, similarly, 
seemed capable of inducing apoptosis in SiHa cells (Figure 3.13A). However, they 
did not cause a decrease in the levels of E7 oncoprotein as good as A2 (as discussed 
above). Although A1 and A3 might not be as effective in disrupting E7-pRb 
interactions (Nicol et al., 2013), they could still change the conformation of E7 
oncoprotein which might be affecting its interactions with other cellular proteins, 
resulting in non-pRb mediated apoptosis in HPV positive cells.  
HPV16 and HPV18 only share around ~ 50% homology at the nucleotide level 
(Corden et al., 1999) and they  result in similar disease although HPV16 and 18 differs 
in malignant transformation. HPV18 might be more aggressive than HPV16 
(Badaracco et al., 2002, Fernandes et al., 2005). This could be due to the full 
integration of HPV18 into the host genome even in pre-invasive lesions (Badaracco 
et al., 2002).There are, however, conserved sequences between HPV16 and 18 E7. 
Therefore, cross-reactivity of the E7 aptamers with HPV18 E7 was investigated 
(Figure 3.11). Our main observation was that aptamer A2 seemed to have relatively 
smaller effect on HPV18 E7 when compared to another A-series aptamer A1 and also 
an outlier aptamer J1. These aptamers (especially A1 and J1) resulted in a decrease 
in the levels of HPV18 E7 in HeLa cells. When pRb levels were analysed, there was 
an accompanying increase in its steady state level (figure 3.11C, D). However, this 
was not correlated with the degree of reduction of HPV18 E7 following aptamer 
transfections. Therefore, the interaction of A1 and J1 with HPV18 E7 could be via 
other regions of oncoprotein than the pRb binding site, LXCXE in conserved region 2. 
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RNA polymerases, including phage polymerase, leave a triphosphorylated end at the 
5' end of RNA molecules transcribed in vitro from 5' – to 3' – using a template DNA 
(Kim et al., 2004). Due to possessing this 5' triphosphate moiety, aptamers might 
trigger RIG-I induced upregulation of interferon genes. The recognition of 5' 
triphosphate RNA by RIG-I is known to be independent of the RNA sequence 
(Hornung et al., 2006). In addition to RIG-I, interferon-induced proteins with 
tetratricopeptide repeats (IFITs) were recently discovered and shown to directly 
engage with 5' triphosphate RNAs in a non-sequence specific manner via their 
tetratricopeptide repeat domains (TPRs), resulting in the reduction of viral replication 
in HEK cells (Abbas et al., 2013). RIG-I, however, has been studied extensively well 
and shown to require recoginition by base-pairing to some extent (10 bp) and/or a 5' 
triphosphate group to induce antiviral signaling (Schlee et al., 2009b, Schmidt et al., 
2009).   
 
Interferon production was observed to be enhanced by poly I:C treatment in both SiHa 
and C33A cells (Figure 3.15). Since, RIG-I can be activated by poly I:C (Yoneyama 
et al., 2004), in particular by shorter size fractions (300 bp) (Kato et al., 2008), which 
is a dsRNA polymer generated by polynucleotide phosphorylase and harbours 
5`monophosphates (Grunberg-Manago, 1967). However, 21-2 bearing a 2' – OH at 
the 5' end of RNA did not induce upregulation of interferon genes (Figure 3.15A, B).  
Aptamer A2 and SF1 (control aptamer) as well as dephosphorylated A2 and SF1 were 
used for transfection of SiHa (HPV positive) and C33A (HPV negative) cells in order 
to analyse by RT-qPCR whether some interferon response genes, MX1 and IFNβ, 
were upregulated (Figure 3.15). A2 and SF1 were both found to induce production of 
MX1 and IFNβ in SiHa and C33A cells. Dephosphorylation of aptamers did not result 
in a significant decrease in interferon production in SiHa cells although mean values 
were indicating that dephosphorylation did reduce the response. However, IFNβ 
expression were found to be significantly downregulated by transfection with 
dephosphorylated aptamers compared to 5`triphosphate aptamers in C33A cells 
although overall production of interferon were higher in SiHa cells than C33A cells. 
This could be due to the difference in localisation of aptamer/RIG-I complexes in 
different cells.  
Modifications of bases (pseudouridine, 2-thio-uridine) and backbone (2'-O-methyl-
uridine, 2'-fluoro-uridine) have been shown to abolish innate immune signalling via 
both TLR7/8 and RIG-I by triphosphate RNA (Hornung et al., 2006, Uzri and Gehrke, 
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2009, Morrissey et al., 2005). HCV 3 - UTR and poly (U/UC) RNAs transcribed with 
2'- fluoro-dUTP, 2'-fluoro- dCTP and pseudouridine were demonstrated to be impaired 
in their immunostimulatory effects (Uzri and Gehrke, 2009) although they were still 
able to bind RIG-I, suggesting that these modifications might be inhibiting the 
subsequent conformational change, dimerisation or ATPase activation of RIG-I. 
Conversely, HPV16 aptamers as well as control aptamer SF1 with 5' triphosphate 
triggered an interferon response, especially IFNβ production despite incorporation of 
2'-deoxy-2'-fluoro-UTP or CTP (in order to increase the stability against 
endonucleases).  
Dephosphorylated aptamers seemed also to induce IFNβ and MX1 gene expression 
although the average fold activation of the response were slightly lower than for 5' 
triphosphate aptamers. This could have resulted from the fact that dephosphorylation 
might not be 100% efficient. Similar studies have been perfomed using siRNAs. These 
molecules were treated with RNase T1 or phosphatase which abolised the interferon 
production triggered by transcribed RNA  molecules (Kim et al., 2004). These 
dephosphorylated (mono-phosphate) aptamers could be activating innate immunity 
via some other pathways such as TLR3. Since, synthetic mono-phosphate 2' fluoro 
modified siRNA molecules were shown to induce type I interferon (IFNα and β), IL-8 
and TNF-α production through TLR3 (Kariko et al., 2004). It has been shown that 
although TLR expression was reduced in HPV positive cells when compared to HPV 
negative (C33A) cells, TLR3 however was found to be expressed relatively better 
among other TLRs in HPV positive cells (Yu et al., 2012). Activation of TLR3 triggers 
intracellular pathways mediated by NFκB and MAPK, resulting in the upregulation of 
IFNβ and TNF-α gene expression (Alexopoulou et al., 2001, Kenny and O'Neill, 2008). 
NFκB will then result in the expression of pro-inflammatory cytokines (e.g. IL-1) which 
induces senesence and apoptosis along with IFN-β (Chiantore et al., 2012, Duan et 
al., 2011). This could be one of the reasons why relatively higher background of 
induction of apoptosis in cells by 5' triphosphate aptamer transfection was observed. 
Therefore, the effect of 5' triphosphate as well as dephosphorylated aptamers in the 
induction of apoptosis was analysed by Annexin V apoptosis assays (Figure 3.15). 
Although apoptosis induced by A2 was significantly higher than that by control 
aptamer SF1, dephosphorylation of aptamers also resulted in a decrease in 
apoptosis. Therefore, we could suggest that some of the apoptosis reported might be 
due to the 5' triphosphate moiety.  
 
103 
 
 PATHWAYS OF E7 DEGRADATION BY APTAMER 
TRANSFECTION 
 
4.1 Use of inhibitors to study the degradation of E7 in the 
presence or absence of aptamers 
4.1.1 Introduction 
In eukaryotes, protein degradation occurs via four different mechanisms (Ryhanen et 
al., 2009). Proteasomes are the major pathway which is responsible for the 
degradation of normal or mis-folded long- or short- lived proteins. Second is 
mitochondrial proteases that are responsible for degradation of mitochondrial 
proteins. Third is the degradation of membrane associated proteins or enzymes as 
well as cytoskeletal proteins via calcium-activated calpains (cysteine proteases). Last 
is lysosomal degradation/autophagy where membrane proteins, endocytosed 
proteins and organelles are degraded. 
Proteasomes are located both in the nucleus and cytosol of all cells both free or 
attached to the endoplasmic reticulum. They are responsible for the ATP-ubiquitin-
dependent protein degradation. This means that proteasomes recognise and digest 
proteins that targeted for degradation with an ubiquitin group. The proteasome is a 
large 26S multicatalytic complex which is responsible for degradation of 
polyubiquitinated substrates generated by the polyubiquitinating enzymatic 
machinery (Ciechanover, 2005). It consists of two subcomplexes one of which is ATP-
dependent 19S regulatory particle responsible for recognition of polyubiquitinated 
substrates (Ciechanover, 2005). The 20S subcomplex is the core of the proteasome 
which harbours multiple peptidase activities including chymotryptic, tryptic-, and 
peptidylglutamyl-like activity (Bochtler et al., 1999). 20S proteasome has a cylindrical 
shape with four rings. Two rings with seven α-subunits are located on the outer sides 
and other two rings with seven β-subunits are both located on the inner side (Craiu et 
al., 1997). Centre of this 20S particle somewhere in β-subnuits functions as a 
proteolytic core. There are also a variety of protein substrates which can be degraded 
by proteasomes in a ubiquitin-independent manner such as Rpn4, thymidylate 
synthase and ornithine decarboxylase which functions as a transcriptional regulator 
of proteasome homeostasis, an enzyme in DNA replication and polyamine 
biosynthesis, respectively (Erales and Coffino, 2014).  
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The other mechanism for protein degradation is through lysosomes which are 
membraneous organelles containing digestive enzymes such as aspartin, cysteine 
and serine proteases (Craiu et al., 1997). They can metabolise cytoplasmic proteins 
and organelles as well as endocytosed extra cellular proteins, nucleic acids or other 
substances. In order to be able to degrade cellular proteins, proteins need to be 
internalised by lysosomes. This could happen via “autophagy” where vesicles termed 
“autophagosomes” are formed in the cytoplasm which originates from endoplasmic 
reticulum, mitochondria, glycogen bodies and other cytoplasmic materials 
(Ciechanover, 2005). These vesicles are then fused with lysosomes and degradation 
of their contents occurs by lysosomal enzymes. Uptake by lysosomes is not 
completely nonselective. In the case of starvation, for instance, some cellular proteins 
could be internalised and broken down by lysosomes. These proteins have been 
suggested to contain a consensus amino acid sequence, KFERQ, possibly involved 
in targeting to the lysosomes (Ciechanover, 2005). Molecular chaperons such as 
Hsp70 family could also play a role in the internalisation of proteins into lysosomes by 
unfolding the proteins in order to ensure their transport across the lysosomal 
membrane (Ryhanen et al., 2009).  
As shown in section 3.2, HPV16 E7 aptamers, especially A2, were found to reduce 
the steady state level of E7 in CaSki cells. To further analyse E7 degradation induced 
by A2, several proteasomal and lysosomal inhibitors as well as inhibitors against 
endoplasmic reticulum associated and HDAC6 mediated (for mis-folded proteins) 
degradations were used to look for differences in degradation patterns in the presence 
or absence of aptamer. Levels of E7 oncoprotein and cellular proteins were 
determined by immunoblot analysis and results were also represented as graphs 
obtained by densitometry analysis.  
4.1.2 Effects of MG132 (an inhibitor for proteasomes/lysosomes) on E7 
degradation 
The peptide-aldehyde proteasome inhibitor, MG132 (carbobenzoxyl-L-leucyl-L-
leucyl-L-leucinal) (a natural triterpene) is derived from a Chinese medicinal plant, 
which inhibits 20S proteasome activity by a covalent association with the active site 
of the beta subunits and effectively interrupt the proteolytic function of the 26S 
proteasome complex, which is the most commonly used mammalian cytosolic 
proteasome, reversibly (Guo and Peng, 2013). In order to determine the toxicity of 
this inhibitor in CaSki cells, the concentration of MG132 for use was optimised by 
treatments of 50, 100 and 200 µM. At 100 µM, protein translation was not completely 
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abolished but degradation was inhibited (data not shown). CaSki cells that were 
transfected with aptamers for 16 hours were treated with MG132 for 0, 3 and 6 hrs. 
Treatments were performed for 16 hours which should allow enough time to A2 to 
bind E7 without completely depleting E7 levels (Figures 3.4 and 3.5).  
 
 
Figure 4.1 Treatment of CaSki cells with 100 µM MG132 for 0, 3 and 6 hrs to 
analyse E7 degradation following aptamer transfection. CaSki cells were 
seeded on 6-well plates 24 hrs prior to transfection with aptamers. Cells were 
then mock transfected (Lane 1-3) or transfected with 100 nM A2 (Lanes 4-6) or 
SF1 (Lanes 7-9) for 16 hrs. Each transfection was subjected to 0 (Lanes 1, 4, 7), 
3 (Lanes 2, 5, 8) and 6 (Lanes 3, 6, 9) hrs incubation with 100 µM MG132 at 37°C. 
Samples were collected, lysed in RIPA (containing protease inhibitors, DNase 
I, MgCl2) and Laemli SDS-loading buffer. Immunoblot analysis was performed 
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to detect p130, pRb, E7 and GAPDH (loading control for E7). Densitometry 
analysis of band intensities were performed and presented as a graph, together 
with standard errors (B) following normalisation against GAPDH relative to % 
of 0 h mock treatment. The result shown is a representative of three (n = 3) and 
two (n = 2) independent experiments, respectively for E7 and, pRb and p130. 
Figure 4.1 showed an increase in E7 levels following MG132 treatment in the 
presence or absence of the aptamer, suggesting that E7 degradation in general 
occurs via proteasomal degradation. The levels of E7 did not appear to be affected 
by MG132 treatment. Therefore, proteasomal pathways might not be responsible for 
A2-mediated effects. In addition, p130 levels were enhanced following MG132 
treatment in a time dependent manner, suggesting that this protein was also degraded 
by the proteasomal pathway. When 0 h MG132 treatments from mock (Lane 1), A2 
and SF1 (Lanes 4 and 7, respectively) were compared in Figure 4.1A, A2 transfection 
was shown to result in the recovery of pRb as expected (section 3.2.2). However, 
overall the effects of MG132 treatment on pRb levels were clouded by possible E7 
build up. An interesting observation from both western blot and densitometry data was 
that 0 h MG132 treatment of aptamer transfected CaSki cells (Figure 4.1A, Lanes 4 
and 7) showed less p130 expression when compared to mock treated cells (Figure 
4.1A, Lane 1). This was not consistent with the increase seen in pRb levels following 
A2 transfections.  
4.1.3 Effects of lactacystin (a proteasome inhibitor) on E7 degradation 
Lactacystin, an antibiotic isolated from Streptomyces, inhibits protein degradation 
irreversibly by covalently modifying chymotryptic, tryptic and peptydylglutamyl peptide 
hydrolysing activities of 20S and 26S proteasomes (Craiu et al., 1997). It is a highly 
specific inhibitor showing no effects on cysteine or serine proteases which belong to 
lysosomal proteases located within all vesicles of the endocytic pathway (Craiu et al., 
1997). 
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Figure 4.2 Treatment of CaSki cells with 20 µM lactacystin for 0, 3 and 6 hrs to 
analyse E7 degradation following aptamer transfection. CaSki cells were 
seeded on 6-well plates 24 hrs prior to transfection with aptamers. Cells were 
then mock transfected (Lanes 1-3) or transfected with 100 nM A2 (Lanes 4-6) or 
SF1 (Lanes 7-9) for 16 hrs. Each transfection was subjected to 0 (Lanes 1, 4 and 
7), 3 (Lanes 2, 5 and 8) and 6 (Lanes 3, 6 and 9) hrs incubation with 20 µM 
Lactacystin at 37°C. Samples were collected, lysed in RIPA (containing 
protease inhibitors, DNase I, MgCl2) and Laemli SDS-loading buffer. 
Immunoblot analysis was performed to detect p130, pRb, E7 and GAPDH 
(housekeeping control for E7). Densitometry analysis of band intensities were 
performed and presented (B) following normalisation against GAPDH relative 
to % of 0 h mock treatment. The result shown is a representative of two 
independent experiments (n = 2) for E7 and single experiment for pRb and p130 
(n = 1). 
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E7 and pRb and p130 degradation with or without aptamers were also investigated 
with the more specific proteasome inhibitor, lactacystin (Figure 4.2). Treatment of 
mock (Lanes 2 and 3) or aptamer transfected (Lanes 5 and 6 for A2; Lanes 8 and 9 
for SF1) CaSki cells with lactacystin resulted in accumulation of E7 oncoprotein 
(Figure 4.2A), indicating that degradation of E7 occurred via proteasomal pathway 
with no difference between mock or aptamer transfections. Figure 4.2A also showed 
the detection of both hypo- and hyper- phosphorylated forms of p130. Inhibitor 
treatment seemed to result in an increase in the hypo-phosphorylated form and a 
decrease in the hyper-phosphorylated p130 with A2 transfected cells (Figure 4.2A, 
Lanes 4, 5 and 6). Whereas, both forms of p130 seemed to increase in mock treated 
cells following incubation with the inhibitor (Lanes 1, 2 and 3). Detection of p130 for 
SF1 treated cells were poor (Lanes 7, 8 and 9), therefore results for the effect of SF1 
on p130 were inconclusive. E7 and p130 protein bands were difficult to quantitate, 
therefore only western blot data is presented here. 
However, pRb was detected by immunoblotting and densitometry analysis was also 
performed (Figure 2.4A and B). Both demonstrated that inhibitor treatment resulted in 
a decrease in pRb levels in mock and aptamer transfected cells despite expectation 
of an increase instead. This could result from accumulation of E7 which could be 
targeting pRb and preventing its build-up. However, the densitometry graph (Figure 
2.4B) was generated from n = 1 data.  
4.1.4 Effects of chloroquine (a lysosomal inhibitor) on E7 degradation 
Chloroquine (well-known as anti-malarial drug) as a weakly basic compound could 
accumulate in acidic organelles such as endosomes and lysosomes, therefore 
prevents lysosomal acidification. Accumulation of this inhibitor in lysosomes results in 
the inhibition of enzymes which are highly dependent on the acidic pH, and 
enlargement of lysosomes (Nujic et al., 2012). Consequently, many cellular functions 
including receptor–mediated endocytosis, autophagy, apoptosis and protein 
degradation could be affected due to inhibition of autophagosome–lysosome fusion 
(Shintani and Klionsky, 2004). Chloroquine seemed to be highly toxic to cells, 
resulting in a dramatic decrease in protein levels possibly by affecting translation of 
proteins including E7 oncoprotein (data not shown). Therefore, first, working and 
nontoxic concentrations of chloroquine were determined and optimised by treating 
CaSki cells with a series of concentrations (10 – 200 µM) for several time points (0 – 
6 hrs), and analysing cell lysates by immunoblotting. Treatment of cells with 30 µM of 
chloroquine, concentration was selected for further experiments due to the lowest 
109 
 
toxicity, was performed in CaSki cells in the presence and absence of aptamer (Figure 
4.3).  
 
Figure 4.3 Treatment of CaSki cells with 30 µM chloroquine for 0, 3 and 6 h to 
analyse E7 degradation following aptamer transfection. CaSki cells were 
seeded on 6-well plates 24 h prior to transfection with aptamers. Cells were then 
mock transfected (Lanes 1-3) or transfected with 100 nM A2 (Lanes 4-6) or SF1 
(Lanes 7-9) for 16 h. Each transfection was subjected to 0 (Lanes 1, 4 and 7), 3 
(Lanes 2, 5 and 8) and 6 (Lanes 3, 6 and 9) hrs incubation with 30 µM chloroquine 
at 37° C. Samples were collected, lysed in RIPA (containing protease inhibitors, 
DNase I, MgCl2) and Laemli SDS-loading buffer. Immunoblot analysis was 
performed to detect p130, pRb, E7 and GAPDH (loading control used for E7). 
Densitometry analysis of band intensities were performed and presented (B) 
following normalisation against GAPDH relative to % of 0 h mock treatment. The 
result shown is one of two independent experiments (n = 2).  
 
Figure 4.3 A and B showed that there was a slight increase in the levels of E7 with 
mock (Lanes 2 and 3) and SF1 (Lanes 8 and 9) transfection following chloroquine 
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treatment, suggesting that E7 could also be degraded via lysosomes. There was no 
A2-mediated build-up of E7 detected (Lanes 5 and 6), however, this was n = 1. pRb 
levels were shown in Figure 4.3A as unaffected by chloroquine treatment, possibly 
due to the fact that pRb degradation could not be mediated by lysosomes. 
Densitometry analysis of pRb could not be performed owing to the poor quality of the 
pRb blot. 
4.1.5 Effects of Tubacin (an inhibitor of HDAC6 which is required for 
degradation of mis-folded proteins) on E7 degradation 
As discussed in section 3.5, E7 oncoprotein might have had a conformational change 
as a result of aptamer binding, therefore resulting in the degradation of the protein via 
pathways involved in mis-folded protein degradation such as HDAC6. Histone 
deacetylase 6 (HDAC6) is a cytoplasmic deacetylase involved in the catalysis of 
alpha-tubulin deacetylation, which result in cell motility (Gao et al., 2007). Data 
obtained from co-localisation experiments of HDAC6 with some aggresome markers 
showed that HDAC6 could translocate to aggresomes in response to stress or potent 
agent that induce mis-folding of proteins such as DTT and tunicamycin (Kawaguchi 
et al., 2003). The same report also indicated by immunoprecipitation of HDAC6 with 
polyubiquitinated and unubiquinated species of the same protein that HDAC6 
selectively co-precipitates with polyubiquitinated proteins, and therefore facilitates the 
formation of polyubiquitinated mis-folded proteins in aggresomes (Kawaguchi et al., 
2003). Inhibition of HDAC6 diminishes the recruitment of polyubiquitinated proteins to 
dynein, the clearance of mis-folded protein aggregates from the cytoplasm, and 
aggresome formation (Kawaguchi et al., 2003). Therefore, an inhibitor against 
HDAC6, Tubacin was utilised in order to disrupt HDAC6-mediated protein 
degradation. Due to the fact that tubacin has been reported to induce tubulin 
acetylation (Chou and Chen, 2008), an acetylated tubulin antibody were also included 
in immunoblotting in order to confirm the efficiency of tubacin treatments as a positive 
control (Figure 4.4).  
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Figure 4.4 Treatment of CaSki cells with 25 µM tubacin for 0, 3 and 6 hrs to 
analyse E7 degradation following aptamer transfection. CaSki cells were 
seeded on 6-well plates 24 hrs prior to transfection with aptamers. Cells were 
then mock transfected (Lanes 1-3) or transfected with 100 nM A2 (Lanes 4-6) or 
SF1 (Lanes 7-9) for 16 hrs. Each transfection was subjected to 0 (Lanes 1, 4 and 
7), 3 (Lanes 2, 5 and 8) and 6 (Lanes 3, 6 and 9) hrs incubation with 25 µM 
Tubacin at 37°C. Samples were collected, lysed in RIPA (containing protease 
inhibitors, DNase I, MgCl2) and Laemli SDS-loading buffer. Immunoblot analysis 
was performed to detect p130, pRb, E7 and GAPDH (loading control used for 
E7). Densitometry analysis of band intensities were performed and presented 
(B) following normalisation against GAPDH relative to % of 0 h mock treatment. 
The result shown is a representative of two independent experiments (n = 2). 
 
112 
 
Figure 4.4A showed that tubacin treatment resulted in a dramatic increase in 
acetylated tubulin (~55 kDa) in a time-dependent manner. Conversely, E7 levels 
seemed unaffected or slightly decreased with inhibitor treatment, suggesting that mis-
folded protein response is not responsible for normal E7 degradation (Figure 4.4 A, 
B). Even if A2 causes conformational change of E7, it does not seem to trigger this 
pathway.  pRb and p130 data could not be obtained for tubacin treatment.  
4.1.6 Effects of Eeyarestatin I (an inhibitor for ER-associated protein 
degradation) on E7 degradation   
The ER-associated degradation (ERAD) pathway is responsible for ubiquitin-
mediated degradation of several ER-associated mis-folded as well as normal proteins 
in cytosol by proteasome. This pathway requires AAA ATPase p97, which is a 
cytosolic ATPase and its function is to carry polyubiquitinated mis-folded proteins from 
the ER membranes in to the proteasome for degradation (Wang et al., 2008). ERAD 
can be inhibited by Eeyarestatin I in mammalian cells. This inhibitor was shown to 
form complexes with p97 (Wang et al., 2008). These complexes were detected to emit 
higher fluorescence from eeyarestatin I treated cells when compared to untreated 
cells or complexes formed by another cytosolic protein, heat shock protein 90 (Hsp90) 
(Wang et al., 2008). Formation of eeyarestatin I and p97 complexes were later 
indicated by surface plasmon resonance (SPR) analysis as a result of a direct 
interaction (Wang et al., 2010). This inhibitor, eeyarestatin I was employed so as to 
investigate E7 degradation in CaSki cells in the presence or absence of aptamers 
(Figure 4.5).  
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Figure 4.5 Treatment of CaSki cells with 8 µM eeyarestatin I for 0, 3 and 6 hrs to 
analyse E7 degradation following aptamer transfection. CaSki cells were 
seeded on 6-well plates 24 hrs prior to transfection with aptamers. Cells were 
then mock transfected (Lanes 1-3) or transfected with 100 nM A2 (Lanes 4-6) or 
SF1 (Lanes 7-9) for 16 hrs. Each transfection was subjected to 0 (Lanes 1, 4 and 
7), 3 (Lanes 2, 5 and 8) and 6 (Lanes 3, 6 and 9) hrs incubation with 8 µM 
eeyarestatin I at 37°C. Samples were collected, lysed in RIPA (containing 
protease inhibitors, DNase I, MgCl2) and Laemli SDS-loading buffer. 
Immunoblot analysis was performed to detect p130, pRb, E7 and GAPDH 
(loading control for E7). Densitometry analysis of band intensities were 
performed and presented (B) following normalisation against GAPDH relative 
to % of 0 h mock treatment. The result shown is a representative of two 
independent experiments (n = 2).  
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Figure 5.5A and B demonstrated that E7 levels from mock (Lanes 1, 2 and 3) and A2 
(Lanes 4, 5 and 6) transfected cells slightly increased with eeyarestatin I treatment, 
suggesting that this pathway might be involved in normal E7 degradation. However, 
SF1 transfected cells showed a decrease in E7 levels with inhibitor (Lanes 7, 8 and 
9). This could be related to toxicity issues of the inhibitor or issues with poor quality of 
western blot. Levels of pRb as well as p130 seemed to decrease with inhibitor 
treatment, and protein bands were difficult to quantitate.  
4.2 Investigation of the E7 cellular localisation in the 
presence and absence of aptamers 
4.2.1 Introduction 
E7 localisation in CaSki cells has shown previously in soluble cytoplasmic fraction by 
subcellular fractionation using a radioactively labelled cysteine, L – [35S] cysteine 
(Smotkin and Wettstein, 1987). Immunofluorescence studies indicated that E7 also 
localised in the nucleus (Smith-McCune et al., 1999). In addition, HPV16 E7 was 
reported to be associated with nucleolus of HPV16 positive CaSki cells by 
immunofluorescence and electron microscopy immuno-gold labelling (Zatsepina et 
al., 1997). There is a discrepancy in the literature regarding the localisation of E7 in 
cells. It appears to be cytoplasmic by subcellular fractionation, however it was shown 
also to be nuclear by immunofluorescence staining and immunocytochemistry. This 
was explained by the assumption that cell fractionation disrupts E7 – nuclear 
associations due to a broken cell structure (Sato et al., 1989). Another explanation 
could be the fact that E7 has been shown to exist as dimers in the nucleus, therefore 
it might easily escape into the cytoplasmic fraction during subcellular fractionation. It 
was shown using antibodies with high discrimination capacity against monomeric, 
dimeric as well as oligomeric forms of E7 in immunofluorescence that E7 exist as a 
dimer in the nucleus but as in an oligomeric form in the cytoplasm of CaSki cells 
(Dantur et al., 2009). HPV16 E7 contains nuclear localisation and export sequences, 
therefore could shuttle between cytoplasm and nucleus (Knapp et al., 2009). When 
nuclear export was blocked by treatment of cells with Leptomycin B, accumulation of 
E7 was detected in the nucleus (Knapp et al., 2009, Laurson and Raj, 2011). With the 
use of an rabbit monoclonal antibody raised against conformational epitope (86 – 
TLGIVCPICSQK – 97) in the carboxyl-terminal domain of the HPV16 E7, it was shown 
that E7 is less homogenously distributed in both cytoplasm and nucleus of HPV16 
positive CaSki cells as well as tumour cells (Dreier et al., 2011). Confluency of cell 
culture was also shown by immunocytochemistry to have an effect on E7 localisation, 
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being predominantly cytoplasmic in confluent cells whereas locating to both nucleus 
and cytoplasm in sub-confluent cells (Laurson and Raj, 2011).  
E7 localisation was investigated in SiHa cells by an antibody raised against full-length 
HPV16 E7. Fluorescent signal could be seen visible throughout the cell membrane in 
surface of non-permeabilised cells, however permeabilisation allows staining 
detected in the cytoplasm (Shrimal et al., 2012). Therefore, permeabilised and non-
permeabilised cells were used in order to be able to detect E7 on the plasma 
membrane of HPV16 positive SiHa cells.  
4.2.2 Localisation of E7 on cellular membrane and co-localisation with 
Cell Mask-Orange (a membrane stain) 
HPV16 E7 were analysed by immunofluorescence using an HPV16 E7 specific 
antibody as well as a fluoro-labelled secondary antibody for microscopic detection. 
SiHa (HPV16 E7 expressing), SaOS-2 (derived from osteosarcoma, an HPV negative 
cell line) and HaCaT (immortalised human keratinocytes, an HPV negative cell line) 
cells were utilised. Both permeabilised and non-permeabilised cells were employed 
in order to investigate both intracellular protein as well as possible membrane 
localised E7.  
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Figure 4.6 E7 distributes to the plasma membrane of HPV-transformed cells. 
HPV16 E7+ SiHa cells (i and ii) (A), SaOS-2 and (B) HaCaT cells (C) (as negative 
controls, containing no E7) were fixed, permeabilised and incubated with 
antibodies recognising full-length HPV16 E7 (A-i, C-i) and (B), and residues 35-
56 (A-ii) and (C-ii). A comparable group of live cells was incubated with these 
antibodies in parallel. Incubation with anti-E7 antibody was performed for 1 h 
at 4°C. Cells were fixed with 4% formaldehyde and stained with AlexaFluor568 
anti-mouse antibodies. Fluorescent imaging was performed using either a Zeiss 
LSM700 or LSM510 inverted microscope. Blue and red are DAPI (nucleus) and 
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E7, respectively. The scale bar is 10 µm. Representative images are shown for 
SiHa, SaOS-2 and HaCaT cells, respectively with n = 3, n = 2 and n = 2.  
 
Permeabilised SiHa cells showed that E7 oncoprotein were predominantly localised 
to the cytoplasm of the cells (Figure 4.6A). However, when these cells were left non-
permeabilised and unfixed, E7 antibody was able to recognise E7 located on the outer 
layer of plasma membrane (Figure 4.6A). Same antibody was used in SaOS-2 and 
HaCaT cells (Figure 4.6B anc C) as a negative controls to check specificity of the 
antibody and showed no E7 detection as expected. 
In order to confirm the localisation of E7 on the plasma membrane, a cell membrane 
marker, CellMask Orange was used for co-localisation experiment. This stain is an 
amphipathic molecule, consisting of a lipophilic region for membrane loading and a 
negatively charged hydrophilic dye for attachment of the probe in the plasma 
membrane. It can be seen from Figure 4.7A that E7 seemed to be co-distributed with 
the CellMask Orange, indicating possible membrane localisation of E7 oncoprotein. 
Cell-mask is not suitable for experiments where an intracellular target also needs to 
be probed with an antibody due to the fact that it cannot survive membrane 
permeabilisation. However, E7 on the surface was also detected in non-permeabilised 
cells without the need for permeabilisation.  
Since E7 fluorescence was observed on the cell membrane in non-permeabilised 
cells, an internalisation experiment were also performed by incubating these cells with 
an anti-E7 antibody (abcam), which were kept at 4°C (to minimise the temperature 
related internalisation). These cells were then moved onto 37°C water bath and fixed 
at different time points in order to investigate whether E7 on the cell surface was taken 
up via endocytic vesicles in to the cytoplasm in a time and temperature-dependent 
manner. Results from 0 min and 30 min incubation were shown in Figure 4.7B, 
indicating surface distribution of E7 and localisation of E7 at peri-nuclear area, 
respectively. E7 could not be detected in the cytoplasm after incubation at 37°C at 
earlier time points such as 1, 2, 5 and 10 min possibly due to the dispersion of E7 
punctate inside the cytoplasm which does not allow detection of weak signals by 
confocal imaging (data not shown).  
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Figure 4.7 (A) Co-distribution of E7 with the cell membrane marker CellMask-
Orange (red) in unpermeabilised SiHa cells. Cells were grown on glass 
coverslips for 48 hrs. Live cells were dual-stained with anti-E7 (Abcam) and 
CellMask Orange (1:2000) for 1 h at 4°C. Cells were washed at least 3 x with 
PBS, fixed with 4% formaldehyde and stained with AlexaFluor568 anti-mouse 
antibodies. Representative images are shown from three independent 
experiments (n = 3) (B) Time and temperature-dependent internalisation of cell 
surface E7, chased by anti-E7 antibody (Abcam). SiHa cells were incubated with 
the anti-E7 antibody for 1 h at 4°C and incubated at 37°C for 30 min to allow E7 
internalisation. Cells were fixed, permeabilised and stained with AlexaFluor568 
anti-mouse antibodies. Fluorescent imaging was performed using either a Zeiss 
LSM700 or LSM510 inverted microscope. Blue, green and red are DAPI 
(nucleus) and E7 and cell membrane, respectively. Images are from single 
experiment (n = 1). The scale bar is 10 µm. 
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4.2.3 Co-localisation of E7 in cellular compartments 
Internalisation of ligands, extracellular molecules, plasma membrane proteins and 
lipids occurs through endocytosis. This can be grouped into these two mechanisms; 
clathrin-dependent and in-dependent as discussed in the chapter 5. First, an 
endocytosed cargo molecule is delivered into the early endosomes, then it moves to 
late endosomes and lysosomes for degradation, trans-golgi network (TGN) or 
recycling endosomes in order to return the cargo back to the cell membrane (Grant 
and Donaldson, 2009). It was suggested that cargo usually is delivered into early 
endosomes regardless of the mechanism of internalisation (Grant and Donaldson, 
2009). Early endosomal markers are a small GTPase Rab5, phosphatidylinositol 3-
kinase (PI3K) and its product phosphatidylinositol-3-phosphate (PtdIns3P), which are 
required for its activity (Grant and Donaldson, 2009). When late endosomes are fused 
with lysosomes, it becomes a degradative compartment (Russell et al., 2006). The 
lysosome is generally considered the end point of the endocytic pathway. Marker 
could be used for late endosomes is Rab7 GTPase (Russell et al., 2006). Lysosome-
associated membrane protein 1 (LAMP1, also known as CD107a) was utilised for the 
detection of lysosomes/late endosomes.  
E7 localisation throughout the plasma membrane (Figures 4.6 and 4.7) suggested a 
new hypothesis for how E7 aptamers might be affecting E7 degradation. That would 
be due to binding of aptamers to cell surface E7 leading to internalisation of aptamer 
along with the protein through transfection or endocytosis. Degradation of E7 caused 
by aptamers (Section 3.2.2), especially A2, therefore could be via 
endosomal/lysosomal pathways. In order to investigate this, co-localisation studies 
with E7 and endosomal markers were performed by immunofluorescence. Since 
autophagosomes could fuse with lysosomes and generate autolysosomes in order to 
play a role in degradation using lysosomal hydrolases, an autophagosomal marker 
LC3 was also utilised in co-localisation experiments with E7 oncoprotein in the 
presence or absence of A2. LC3 (microtubule-associated protein 1A/1B-light chain 3) 
is a 17 kDa soluble protein that is ubiquitously expressed in mammalian cells (Tanida 
et al., 2008). During autophagy, a cytosolic form of LC3 (LC3-I) conjugates to 
phosphatidylethanolamine forming LC3-phosphatidylethanolamine conjugate (LC3-
II), which localises to the membranes of autophagosomes (Tanida et al., 2008). 
Calreticulin are components of the quality control system that promotes correct folding 
of proteins that enter the secretory pathway and targets misfolded proteins for 
degradation. Due to low efficiency of labelling A2 in vitro (Figure 5.3), this could not 
be included in the co-localisation experiments.  
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Figure 4.8 E7 does not co-localise with the early endosomal marker, EEA1 (A) 
or the late endosomal (lysosomal) marker, LAMP1 (B). SiHa cells were mock-
transfected (M) or transfected with 100 nM A2 or SF1 using Oligofectamine. At 
14 h post-transfection, cells were washed with PBS, fixed with 4% 
formaldehyde, permeabilised with 0.1% Triton-X100 and co-stained with either 
anti-EEA1 or anti-LAMP1 (staining early and late endosomes, respectively) 
(1:400) prior to incubation with AlexaFluor488 goat anti-rabbit secondary 
antibody. Cells were then incubated with anti-E7 antibody (Abcam) (1:2000) 
followed by AlexaFluor568 rabbit anti-mouse secondary antibody. Confocal 
imaging was performed using the Zeiss LSM700. Red, green and blue are E7, 
FITC (early or late endosomes) and DAPI (nucleus), respectively. The last panel 
is a zoom of merged images. The scale bar is 10 µm. E7/EEA1 and E7/LAMP1 
colocalisation were analysed using Bitplane: Imeris image analysis software 
based on the calculation of Pearson`s correlation coefficient values and 
presented as percentage co-localisation, together with standard errors (C). 
Number of of cells analysed were n = 27, 23 and 4 for E7/EEA1 and n = 12, 24 
and 9 for E7/LAMP-1 in mock-, A2- and SFI-treated SiHa cells, respectively.  
E7 colocalisation with both EEA1 and LAMP was analysed using Bitplane: Imeris 
image analysis software based on the calculation of Pearson`s correlation coefficient 
values. Data were presented as percentage co-localisation. It was shown in Figure 
4.8 that only minimal co-localisation of E7 with the endosomal marker EEA1 (Figure 
4.8A and C) was observed with values of 12.6, 13.0 and 16.0 % for mock-, A2- and 
SF1-transfected SiHa cells, respectively. No statistical significant differences were 
detected between the three treatments. There was no colocalisation of E7 with 
LAMP1 (Figure 4.8B and C), and colocalisation values were very similar for the three 
treatments (ranged between 2.0 and 2.5 %) with no significance. The level of 
colocalisation between the autophagosomal marker LC3 (Figure 4.9A and C) and E7 
also showed no difference between the three treatments (12.7, 10.2, 11.6 %, no 
significance). In contrast, there was an increased colocalisation of E7 with the ER 
marker, calreticulin, upon transfection with A2 (Figure 4.9B and C). Colocalisation in 
mock- and SF1-transfected cells was 15.1 and 15.1 %, but significantly higher at 32.3 
% in A2-transfected cells (p ≤ 0.01). Taken together, these data suggest that A2 
perturbs normal E7 trafficking and cellular distribution through enhancing E7 ER 
retention following E7 binding.  
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Figure 4.9 E7 does not co-localise with an autophagosome marker, LC3 (A) but 
appears to co-localise with endoplasmic reticulum marker calreticulin (B) in the 
presence of A2. SiHa cells were mock-transfected (M) or transfected with 100 
nM A2 or SF1 using Oligofectamine. At 14 h post-transfection, cells were co-
stained with anti-E7 (Abcam) and either anti-LC3 (an autophagosomal marker) 
123 
 
(1:2000) or anti-calreticulin (an ER marker) (1:200) overnight at 4°C prior to 
incubation with either AlexaFluor568 rabbit anti-mouse or AlexaFluor488 goat 
anti-rabbit secondary antibodies for 1 h at room temperature. Red, Green and 
Blue are E7, FITC (LC3, autophagosome or calreticulin, ER) and DAPI (nucleus), 
respectively. The last panel is a zoom of merged images. Images were taken 
using the Zeiss LSM700. The scale bar is 10 µm. E7/LC3 and E7/calreticulin 
colocalisation was analysed using Bitplane: Imeris image analysis software 
based on the calculation of Pearson`s correlation coefficient values and 
presented as percentage co-localisation, together with standard errors (C). 
Number of cells were analysed was n = 21, 23 and 17 for E7/LC3 and n = 19, 39 
and 20 for E7/calreticulin with mock-, A2- and SF1-treatment, respectively. p* ≤ 
0.0005, p** ≤ 0.002.  
 
4.3 Chapter Discussion 
Genetic mutations, presence of excessive amounts of protein subunits and several 
enviromental denaturing stress conditions causes proteins to misfold and nonfunction 
(Goldberg, 2003). In addition, a good deal of newly synthesized proteins contains 
misfolded products and accumulates as nonfunctional proteins in cells (Schubert et 
al., 2000). These misfolded proteins potentially assemble into aggregates (Kawaguchi 
et al., 2003, Sherman and Goldberg, 2001) and several mechanisms operates in order 
to eleminate their cytotoxic effects for example via degradation. The 
proteasome/ubiquitin system is mostly responsible for clearance of cellular misfolded 
proteins. One of the hyphotheses was that if binding of the HPV16 E7 aptamer A2 to 
E7 preventing its major interaction with (pRb or possible other cellular targets), E7 
could be destabilised and/or conformationally changed, resulting in its degradation. In 
order to investigate this, proteasome, lysosome inhibitors as well as inhibitors against 
mis-folded protein degradation were utilised to determine their involvement in the 
degradation of E7 in the presence or absence of aptamers.  It was shown in section 
3.2.2 that transfection of CaSki cells with HPV16 E7 aptamer A2 resulted in a 
decrease of E7 levels. Therefore, mechanism of E7 degradation following A2 
transfections were further studied by treating mock or aptamer transfected cells with 
several inhibitors. E7 is a short – lived protein with a 30 – 40 min half-life (Smotkin 
and Wettstein, 1987), allowing detection of protein accumulation at early time points 
such as 3 and 6 hrs following addition of inhibitors. It was demonstrated here that 
treatment of cells with a peptide aldehyde, MG132 resulted in the accumulation of E7 
oncoprotein in mock and aptamer-transfected cells. Peptide aldehydes are not a very 
specific inhibitors for proteasomes, they could also inhibit cysteine (thiol) proteases in 
lysosomes (Craiu et al., 1997), therefore inhibiting degradation of endocytosed 
proteins. In order to ensure the degradation was proteasomal, cells were also treated 
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with another inhibitor for lysosomes, chloroquine (blocking H+ ion, resulting in 
dysfunction of lysosomal enzymes). Inhibition of lysosomal protein degradation by 
chloroquine did not result in the accumulation of E7 as much as it was detected with 
MG132 treatment. However, there was a slight increase in the E7 level with 
chloroquine, suggesting possible involvement of lysosomes for E7 degradation in 
addition to proteasomes. In order to confirm, E7 degradation in the presence and 
absence of aptamers is most likely proteasomal, a more specific inhibitor of β-subunit 
of the proteasome, lactacystin was utilised. Treatment of CaSki cells with lactacystin 
was shown to result in accumulation of E7 oncoprotein both in the presence or 
absense of aptamer. Together with data from MG132 treatment, it can be concluded 
that degradation of E7 oncoprotein is possibly via proteasomes which is the major 
protein degradation pathway in mammalian cells. Aptamer A2 did not seem to alter 
the mode of normal degradation pathway of E7.  
HDAC6 plays an important role in clearance of misfolded protein aggregates. Co-
localisation experiments of HDAC6 with some aggresome markers showed that 
HDAC6 could translocate to aggresomes in the case of stress or treatment with potent 
agents, inducing protein mis-folding (Kawaguchi et al., 2003). In addition, HDAC6 was 
shown that selectively co-precipitates with polyubiquitinated proteins, therefore 
facilitates the formation of polyubiquitinated mis-folded proteins in aggresomes 
(Kawaguchi et al., 2003). Inhibition of HDAC6 found to be distrupting the transport of 
polyubiquitinated proteins to dynein motor, therefore aggresome formation 
(Kawaguchi et al., 2003). When proteasomes are not adequate in degradation of 
misfolded proteins accumulated in aggresomes (Hao et al., 2013), they could be 
cleared by autophagic machinery mediated by HDAC6 (Iwata et al., 2005).  HDAC6 
inhibitor, tubacin was used in this study in order to determine whether misfolded 
protein response is also involved in the degradation of E7 oncoprotin with aptamer 
A2. Acetylated tubulin levels seemed to increase with tubacin treatment in a time-
dependent manner, indicating that the inhibitor is functioning properly. Treatment of 
CaSki cells with tubacin showed that E7 levels were either not affected or decreased 
possibly due to cytotoxic effects of the inhibitor.  Accumulation of E7 with tubacin was 
not detected in the A2 transfected cells, suggesting that degradation of E7 
oncoprotein in A2 transfected cells was not likely to be due to HDAC6-mediated 
misfolded protein degradation. Decrease  in E7 levels with inhibitor treatment could 
result from depletion of HDAC6 and reactivation of cellular anti-tumour response. 
Histone deacetylases (HDACs), which removes acetyl groups from histones, were 
indicated to be upregulated in various tumours (Bolden et al., 2006). Threfore, 
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inhibitors of HDAC lead to histone hyperacetylation and could be reactivating tumour-
suppressor genes such as p21 (a cyclin-dependent kinase inhibitor), inducing 
apoptotic pathways (Peart et al., 2005, Rocchi et al., 2005). Tubacin treatment was 
performed at 25 µM for 0, 3 and 6 hrs. However, lower doses could also be tried in 
order to minimise its cytotoxic effects. Tubacin is specific for HDAC6 inhibition, 
however another inhibitor trichostatin A could also be used to inhibit HDAC1-11 
(Kawada et al., 2009). 
Eeyarestatin I treatment caused a slight increase of E7 in mock and A2 transfected 
cell. However, the level of protein seemed to decrease in SF1 transfected cells. It is 
possible that A2 is affecting endoplasmic reticulum-associated protein degreadation. 
The increase in E7 levels with eeyarestatin I might be indicating accumulation of the 
newly synthesised and incorrectly folded nonfunctional E7. Decrease in E7 in SF1 
transfected cells could be dose-related. Since higher doses could result in ER stress, 
leading to reduced protein translation or translocation into the ER (Harding et al., 
1999, Kang et al., 2006). Therefore, inhibition studies was mostly performed by using 
5 – 10 µM of the inhibitor in cells, however higher concentrations were utilised in vitro 
protein translocation experiments with around ~70 µM (Cross et al., 2009). Another 
alternative to eeyarestatin I is DBeQ, N2,N4-dibenzylquinazoline-2,4-diamine, which 
is a selective, potent and reversible  p97 inhibitor. DBeQ has been shown to inhibit 
multiple pathways which requires p97 (by RNAi) including degradation of ubiquitin 
fusion proteins, endoplasmic reticulum-associated degradation (using α-chain of T-
cell receptor-GFP reporter in a reporter assay due to the fact that overexpression of 
this reporter in non-T cells locates in the ER as an unfolded protein and degradation 
occurs in a p97-dependent manner) and autophagasome maturation (using 
autophagasome markers along with siRNA to p97 or expression of dominant-negative  
mutants to inhibit p97) (Chou et al., 2011).  
It was shown here by the use of several inhibitors on HPV 16 E7 positive CaSki cells 
that degradation of E7 in general is proteasome-mediated, and could partly be 
lysosomal. In addition, tranfection of cells with A2 did not seem to change this pathway 
of degradation. However, inhibitors used here were limited, therefore using several 
other inhibitors for protein degradation could enable to determine the exact pathway 
of E7 degradation following aptamer transfections. In order to investigate the 
degradation pathway of E7, HPV 16 positive SiHa cells were utilised for co-staining 
with several endosomal markers and E7 oncoprotein in the presence and absence of 
A2 and a control aptamer SF1.  This experiment was perfomed due to the fact that 
E7 was detected on the cell surface of SiHa cells using non-permeabilised and non-
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fixed cell by imaging and shown to co-localised with a cell surface marker. It was 
hypothysised here that E7 on the cell surface might be internalising along with the 
bound aptamer and resulting in the accumulation in endosomes and then late 
endosomes/lysosomes or autophagosomes for degradation. Immuno co-staining with 
E7 and several endosomal markers showed that A2 transfection did not increase the 
localisation of E7 in early/late endosomes or autophagasomes. However, E7 
localisation in ER (using Calreticulin as a marker) seemed to increase significantly in 
cells transfected with A2. Interestingly, E7 localisation to the ER has been 
demonstrated previously in CaSki cells (using calnexin as a marker) (Valdovinos-
Torres et al., 2008). These data suggest that a possible conformational change of E7, 
mediated by A2 binding, may lead to an accumulation in the ER. This would be 
predicted to perturb normal biosynthetic delivery of E7 to the plasma membrane or 
other organelles (Figure 4.10). As E7 does not possess common peptide ER retention 
motifs such as [K/H]DEL, KKXXX, KXKXXX and PL[Y/F][F/Y]XXN, it is therefore likely 
that A2 binding prevents correct E7 folding or oligomerisation leading to its 
accumulation in an unfolded/aberrant state. This accumulation of unfolded E7 and 
subsequent stimulation of related stress responses may contribute to the stimulation 
of apoptosis previously observed in HPV+ cells (Casagrande et al., 2000, Liu and 
Kaufman, 2003, Nicol et al., 2013, Travers et al., 2000).  
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Figure 4.10 The schematic shows the model proposed for A2-mediated E7 
degradation. A2 can enter the cells alone or via the endosomal system. Upon 
contact with E7; either at the plasma membrane or intracellularly, A2 enhances 
E7 retention in the ER. This would be predicted to reduce E7 delivery to the 
plasma membrane via its normal biosynthetic route. ER: endoplasmic 
reticulum, EE: early endosome, LE: late endosome, MVB: multivesicular bodies, 
RE: recycling endosome. 
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 APTAMER DELIVERY 
 
5.1 Introduction 
Structured single-stranded DNA and RNA molecules known as aptamers are a viable 
and promising alternative to antibody and small drug-based therapies. They can be 
potent biological agonists or antagonists (Section 1.3.4). Several aptamers have been 
selected to date against a wide range of targets from membrane proteins to whole 
living cells, intracellular or extracellular proteins, etc. (see Section 1.3.1).  
5.1.1 Advantages and disadvantages of using aptamers in therapy 
Aptamers adopt a three-dimensional, globular-structure and possess excellent 
therapeutic potential. This is partly because of binding target molecules with high 
affinity and specificity (Huang et al., 2003). In addition, they are non-toxic and non-
immunogenic. They have great potential to replace monoclonal antibodies in therapy 
due to the fact that they can be made synthetically in large scale and modified to 
improve their stability and bioavailability. Use of first generation aptamers in therapy 
was limited until several modifications were applied to the molecule such as 
incorporation of modified or unnatural locked nucleotides, dT cap at 3 end and 
conjugation of a polymer to the 5' end of the aptamer (see section 1.3.2 for generation 
of aptamers and 1.3.3.1 for aptamer modification). Aptamers are small (approx. 5 – 
25 kDa). Therefore can relatively easily be internalised by cells and tissues. One 
shortcoming is that aptamers selected against human proteins might not be effective 
in animal models. This could be a particular problem when considering possible 
therapeutic applications, which need to be tested in animal systems before moving 
onto human clinical trials. The problem can be overcome by generating aptamers to 
recognise common and conserved motifs in both human and prospective animal 
models.       
5.1.2 Importance of reagent-free uptake 
Aptamers can be selected to bind intracellular or extracellular proteins. The aptamers 
that bind to the latter hold great therapeutic potential owing to the fact that their 
administration could be done intravenously or subcutaneously (see section 1.3.4 for 
aptamers in clinical trials). For an aptamer to be used as a delivery vehicle, the 
aptamer must be efficiently internalised following binding to its target receptor 
molecules (Shigdar et al., 2011). A great number of aptamers have been identified 
against cell-surface/receptor proteins which do not require intracellular delivery 
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(Lupold et al., 2002). Several aptamers have been used as promising tools for drug 
delivery by incorporating them on the surface of a virus vector or a nanoparticle in 
order to recognise a specific cell type (Que-Gewirth and Sullenger, 2007) . These 
delivery cargos might be internalised by cells along with the bound receptor, or cargos 
might be further modified by conjugation to cell penetrating peptides to facilitate their 
entry. 
5.1.3 Techniques used in RNA delivery 
Most of the literature in this area relates to the delivery of siRNAs. There are two 
predominant techniques which have been used to introduce siRNA into primary cells. 
One of these is transient transfection, where cationic lipids that interact with negatively 
charged DNA or RNA form liposome complexes and are taken up by electrostatic 
forces via endocytic routes. The second is electroporation which involves the use of 
an external electric field in order to increase membrane permeability, resulting in pore 
formation on cell membranes, allowing DNA and RNA molecules to enter cells directly 
(Neumann et al., 1982, Zuhorn et al., 2007). Non-lipid, nanoparticle-forming 
transfection reagents can also be used for transfection of small oligonucleotides into 
a wide range of cell types with low toxicity. Nanoparticles can be classified into 
inorganic NPs including gold NPs, Qdots, superparamagnetic iron oxide NPs, 
paramagnetic lanthanide ions and organic NPs including dendrimers, micelles, 
liposomes and ferritin. For example, hydrophobic hyaluronic acid–spermine 
conjugates (HHSC) self-aggregate in water to form nanoparticles, which can be used 
for efficient delivery of siRNA molecules (Shen et al., 2011). 
5.1.4 Pathways of endocytosis 
Understanding the mechanism of uptake of small RNAs with therapeutic potential is 
clearly very important, but not yet fully understood (Meade and Dowdy, 2009). 
Different pathways may be used by different molecules in different cell types. 
Dynamin-dependent, dynamin-independent and phagocytosis are known pathways of 
endocytosis. Dynamin-dependent endocytosis (which can be blocked by dynasore) 
can be clathrin-mediated or caveolar-mediated. These subtypes of endocytosis can 
be inhibited by cholorpromazine, and genistein, nystatin and filipin III, respectively. 
Dynamin-independent pathways are non-clathrin/non-caveolar, lipid-raft mediated 
and macropinocytosis. Inhibitors used to block lipid-raft mediated endocytosis and 
macropinocytosis are genistein and amiloride, respectively (Doherty and McMahon, 
2009, Kotula et al., 2012). 
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Uptake of plasmid DNA was found to require surface proteoglycans and also some 
proteins or peptides such as antimicrobial Peptide LL-37. This is secreted from 
mammalian cells and is able to bind the DNA and carry it in to the cytosol or nucleus 
(Sandgren et al., 2004, Wittrup et al., 2007). It was shown that full length 70-kDa heat 
shock protein Hsp70, which is an ATP-dependent chaperone that is involved in protein 
folding, assembly and transport of proteins across cellular membranes, was able to 
deliver bound RNA molecules into the cytoplasm of mammalian cells (Henics and 
Zimmer, 2006). 
Macropinocytosis presents advantages over other mechanisms of endocytosis due to 
the nature of resulting macropinosome vesicles, facilitating the escape of cargo 
molecules (see section 1.3.3.4). Macropinocytosis can be enhanced by several 
compunds including fetuin, PMA and epidermal growth factor (EGF) and exogenous 
factors such as G-rich nucleic acids. These treatments could be cell-type specific. 
EGF (but not fetuin) treatment increased the expression of naked plasmid DNA in 
stomach of mice following administration onto cells of the gastric surface (Fumoto et 
al., 2009). Hyperstimulation of macropinocytosis by continuous uptake of molecules 
results in a novel form of apoptosis defined by vacuolisation, irregular nuclei and 
swollen cells (Overmeyer et al., 2008). However, although enhancers could increase 
the uptake of plasmid DNA, some other critical factors might be involved in the 
reduced expression of transgenes such as endosome/macropinosome escape of 
vectors (Reyes-Reyes et al., 2010). In addition, these enhancers should be applied 
with caution due to their tumorigenicity or tumour promoting activity (such as PMA 
and EGF), and also their ability to trigger inﬂammation (such as zymosan and 
leukotriene B4). However, stable and non-immunogenic G-rich nucleic acids have 
been shown to increase macropinocytosis followed by enhanced cellular uptake in 
mono layer cell culture with anti-proliferative effects (Reyes-Reyes et al., 2010).  
Internalisation of RNA has been well-studied in C. elegans. A multispan 
transmembrane protein, SID-1 (systemic RNAi deficient-1) mediates the 
internalisation of RNA in C. elegans, possibly functioning as a membrane channel to 
transport RNA molecules into cells (Feinberg and Hunter, 2003). In addition, 
overexpression of FLJ20174, the mammalian homologue of SID-1, facilitates the 
internalisation of RNA (Duxbury et al., 2005) and due to the fact that uptake was not 
affected by incubation in the or ATP depletion (using an ATPase inhibitor, oligomycin), 
the mechanism involved was suggested to be a passive, not a receptor-mediated 
uptake.  Another channel forming protein, SID-2, is an apical intestinal membrane 
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protein, which is not as well-studied as SID-1. C. elegans SID-2 mutants are unable 
to deliver RNA from the intestinal lumen of the nematode to the cytoplasm (McEwan 
et al., 2012). Therefore, uptake in C. elegans requires both of these channel forming 
membrane proteins sequentially. Cellular entry of RNA via the SID-2 channel is highly 
dependent on the acidity of the extracellular environment which reflects the intestinal 
lumen conditions (McEwan et al., 2012). Structure-function analysis revealed that 
three positively charged extracellular histidine residues (at low pH) might be 
interacting with negatively charged RNA to facilitate its internalisation. In addition, 
uptake was found to be significantly decreased following treatment with oligomycin, 
latrunculin A (an actin polymerisation inhibitor) or bafilomycin A1 (an endosome 
maturation inhibitor), suggesting an energy-dependent endocytosis, which is totally 
opposite to that of SID-1 forming a receptor or pump in order to passively internalise 
the RNA (McEwan et al., 2012). Vertebrates also possess SID-1 homologues called 
SID transmembrane protein 1 (SIDT1) and 2 (SIDT2), which are involved in RNA 
transport.  
Aptamer 21-2, selected against human IL-17A, binds IL-17A, blocking its interaction 
with its receptor IL-17R which results in the inhibition of IL-17A-induced production of 
IL-6 cytokine (Ishiguro et al., 2011). Neutralising effects of aptamer 21-2 was 
investigated in fibroblast T cell co-culture systems which represent a psoriatic 
inflammation as well as fibroblasts alone (Doble et al., 2014). However, these 
suggested effects of the aptamer were absent in keratinocytes. It was suggested to 
be due to reduced levels of the aptamer in extracellular matrix upon non-specific 
internalisation of the aptamer into keratinocytes (Doble et al., 2014). Thus, the 
conclusion was that this aptamer may not be used as a neutralising agent for 
extracellular inflammatory mediators. However, it can be a valuable tool to understand 
the uptake mechanism of some of the aptamers as model molecules and could also 
be used as a drug delivery agents.  
There is relatively little data on the uptake of RNA aptamers in the literature. In this 
chapter, labelled 21-2 and a model aptamer of a similar size 47tr, selected against 
FMDV RNA-dependent RNA polymerase (Ellingham et al., 2006) were used to study 
uptake mechanisms and cellular localisation of aptamers with or without lipofection. 
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5.2 Delivery of aptamers into cells 
5.2.1 Reagent-free uptake of aptamers (47tr and 21-2) into primary cells 
In order to study if aptamers can be delivered in to cells without the need for a 
transfection reagent, primary cells and a HPV16 positive cervical cancer cell line SiHa 
cells were used for confocal imaging. Cells were grown until they reach at a 
confluency of around 60% prior to incubation with aptamers. Chemically synthesised 
Cy3 and Cy3/Cy5 labelled aptamer 21-2 and Cy3 labelled 47tr were used. 21-2 and 
47tr contain 33 and 32 nucleotides, respectively. Single-labelled aptamers were 5' 
Cy3 labelled 21-2 and 47tr (Cy3 21-2 and Cy3 47tr) and double-labelled aptamer was 
5' Cy5 and 3' Cy3 labelled (Cy5 21-2 Cy3). Cells were incubated with aptamers in the 
absence of foetal bovine serum (10%).  Following the incubation at 37°C for 4-6 hrs, 
confocal images were taken using a LSM510 upright and LSM700 inverted confocal 
microscopes.  
First, primary cells were used to study internalisation of aptamers Cy5 21-2 Cy3, Cy3 
21-2 and Cy3 47tr. Interestingly, uptake of both aptamers (red) were detected by 
confocal microscopy in primary cells (Figure 5.1). These cells were able to internalise 
Cy3 21-2 and Cy3 47tr, presumably in the absence of their ligand/receptor or target 
protein (Doble et al., 2014).  
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Figure 5.1 Reagent-free uptake of Cy3 21-2 (A) and Cy3 47tr (B) was detected in 
primary cells. Primary cells were plated on coverslips on 12-well tissue culture 
plates 24 hrs prior to incubation with aptamers. Cells were maintained in the 
keratinocyte growth medium lacking serum to prevent cell differentiation. 
Aptamers were added at 80 nM (final concentration) for 5 hrs. Coverslips were 
then washed with PBS, fixed with 4% formaldehyde for 10 min followed by 
mounting on microscope slides using a glycerol-based mounting media 
containing DAPI. Nuclear staining with DAPI and aptamers with Cy3-label, are 
blue and red, respectively. Images are representatives of three independent 
experiments (n =3). The scale bar is 10 µm. 
HPV18+ primary keratinocytes (Figure 5.2A) and HeLa (HPV18+) (Figure 5.2B) cells 
were also tested for their ability to internalise these aptamers as well as SiHa 
(HPV16+). HPV18 positive keratinocytes were also able to internalise the double-
labelled aptamer 21-2. According to our observations, all cell types except HeLa cells 
were able to internalise both the 47tr and 21-2 aptamers.  HeLa and SiHa cells are 
both cervical cancer cell lines, however HeLa is derived from adenocarcinoma 
whereas SiHa is derived from grade II, squamous cell carcinoma. Having originated 
from different cell types might explain the results seen. 
Cy3 21-2 DAPI Merge 
Cy3 47tr  DAPI Merge 
A 
B 
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Figure 5.2 Reagent-free uptake of (A) Cy3 21-2 Cy5 in HPV18 + primary 
keratinocytes and (B) Cy3 21-2 in HeLa cells. Primary and HeLa cells were 
plated on coverslips on 12-well tissue culture plates 24 hrs prior to incubation 
with aptamers. Cells were maintained in the keratinocyte growth medium 
lacking serum to prevent cell differentiation for primary cells and DMEM for 
HeLa cells. Aptamers were added at 80 nM (final concentration) for 5 hours. 
Coverslips were washed with PBS, fixed with 4% formaldehyde for 10 min 
followed by mounting on microscope slides using a glycerol-based mounting 
media containing DAPI. Nuclear staining with DAPI (blue) and aptamers with 
both Cy3 (red) and Cy5 (green) - labelled. Images are representatives of two 
independent experiments (n = 2) for Panel A and a single experiment (n = 1) for 
Panel B.The scale bar is 10 µm. 
The uptake experiment was repeated using a fluorescently labelled HPV16 E7 
aptamer, A2 in SiHa cells (Figure 5.3). When Fl-A2 (75 nucleotides in size) was used 
for reagent-free uptake experiments, the amount of aptamer detected in intracellular 
compartments was much lower compared to those of 21-2 and 47tr (Figure 5.3A). 
However, increased levels of Fl-A2 were detected in cells when it was introduced by 
oligofectamine transfection (Figure 5.3B). However, the labelling efficiency of the A2 
with fluorescein was not sufficient for it to be used for further uptake experiments. 
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Figure 5.3 Internalisation of Fl-A2 in transfected (A) and non-transfected (B) 
keratinocytes. 5' end of the aptamer was re-modified using 5' EndTagTM Nucleic 
Acid Labeling system (Vector Laboratories). Aptamer (0.6 nM) was incubated 
with alkaline phosphatase at 37°C for 30 min to obtain 5' hydroxyl group. 
Fluorescein maleimide was incorporated into the 5' hydroxyl position using 
ATPγS and T4 polynucleotide kinase according to manufacturer`s instructions. 
The resulting labelled aptamer was with phenol: chloroform and precipitated 
with ethanol. Primary cells were plated on coverslips on 12-well tissue culture 
plates 24 hrs prior to incubation with aptamers. Cells were maintained in the 
keratinocyte growth medium lacking serum to prevent cell differentiation. Fl-A2 
was added at 80 nM (final concentration) for 5 hrs in the presence (A) or absence 
(B) of lipofection (using Oligofectamine). Cells were fixed and mounted on 
microscope slides prior to imaging using the Zeiss LSM510 upright confocal 
microscope. Nuclear staining with DAPI and aptamers with fluorescein 
maleimide (excitation and emission wavelengths are 494nm and 518 nm, 
respectively), are blue and red, respectively. Data is a representative of two 
independent experiments (n = 2). The scale bar is 10 µm. 
Aptamers were detected in primary cells for the first time following a passive or 
receptor-mediated uptake mechanism that is not yet known (Figure 5.1). To determine 
whether the aptamers were still intact, a double-labelled, chemically synthesised 
aptamer 21-2 was used. This aptamer had Cy5 and Cy3 at the 5' and 3' ends, 
respectively. The formation of secondary structures should bring both ends to a very 
close proximity so that co-localisation could be detected by confocal imaging.  
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Incubation of primary cells with double labelled aptamer 21-2 in the absence of any 
transfection reagent resulted in internalisation of the aptamer as an intact molecule 
with the demonstration of red and green referring to 3' and 5' ends, respectively co-
localisation (Figure 5.4A). Oligofectamine transfection of Cy3-5 labelled 21-2 into 
primary cells was used as a positive control to show the co-localisation of both ends 
of the aptamer (Figure 5.4C). 
Pearson`s co-localisation coefficient values were calculated for reagent-free and 
Oligofectamine-transfected aptamers. The aim was to determine the degree of 
correlative variation as well as the overlap between Cy3-labelled 3' and Cy5' labelled 
5' ends of the aptamer upon internalisation using confocal images and software called 
Imaris.  It gives values closer to 1, are indicative of a high level co-localisation. Values 
between 0 and -1 are indicative of random localisation ranging to perfect exclusion, 
respectively. Pearson`s coefficient values for Oligofectamine-transfected and 
reagent-free internalised Cy5 21-2 Cy3 were found to be 0.9448 (Figure 5.4D) and 
0.732 (+/-0.03) (Figure 5.4B), respectively, showing a strong co-localisation of Cy3 
and Cy5 channels indicating that both ends of the aptamer are co-localising together 
in the cells. Other parameters indicating the co-localisation were percentage volumes 
of Cy3 co-localising with Cy5 or vice versa. Although these values were slightly higher 
when Oligofectamine transfection was utilised to deliver the aptamer into cells, they 
also showed a strong overlap between red and green channels indicating that a large 
proportion of RNA in cells was still intact upon internalisation. 
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Figure 5.4 Co-localisation of 3' and 5' ends of aptamer 21-2 double-labelled with 
Cy3 and Cy5 in keratinocytes.The confocal image shows the co-localisation of 
both channels when a reagent-free delivery approach (A) or oligofectamine 
transfection (C) was performed for delivery of the aptamer. Co-localised pixel 
scatter plots B and D were analysed from images A and C, respectively using 
Imaris software in order to calculate the Pearson`s coefficient and % co-
localisation of Cy3 with Cy5 or vice versa (+/- standard erros, from three (n = 3) 
and two (n = 2) independent experiments for A, B and C, D, respectively). For 
the analysis on Imaris, thresholds for each channels were set to 25%. DAPI was 
used to stain the nucleus. The scale bar is 10µm. 
5.2.2 Delivery of aptamers in SiHa cells using a nanoparticle-based 
transfection reagent, NanocinTM   
Nanocin is invented as a clinically safe polymer which can spontaneously form 
nanoparticles with nucleic acids, protein and peptides and mediate their uptake into a 
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wide range of cells including those of mammalian, fungal, bacterial and parasitic 
origin. Use of nanoparticles as delivery agents for aptamers could be advantageous 
over lipofection due to the drawbacks of using lipid-based transfection reagents (see 
chapter discussion 5.4). When cargo molecules, in this case aptamers, are mixed with 
Nanocin, particles are formed, which then facilitate the delivery of molecules into the 
cytoplasm of target cells.  
SiHa cells were grown for 48 hrs on glass coverslips and used for Nanocin 
transfection. Double-labelled aptamer Cy5 21-2 Cy3 was used as a model aptamer 
for transfections. Aptamer at 80 nM final concentration was mixed with Nanocin and 
applied to cells. Following incubation at 37°C for 5 hrs, cells were washed, fixed and 
mounted onto microscope slides prior to imaging by confocal microscopy, followed by 
co-localisation analysis (as above). Analysis of co-localisation by Imeris showed a 
Pearson`s value of 0.82, indicating that both ends were mostly co-localising.  
 A further aptamer, Cy3 47tr, was also used for transfection of SiHa cells with Nanocin, 
with similar results. Nanocin could be used as apossible delivery reagents for 
aptamers although the pathway of entry into cells is yet unknown.  
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Figure 5.5 Use of Nanocin as a transfection reagent to deliver aptamers into 
SiHa cells. Double labelled Cy5 21-2 Cy3 (80 nM) (A, B) or single labelled Cy3 
47tr (80 nM) (C) was mixed with 4 µl of Nanocin (trade name HappyFectTM) in a 
total volume 50 µl of serum-free medium. The medium of SiHa cells grown for 
48 hrs was replaced with serum-free media and the Nanocin-aptamer mixture 
was applied to cells.  Internalisation and/or co-localisation 21-2 and 47tr was 
analysed by confocal microscopy (Panels A and B, respectively) and a scatter 
plot of co-localised pixels from (Panel A) was shown in Panel B along with the 
Cy5 
Cy3 
  Merge 
Cy5 
Cy3 DAPI 
  Merge 
A B 
C 
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calculated Pearson`s coefficient and the % volume of co-localised pixels which 
was analysed by Imeris. Results are representatives of two independent 
experiments (n = 2). For the analysis on Imaris, thresholds for each channel 
were set to 25%. DAPI was used as a nuclear stain. The scale bar is 10µm. 
5.2.3 Effects of dynasore (dynamin-dependent endocytosis inhibitor) 
and amiloride (macropinocytosis inhibitor) on the uptake of 
aptamers 21-2 and 47tr  
In order to study if the uptake of aptamers 21-2 and 47tr was via macropinocytosis 
and/or dynamin-mediated endocytosis, inhibitors of each processes were used. First, 
SiHa cells were treated with Dynasore, a dynamin-dependent uptake inhibitor, at a 
final concentration of 80 µM or (0.04% DMSO, the control vehicle) for 2 hrs at 37°C. 
The aptamers, 47tr (Cy3-labelled) and 21-2 (double-labelled) were added to cells at 
a final concentration of 80 nM for a further 5 hrs. Cells from each treatment were then 
imaged, and approximately 30 cells were analysed from different focal planes. The 
percentage of cells with internalised aptamer was determined and represented as a 
graph for DMSO or dynasore treatment of cells exposed to Cy3 47tr or Cy5 21-2 Cy3 
uptake (Figure 5.6).  
Dynasore treatment seemed to reduce the internalisation of aptamers, Cy3 47tr and 
Cy5 21-2 Cy3 up by 35 and 20%, respectively (Figure 5.6C). However, there was still 
a relatively high proportion of cells with internalised aptamers. Therefore, although 
dynamin-mediated endocytosis may be involved in uptake, there may be further 
pathways. The ring-like pattern of aptamers around the cell membrane that was 
observed following inhibitor treatment might be an indication of receptor-mediated 
endocytosis (Figure 5.6A, B).  
FITC-Transferrin was used as a marker for endocytosis (Figure 5.7). When cells were 
treated with DMSO, transferrin was taken up and transported to the peri-nuclear 
region of the cell, whereas dynasore treatment caused the accumulation of transferrin 
on the outside of the cell membrane. 47tr co-localised with transferrin in both DMSO-
treated (where transferrin was perinuclear) and dynasore-treated cells (where 
transferrin localised on the plasma membrane), indicating a receptor-mediated uptake 
of the aptamer (Figure 5.7). However, 21-2 was not detected in an association with 
transferrin in DMSO-treated cells (Figure 5.7B). When endocytosis was blocked by 
dynasore treatment, transferrin and only small amounts of 21-2 co-localised on the 
plasma membrane, suggesting that an alternative pathway (such as 
macropinocytosis) might be involved in the internalisation of 21-2.  
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Figure 5.6 Internalisation of aptamers in the presence or absence of dynasore 
(an inhibitor of dynamin-dependent endocytosis). Cy3 47tr (Panel A) and Cy5 
21-2 Cy3 (Panel B) were used for transfection and a representative graph 
showed the percentage of cells in which aptamers were internalised (Panel C), 
in the presence or absence of the inhibitor. SiHa cells were grown on glass 
coverslips for 48 hrs. Prior to incubation with Cy3 47tr (A) and Cy5 21-2 Cy3 
aptamers (80 nM final concentration), cells were subjected to 0.4% DMSO or 80 
µM dynasore treatment for 2 hrs at 37°C. Following addition of aptamer, cells 
were incubated for a further 5 hrs to allow uptake. Coverslips were washed with 
PBS and fixed with 4% formaldehyde followed by mounting on microscope 
slides. Images were taken using the Zeiss LSM510 upright microscope. Cy3, 
Cy5 and DAPI were visualised as red, green and blue, respectively. N = 30 cells 
were counted for each aptamer for Dynasore or control treatments and 
represented as a percentage of cells with internalised aptamers in the presence 
or absence of dynasore (Panel C). The scale bar is 10 µm. 
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Figure 5.7 Inhibition of uptake of Cy3 47tr (A) and Cy3 21-2 (B) by dynasore and 
co-localisation of aptamers with a labelled marker for endocytic pathway 
(Transferrin). Cy3-labelled aptamers were incubated with SiHa cells, which were 
pre-treated with 80 µM dynasore or DMSO (0.04%) for 2 hrs at 37°C, in the 
presence of FITC-Transferrin as a marker for dynamin-dependent endocytosis. 
Images were taken using the Zeiss LSM510 upright microscope. Cy3 (aptamer 
47tr or 21-2, Red), transferrin (green) and DAPI (blue, nucleus) were detected as 
red, green and blue, respectively. The last panel showed red and green co-
localisation. The scale bar is 10 µm. N = 2.  
 
Second, SiHa cells were treated with an inhibitor of micropinocytosis, amiloride. 
Amiloride treatment, but not DMSO (as negative control) caused a reduction in the 
internalisation of the uptake of both aptamers, but preferentially 21-2 (Figure 5.8A and 
B). The number of cells that were with or without internalised aptamer was counted 
from several focal planes and percentage of decrease in the number of cells still 
bearing the signals was calculated (Figure 5.8C). Amiloride treatment resulted in a 
40% and 10% decrease in the number of aptamer positive cells in SiHa cells 
incubated with aptamer 21-2 and 47tr, respectively. 
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Figure 5.8 Effect of an inhibitor of micropinocytosis, amiloride, on aptamer 
internalisation. SiHa cells were grown on glass coverslips for 48 hrs. Prior to 
incubation with aptamers Cy3 47tr (A) and Cy3 21-2 (B) (80 nM), cell were 
subjected to 0.4% DMSO and 75 µM Amiloride treatments for 2 hrs at 37°C. Cells 
were incubated with aptamers for 5 hrs. Coverslips were washed with PBS and 
fixed with 4% Formaldehyde followed by mounting on microscope slides. 
Images were taken using LSM510 upright microscope. Cy3 and DAPI were 
visualised as red and blue, respectively. The scale bar is 10 µm. N = 30 cells 
were counted for each aptamer for Amiloride and control treatments and 
represented as percentage of cells with internalised aptamers in the presence 
or absence of the inhibitor (C). 
Receptor-mediated uptake can be blocked by cold incubation of aptamers with cells. 
Therefore, cells were incubated with aptamers 21-2 and 47tr at 4°C for 6 hrs. It was 
shown in the Figure 5.9 that internalisation of 47tr did not appear to be as efficient as 
that of 21-2. Transfection efficiency for 21-2 was 73.91% at 4°C, whilst that for 47tr 
was 12.50% when n = 46 and n = 40 cells were counted, respectively. This may 
indicate that 21-2 internalised by such mechanisms that do not require energy (e.g. 
micropinocytosis), while internalisation of 47tr requires energy-dependent 
mechanisms.  
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Figure 5.9 Uptake of aptamers into SiHa cells at 4°C. Cells were plated on glass 
coverslips on 12-well tissue culture plates 48 hour prior to incubation with 
aptamers. Aptamers Cy3 21-2 (A) and Cy3 47tr (B) were added at 80 nM (final 
concentration) in serum-free medium for 5 hrs and plates were kept at 4°C. 
Coverslips were then washed with PBS, fixed with 4% formaldehyde for 10 min 
followed by mounting on microscope slides using a glycerol-based mounting 
media containing DAPI. Nuclear staining with DAPI and aptamers with Cy3-
label, are blue and red, respectively. Number of cells were counted was n = 46 
and n = 40 respectively, for 21-2 and 47tr. The scale bar is 10 µm. 
5.2.4 Prediction of G-quadruplex structure in aptamers  
Guanine-rich phosphodiester oligonucleotide sequences (more than 25% G-content) 
that can form quadruplex structures (G-quartets) (Dapic et al., 2003) are thought to 
be internalised more efficiently compared to non- guanine-rich sequences via 
micropinocytosis in cells grown in monolayer culture (Reyes-Reyes et al., 2010). The 
G-contents (%) of 21-2 and 47tr were 36 and 28, respectively. In order to reveal 
whether 21-2 and 47tr were forming G-quadruplexes, the sequences of these 
aptamers were analysed using QGRS software which calculates G-scores. 
Sequences with higher score`s would form more stable structures. The highest 
possible G-score for a maximum 30-nucleotide sequence is 105. Here is an example 
of such sequences: GGGGGGTGGGGGGTGGGGGGTGGGGGG. G-scores have 
been devised to evaluate the likelihood of a sequence to form stable G-quadruplexes 
Figure 5.10 showed that there was one possible predicted structure for 21-2 with a G-
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score of 11. No G-quadruplex structure was predicted for 47tr although it contained 
~28% of guanine.  
 
Aptamer 
 
Positio
n 
 
Length 
 
QGRS prediction 
G-
content 
(%) 
G-score 
 
21-2 1 33 GGUCUAGCCGGAGGAGU
CAGUAAUCGGUAGACC 
36 11 
47tr N/A 32 GGGUUAACAGAAAACCU
CAGUUGCUGGGUUGU 
28 N/A 
 
Figure 5.10 G-quadruplex structure predictions of 21-2 and 47tr by using QGRS 
software. 21-2 and 47tr aptamer sequences with G-contents of 36% and 28% 
respectively were analysed using the software. There was one G-quadruplex 
prediction for 21-2 with a G-score of 11. A similar size aptamer, 47tr was not 
suggested to form these structures according to the software (Kikin et al., 
2006).  
5.2.5 Transfection efficiency of aptamers as measured by flow 
cytometry 
The levels of aptamer uptake into primary keratinocytes and SiHa cells were 
determined by flow cytomery using aptamer cy5 21-2. Keratinocytes and SiHa cells 
were plated on 12-well plates at 24 or 48 hrs prior to incubation with aptamers, 
respectively. Incubation of cells with aptamers was performed in the presence or 
absence of transfection reagents for 5 hrs, followed by cell harvesting and several 
washes of the cell pellets in PBS, including an acidic wash to remove the surface 
bound RNA molecules. Cells were stained with propidium iodide and analysed by flow 
cytometer using the APC (allophycocyanin) channel (Excitation at 633 nm, emission 
at 660 nm) (Cy5 and APC have the same excitation) and PI (Propidium Iodide) 
(Excitation at 488 nm, emission at 617 nm) channels by counting 10, 000 cells. The 
results are represented as percentage of cells that are positive for Cy5.  
5.2.5.1 Uptake in primary cells 
Primary cells were grown in keratinocyte growth medium lacking serum to prevent cell 
differentiation. Cells were incubated with aptamers in the same medium conditions 
prior to flow cytometry analysis to measure the efficiency of uptake.  
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The Sample 
The percentage of Cy5 positive keratinocytes 
under different conditions 
Oligofectamine transfection Incubation in media 
Mock 3.5 6.2 
5 nM 21-1 27.4 4.0 
80 nM 21-2 99.2 19.3 
 
Figure 5.11 Flow cytometric analysis to detect percentage of primary cells with 
aptamer 21-2 internalised in the presence/absence of Oligofectamine 
transfection. Primary cells were plated onto 12-well plates 24 hrs prior to 
incubation or transfection with aptamer 21-2. Primary cells were either 
incubated or transfected with 5 or 80 nM cy3-5 double labelled aptamer 21-2. At 
5 hrs post-transfection, cells were washed with PBS and trypsinised. Cells were 
pelleted and washed with PBS twice followed by an additional wash with an 
acidic wash buffer to remove surface-bound RNA molecules. Flow cytometry 
was performed following staining the cells with propidium iodide (PI). 10, 000 
cells were counted for each transfection. Results are shown as percentage of 
Cy5-positive and therefore aptamer positive cells from a single experiment (n = 
1).  
Figure 5.11 showed the percentage of keratinocytes containing a Cy5 signal from 
mock-transfected, cells transfected with 5 or 80 nM cy5-21-2 in the presence/absence 
of oligofectamine (a cationic transfection reagent). Oligofectamine transfection was 
reported to deliver 5nM and 80 nM cy5-21-2 to up to 27 and 99% of primary cells, 
respectively. The transfection efficiency of Oligofectamine was found to be quite high 
even when as little as 5 nM of aptamer was used. Therefore, 80 nM aptamer was 
sufficient to target almost all of the cells in the culture. As propidium iodide was used 
to distinguish dead cells, the percentage of Cy5 positive cells represented only living 
cells. Another set of cells were not transfected but only incubated with Cy5-21-2 
without replacing the growth medium. Although the use of low concentrations of 21-2 
(5 nM) was not adequate to obtain a detectable signal, 80 nM of 21-2 was delivered 
to delivered approximately 20% of cells that were counted by flow cytometry.  
5.2.5.2 Uptake in SiHa cells 
Reagent-free uptake was also studied in a cervical cancer cell line, SiHa, derived from 
grade II, squamous cell carcinoma which contains 1 or 2 copies of HPV16 integrated 
into the host genome. Nanocin was evaluated together with Oligofectamine.  
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Figure 5.12 Uptake of aptamer 21-2 by SiHa cells in the presence or absence of 
transfection reagents (Nanocin and Oligofectamine) detected by flow 
cytometry. Cells were plated onto 12-well plates 48 hrs prior to transfection or 
incubation with double labelled aptamer 21-2 (Cy5 21-2 Cy3). Cells were either 
incubated or transfected with 5, 80 or 150 nM Cy5- labelled aptamer 21-2 with 
(oligofectamine or nanocin). At 5 hrs post-transfection, cells were collected and 
washed with PBS twice followed by an additional wash with an acidic wash 
buffer to remove surface-bound RNA molecules. Flow cytometry was 
performed following staining the cells with propidium iodide (PI) to remove 
dead cells from the analysis. 10, 000 cells were counted for each transfection. 
Results were presented as percentage of Cy5-positive cells, therefore aptamer 
positive cells. The data was obtained from three independent experiments (n = 
3), shown together with standard errors. 
 
SiHa cells were incubated or transfected (using either nanocin or oligofectamine) with 
5, 80 or 150 nM of Cy5 21-2 Cy3. Similar to primary keratinocytes, SiHa cells were 
also able to internalise aptamer without the need for a transfection reagent, with up to 
around 40% of cells being detected aptamer positive when 150 nM of Cy5 21-2 Cy3 
was used. The use of 80 nM of aptamer resulted in ~20%, which seemed similar to 
the data from keratinocytes (section 5.2.5.1). Oligofectamine and nanocin 
transfections with the highest concentration of aptamer (150 nM) significantly 
increased the uptake up to 95 and 80 %, with p values of ***0.008 and *0.013, 
respectively. Although the difference between nanocin and oligofectamine 
transfections was not significant with 150 nM aptamer transfections, when lower 
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concentrations of aptamer such as 80 nM were used, oligofectamine delivered the 
aptamer into more cells than that of nanocin (p** = 0.00016). Nanocin had little toxicity, 
resulting in only up to 20-30% cell death detected by PI staining (data not shown). In 
addition, use of nanocin as a delivery agent will require more cells to avoid cytotoxicity 
and more RNA molecules to be able to target all cells present, although reagent was 
used at very small amounts which could be advantages over other transfection 
reagents to economise on its excessive use.  
5.3 Co-localisation of aptamers in cellular compartments 
upon internalisation  
In common with keratinocytes, SiHa cells were shown to be internalising 21-2 and 
also 47tr without the need for transfection. There is little published data on cellular 
localisation of RNA aptamers upon internalisation (Homann and Goringer, 2001). 
Therefore localisations of aptamers were studied with or without lipofection looking at 
the co-localisation with some of the endosomal markers such as EEA1 for early 
endosomes and LAMP1 for late endosomes/lysosomes.  
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Figure 5.13 Cellular localisation of aptamer 21-2 in SiHa cells predominantly in 
early and late endosomes following Oligofectamine transfection. Cells were 
plated onto glass coverslips in 12-well plates and grown for 48 hrs. Then, cells 
were transfected with 80 nM Cy3 labelled 21-2 using Oligofectamine. At 3 (Panel 
A) or 6 hrs (Panel B) post-transfection, cells were washed with PBS, fixed with 
4% formaldehyde and permeabilised with 0. 01% Triton-X100. Cells on 
coverslips were blocked with BSA for 30 min at room temperature. Primary 
antibodies anti-EEA1 (early endosomes) (1:400) and anti- LAMP1 (late 
endosomes) (1:400) were added onto cells and left at 4°C overnight on a 
shaking platform. Coverslips were washed on the following day with PBS and 
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AlexaFluor488 goat anti-Rabbit secondary was added in BSA for 1 h at room 
temperature. Secondary antibody was washed and coverslips were mounted on 
microscope slides. Images were taken using the Zeiss LSM700. The level of co-
localisation was analysed by Bitplane: Imeris image analysis software (Panel 
C).  For EEA1 and LAMP1 colocalisation respectively, n = 8 and 29 at 3 h and n 
= 30 and 19 at 6 h (p* ≤ 0.003). Red, Green and Blue are Cy3 (21-2), FITC (early 
or late endosomes) and DAPI (nucleus), respectively. The last panel is a zoom 
of merged images. The scale bar is 10 µm. 
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Figure 5.14 Cellular localisation of aptamer 47tr in SiHa cells predominantly in 
early and late endosomes following Oligofectamine transfection. Cells were 
plated onto glass coverslips in 12-well plates and grown for 48 hrs. Cells were 
transfected with 80 nM Cy3-labelled 47tr using Oligofectamine. At 3 (Panel A) 
or 6 hrs (Panel B) post-transfection, cells were washed with PBS, fixed with 4% 
formaldehyde and permeabilised with 0. 01% Triton-X100. Cells on coverslips 
were blocked with BSA for 30 min at room temperature. Primary antibodies anti-
EEA1 (early endosomes) (1:400) and anti- LAMP1 (late endosomes) (1:400) were 
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added onto cells and left at 4°C overnight on a shaking platform. Coverslips 
were washed on the following day with PBS and AlexaFluor488 goat anti-Rabbit 
secondary was added in BSA for 1 h at room temperature. Secondary antibody 
was washed and coverslips were mounted on microscope slides. Images were 
taken using the Zeiss LSM700. The level of co-localisation was analysed by 
Bitplane: Imeris image analysis software (Panel C). For EEA1 and LAMP1 
colocalisation respectively, n = 25 and 48 at 3 h and n = 24 and 23 at 6 h (p* ≤ 
9.308E-05, p** ≤ 0.001). Red, Green and Blue are Cy3 (47tr), FITC (early or late 
endosomes) and DAPI (nucleus), respectively. The last panel is a zoom of 
merged images. The scale bar is 10 µm.  
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Figure 5.15 Cellular localisation of aptamer with Cis and Trans-golgi markers, 
ManII and TGN46. Cells were plated onto glass coverslips in 12-well plates and 
grown for 48 hrs. Then, cells were transfected either with 80 nM Cy3 21-2 (Panel 
A) or Cy3 47tr (Panel B) using Oligofectamine. At 6 hrs post-transfection, cells 
were washed with PBS, fixed with 4% formaldehyde and permeabilised with 0. 
01% Triton-X100. Cells on coverslips were blocked with BSA for 30 min at room 
temperature. Primary antibodies anti-ManII (Cis-golgi) (1:400) and anti-TGN46 
(Trans-golgi) (1:400) were added onto cells and left at 4°C overnight on a 
shaking platform. Coverslips were washed on the following day with PBS, and 
AlexaFluor488 goat anti-rabbit or Alexafluor488 donkey anti-sheep secondary 
was added in BSA for 1 at room temperature. Secondary antibody was washed 
and coverslips were mounted on microscope slides. Images were taken using 
the Zeiss LSM700. Red, Green and Blue are Cy3 (21-2 or 47tr), FITC (Cis- or 
Trans- golgi) and DAPI (nucleus), respectively. Images are representatives of 
two independent experiments (n = 2). The last panel is a zoom of merged 
images. The scale bar is 10 µm. 
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Figure 5.16 Co-localisation of aptamer 21-2 in SiHa cells following reagent free 
uptake with actin but not early endosomes. SiHa cells were incubated with 80 
nM Cy3 labelled 21-2 for 6 hrs followed by fixation and permeabilisation of cells. 
Primary antibodies anti-EEA1 (early endosomes) (1:400) (Panel A) and anti-
actin (:/200) (Panel B) were added in BSA and left at 4°C overnight on a shaking 
platform.  Incubation with alexaFluor488 goat anti-Rabbit and donkey anti-Goat 
secondary antibodies was performed in BSA for 1 h at room temperature. 
Images were taken by the Zeiss LSM510 upright confocal microscope. Red, 
Green and Blue are Cy3 (21-2), FITC (early endosomes or actin) and DAPI 
(nucleus), respectively. Images are from a single experiment (n = 1). The last 
panel is a zoom of merged images. The scale bar is 10 µm. 
SiHa cells were seeded on glass coverslips in a 12-well tissue culture plate, and 
grown for 48 hrs prior to incubation or tranfection with the aptamers for 3 hrs and 6 
hrs. Cells were then incubated with primary antibodies for early and late endosomes, 
and FITC-secondary antibodies, overnight at 4°C and room temperature for 1 h, 
respectively.  
In Oligofectamine-transfected cells, most of the aptamer was found to be localised 
predominantly in early and late endosomes. Transfection efficiency for both aptamers, 
21-2 and 47tr was around 87% (number of cells counted was n = 91 and n = 121, for 
21-2 and 47tr). At three hrs post transfection, 21-2 was mostly localised in early 
(63.36%) rather than late endosomes (30.54%) (p* ≤ 0.003) (Figure 5.13A,C). 
However, in cells transfected for 6 hrs, this co-localisation was reduced and the 
aptamer was localised to both early and late endosomes/lysosomes (45.66% and 
33.21% respectively, Figure 5.13B,C) which may indicate the escape of the aptamer 
from endosomes. Aptamer was also detected in the nucleus of some of the cells 
following transfection (Figure 5.13B). Another aptamer, Cy3 47tr also showed a 
similar pattern of distribution to Cy3 21-2 in SiHa cell. At three hrs post transfection, 
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47tr was mostly localised in early (64.44%) rather than late endosomes (37.19%) (p* 
≤ 9.308E-05) (Figure 5.14A,C). Whereas, in cells transfected for 6 hrs, this co-
localisation was significantly reduced (p** ≤ 0.003) and the aptamer was localised to 
both early and late endosomes/lysosomes (42.32% and 36.47% respectively, Figure 
5.14B,C). Data from both aptamers may indicate that RNA aptamers in transfected 
cells can be targeted to early/late endosomal/lysosomal pathways, in which they are 
degraded or manage to escape to complete their function in the cytosol. Markers for 
cis- and trans- Golgi, Man II and TGN46, respectively were also utilised to understand 
the localisation of aptamer (Cy3 21-2 and Cy3 47tr) (Figure 5.15). These aptamers 
did not appear to be localised in the Golgi compartments following transfection.  
Localisation of aptamer 21-2 (Figure 5.16A), when introduced into SiHa cells without 
any transfection reagent, was not detected in endosomes, unlike in lipofection, 
suggesting a different uptake mechanism. In addition, when SiHa cells that had been 
incubated with aptamer 21-2 were reacted with anti-actin antibody, co-localisation of 
actin with aptamer 21-2 was observed. This may indicate the involvement of 
macropinocytosis for internalisation (Figure 5.16B). During micropinocytosis, actin-
driven protrusions along the plasma membrane were formed upon exposure to an 
extracellular stimuli such as growth factors, nutrients and other signals. Extracellular 
fluid then becomes surrounded by these actin protrusions in order to form vesicles to 
“cargo” the content along the microtubules towards the perinuclear area.   
5.4 Chapter Discussion 
Understanding the mechanism of uptake of aptamers or other such molecules with 
therapeutic potential is very important due to the current problems in targeted-cellular 
delivery of small oligonucleotide-based therapeutics such as siRNAs and anti-sense 
oligonucleotides (Meade and Dowdy, 2009). For an aptamer to be used as a delivery 
vehicle, it must be efficiently internalised (Shigdar et al., 2011). 
Reagent-free uptake of a DNA aptamer, AS1411, siRNA and also naked plasmids 
DNAs have been extensively studied, however literature on the uptake of RNA 
aptamers is not substantial.  Here the uptake of labelled RNA aptamers, 21-2 and 
47tr, in primary keratinocytes and also the cervical cancer cell line, SiHa was 
described. Internalisation of 21-2 and 47tr was studied in primary keratinocytes and it 
was shown that cells took up both aptamers.  
To establish an effective and non-toxic delivery system is very important prior to 
clinical use of these molecules. Although, there are two main techniques that are used 
156 
 
to introduce foreign nucleic acid molecules such as siRNAs, DNA and aptamers into 
cells, namely lipofection and electroporation, both techniques have disadvantages 
(Barreau et al., 2006). When HeLa cells were transfected with hyper-unstable 
nonadenylated/non-capped mRNAs, these molecules were as equally stable in cells 
as control mRNAs, and were associated with membrane structures, indicating that 
mRNA could be sequestered in vesicles to protect them from the degradation 
machinery of cells. Therefore, the proportion of the functional RNA released in the 
cytoplasm may be low as opposed to RNAs trapped in membranous structures. In 
addition, large amounts of RNA molecules can be toxic to cells and trigger unwanted 
responses such as the stress response which could alter cell metabolism. Cationic 
liposomes and polymers might have toxic side effects such as liposome/plasmid DNA 
inducing haemagglutination and apoptosis in macrophages (Aramaki et al., 1999, 
Eliyahu et al., 2002). 
In this Chapter, aptamer 21-2 was shown to be internalised into primary cells. When 
double-labelled 21-2 was used for confocal imaging, it was shown that both ends of 
the RNA were taken up and co-localised with each other. A computer program Imaris 
was used for quantitation of co-localisation, and measurement was represented as a 
Pearson`s coefficient value. Although this value is higher for Oligofectamine-
transfected cells (0.9448), indicating that with lipofection, almost all of the aptamers 
appeared to be intact molecules.  In reagent-free uptake of 21-2, this value was 
slightly lower but it was still indicated that most the molecules were intact. 
As siRNAs enter cells by endocytosis following liposome delivery (Lu et al., 2009), 
this might result in RNA escaping from the complexes and being functional (Sioud, 
2005, Yoo et al., 2006). In addition, the efficiency of liposome transfections varies 
amongst different cell types. Electroporation delivers the RNA directly to the cell 
cytoplasm, therefore off-target immune responses can be prevented. However, to 
introduce siRNA in to bovine monocytes with the use of electroporation caused cells 
to be more fragile compared to transiently-transfected cells, and more cell death was 
observed, although gene silencing effects were comparable with lipofection (Jensen 
et al., 2014). Drawbacks of electroporation include high cell death, requirement for 
serum-free transfection conditions, use of highly confluent cell monolayers and 
relatively large amounts of RNA (Gonzalez et al., 2007). However, cargo could still be 
subjected to lysosomal degradation due to accumulation in endosomes. Interestingly, 
when a 25 amino acid synthetic long peptide (SLP), which was designed from a 
melanoma associated antigen as an anti-tumour vaccination agent, was introduced 
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into human dentritic cells by electroporation, it was shown to co-localise in early and 
late endosomes (Menager et al., 2014). 
Aptamer 21-2 and also 47tr were used for co-localisation experiments to understand 
their location after passive uptake or Oligofectamine transfection. Aptamer 21-2 and 
47tr was predominantly localised to both early and late endosomes in Oligofectamine 
transfected SiHa cells. Localisation to early endosomes was particularly striking at 
early timepoints post-transfection (3 hrs). It is interesting to note that the reduction in 
co-localisation seen after 6 h did not correlate with an increase in co-localisation with 
the late endosomal marker. Further time points might be useful, however, this could 
be indicative of escape of aptamers from the endocytic pathway. While there is little 
data on the sub-cellular localisation of aptamers, transfection of siRNAs using cationic 
lipids, nanoparticles or cell-type-specific delivery reagents have shown that siRNAs 
are trafficked to the endosomal pathway (early and then late endosomes), reviewed 
in (Dominska and Dykxhoorn, 2010). When 21-2 was passively internalised by SiHa 
cells, aptamer was not co-localised with the endosomal marker, indicating that 
endocytosis may not be involved in its uptake. Other mechanisms such as 
micropinocytosis could be involved in the uptake of 21-2. In addition, aptamer 21-2 
was found to be associated with actin, which could be due to the involvement of actin 
e.g. during macropinocytosis. 
An alternative to lipid-based transfection, non-lipid, and nanoparticle-forming 
transfection reagents such as Nanocin can also be used for transfection of small 
oligonucleotides into a wide range of cell types with lower toxicity. Nanocin 
(HappyFectTM) was used to test the effectiveness of the aptamer delivery and 
possibility of future use of this reagent for other aptamers such as the HPV16 E7 
aptamer A2 to target intracellular proteins. SiHa cells were used for transfections. A 
simple protocol was used in which RNA molecules and the reagent were mixed and 
applied to the cells. Double-labelled 21-2 was used to transfect these cells, and 
images indicated that RNA was both efficiently internalised and was still intact (with a 
co-localisation of both ends of the RNA, calculated Pearson`s value was 0.82). Nano-
particle forming transfection reagents have been used elsewhere for RNA delivery, 
such as hydrophobized hyaluronic acid–spermine conjugate (HHSC) self-aggregates 
in water to form nanoparticles, which could be used for efficient delivery of RNA 
molecules (Shen et al., 2011). 
Macropinosomes may give aptamers a better chance to escape and avoid 
degradation (Conner and Schmid, 2003, Wadia et al., 2004) as they are non-acidic 
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and non-digestive vesicles and are potentially leaky compared to lysosomes. How 
these DNA or RNA molecules escape from macropinosomes in to cytosol are not yet 
known. Macropinocytosis is thought to be an efficient means of delivering a range of 
different cargos including peptides, intact proteins, bacterial virulence factors and 
viruses into cells (Reyes-Reyes et al., 2010). Reagent-free or passive uptake of 
aptamers could therefore also aid the development of new strategies for drug delivery.  
In fact, aptamers that are passively internalised might be better therapeutics if they 
enter the cells via alternative pathways rather than receptor-mediated endocytosis by 
which they localise in endosomes and lysosomes.  
In order to understand the pathway that those two aptamers, 21-2 and 47tr were 
internalised, inhibitors for macropinocytosis (amiloride) and endocytosis (dynasore) 
were utilised in SiHa cells. Dynasore treatment of SiHa cells did not affect the uptake 
of 21-2 (15% decrease) as it did for 47-tr (30%), suggesting that alternative 
mechanisms could be involved such as macropinocytosis in the uptake of these 
aptamers especially for 21-2. Transferrin was used to test effectiveness of dynasore 
treatments. 47tr but not 21-2 was found to partly co-localise with transferrin around 
the peri-nuclear area and on the cell membrane of DMSO and dynasore treated cells, 
respectively. It is possible that 47tr may use receptor-mediated endocytosis, although 
it was not selected against a receptor protein. Another evidence for receptor-mediated 
endocytosis of 47tr was that uptake of 47tr in SiHa cells at 4°C was strongly inhibited, 
whereas 21-2 was still being internalised although as not efficiently as it was at 37°C. 
Aptamers internalised into cells via receptor-mediated uptake were identified before, 
however, they are mostly selected against plasma membrane proteins. For example, 
an RNA aptamer for cancer stem cell marker CD133, which is a transmembrane 
protein was found to be internalised via receptor-mediated endocytosis as aptamer 
was detected in a ring-like pattern outside the cells on the plasma membrane on 
potassium-depleted and hypertonic treated cells which are used as inhibitors of 
endocytosis (Shigdar et al., 2011).  
Amiloride (an inhibitor to Na+/H exchange and micropinocytosis), treatment of SiHa 
cells decreased the uptake of 21-2 and 47tr by around 40% and 10%, respectively 
(Figure 5.8C), indicating that 21-2 may possibly be internalising via macropinocytosis. 
It was described that a DNA plasmid could be internalised via macropinocytosis 
(Basner-Tschakarjan et al., 2004). However, they were not certain if naked plasmid 
DNA is taken up via constitutive macropinocytosis or binding of the plasmid DNA to 
certain membrane receptor molecules such as integrins, resulting in induction of 
downstream intracellular signalling pathways for macropinocytosis. Therefore, uptake 
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of 21-2 might also involve some membrane receptors to trigger macropinocytosis. 
Dextran-FITC needs to be utilised along with the aptamers especially 21-2 (since 
dextran is known to be internalised via macropinocytosis) and co-localisation of 21-2 
with dextran in amiloride or DMSO treated cells could be studied to confirm that 21-2 
is using macropinocytosis to enter the cells. 
Uptake of 21-2 could be via macropinocytosis in SiHa cells. However aptamers could 
also enter a different cell type via another pathway.  AS1411 appears to be 
internalised by non-malignant Hs27 cells predominantly by clathrin- or caveolae- 
dependent pathways whereas cancer cell line DU145 uses macropinocytosis to 
internalise the aptamer (Merit Reyes-Reyes E., et al., 2010). Amiloride treatment 
reduced the uptake of AS1411 in cancer cells, suggesting the involvement of 
macropinocytosis (Reyes-Reyes et al., 2010).  Even if aptamer 21-2 was suggested 
to enter primary cells via macropinocytosis, downstream mechanisms and molecules 
involved could be different to those in SiHa cells. Mesothelial cells in mice were found 
to internalise plasmid DNA through macropinocytosis. Here, Rac (Rac inhibitor-
NSC2376639 and p21-activated kinase (PAK, downstream molecule of Rac) inhibitor-
PAK1840 inhibited the transgene expression signiﬁcantly) but not Rho pathways (No 
signiﬁcant difference between control and ROCK (a downstream molecule of Rho) 
inhibitor Y-27632 treatments) found to be involved in inducing actin dynamics for 
macropinocytosis of pDNA. Latrunculin B (an actin polymerization inhibitor) and ML-
7 (myosin light chain kinase (MLCK) inhibitor) were found to inhibit the transgene 
expression, indicating the involvement of actin dynamics (Fumoto et al., 2009). Naked 
plasmid DNA can also be taken up by macropinocytosis in keratinocytes. Several 
proteins found to be involved such as ezrin and moesin (Basner-Tschakarjan et al., 
2004) which are parts of downstream Rho pathways unlike the mechanism in 
mesothelial cells of mice (Fumoto et al., 2009). Thus, different pathways might be 
involved for macropinocytosis in different cell types. Another example to show that 
the uptake mechanism is dependent on cell types is that uptake of naked plasmid 
DNA was inhibited by scavenger receptors class A inhibitors (e.g. polyinosinic acid 
and dextran sulphate) in macrophages (Takagi et al., 1998), but not in gastric serosal 
surface cells (Fumoto et al., 2009). 
Proteoglycan-dependent DNA uptake is mediated by macropinocytosis not caveole- 
or clathrin- mediated endocytosis. DNA was shown to form complexes with DNA-
binding proteins that are secreted from cells in conditioned media and resulting 
protein-DNA complexes require cell surface proteoglycans to enter the cells. 
Proteoglycan deficient cells showed decreased levels of uptake (Wittrup et al., 2007). 
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An anti-microbial peptide which is highly expressed in bone marrow and epithelial 
cells is involved in protection of plasmid DNA from serum nucleases. This peptide 
targeted the plamid DNA to the nuclear compartment through non-caveolar lipid raft 
mediated endocytosis involving surface proteoglycans of mammalian cells where 
plasmid DNA was expressed (Sandgren et al., 2004).  
Guanine-rich phosphodiester oligonucleotide sequences that can form quadruplex 
structures (G-quartets) (Dapic et al., 2003) are found to internalise more efficiently 
compared to non-quanine rich sequences (more than 25% G-content) via 
macropinocytosis on in cells grown in monolayer culture (Reyes-Reyes et al., 2010). 
21-2 (with 36.3% G-content) may also form this inter- and intramolecular structures 
as the QGRS software predicted one possible quadruplex structure for 21-2. (Kikin et 
al., 2006). This structure may increase the uptake of 21-2. Another way to facilitate 
the uptake of aptamers can be the pre-treatment of cells with unlabelled 21-2 
overnight prior to incubation with labelled 21-2. This can facilitate internalisation of 
aptamer caused by continuous uptake resulting in the stimulation in 
macropinocytosis.  
SID-1 (systemic RNAi deficient-1 and 2) mediates energy-independent internalisation 
of RNA in C. elegans, possibly functioning as a membrane channel to transport RNA 
into cells (Duxbury et al., 2005). Their mammalian homologues, SID transmembrane 
protein 1 (SIDT1) and 2 (SIDT2), could be responsible for passive uptake of aptamers 
as well as RNAs. SID-2 (apical intestinal membrane protein) from C. elegans was not 
as well-studied as that of SID-1. Both of these channels are required for RNA uptake 
(McEwan et al., 2012). The difference between these channels is that unlike SID-1, 
SID-2 uses energy-dependent endocytosis to internalise RNA. Single-stranded RNA 
(ssRNA) molecules were also found to be internalised by these channels, possibly 
due to folding of the aptamer on itself to form small double-stranded regions (McEwan 
et al., 2012). These channels might also be involved in the escape of RNA molecules 
from endocytic vesicles in to the cytosol.  
Dynasore treatment of SiHa cells, was found to partly inhibit the uptake of 21-2 and 
47tr, indicating the involvement of receptor-mediated endocytosis as well as 
macropinocytosis. The same cells could be using two different mechanisms to 
internalise the same molecules although one of the mechanisms might be stronger 
and more efficient than the other. Expression of SID-1 in Drosophila S2 cells, which 
lack SID protein homologues, resulted in the formation of a RNA-selected channel 
which mediates the passive uptake of the RNA molecules through cellular membrane 
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(Feinberg and Hunter, 2003). However, S2 cells are able to partly internalise the RNA 
from surrounding growth medium via endocytosis using scavenger receptor SR-CL 
(Saleh et al., 2006) although the uptake is relatively slow and dependent on high 
concentrations of RNA present in the extracellular environment.   
Full length 70-kDa heat shock protein Hsp70 was able to deliver bound RNA 
molecules into the cytoplasm of mammalian cells (Henics and Zimmer, 2006). 
However, uptake of 21-2 and 47tr is not likely to be mediated or facilitated by these 
proteins in SiHa, as well as primary cells. These proteins are over-expressed in 
several cancers including cervical cancer. Its over-expression was detected both in 
cervical cancer cells of different origin (HeLa, SiHa, C-33 A and CaSki) and clinical 
cervical SCC samples and was highly linked to cell growth, survival and tumour 
aggressiveness (Garg et al., 2010). If uptake was via these channel-forming 
chaperone proteins, then one would expect internalisation of aptamers into HeLa as 
well as SiHa cells due to the over-expression of Hsp-70 in HeLa cells. However, 
uptake was seen to be limited in HeLa cells compared to SiHa cells in our 
experiments.   
Cy5-labelled aptamer 21-2 was used to study transfection efficiencies following 
lipofection or incubation in medium only in both primary keratinocytes (Section 
5.2.5.1) and SiHa cells (Section 5.2.5.2). Cells were incubated or transfected with 
aptamer and Cy5 fluorescence was determined by flow cytometry.  The percentage 
of aptamer positive primary cells detected was presented in Figure 5.11. Up to 20% 
of cells was found to have taken up the aptamer (at 80 nM) when cells were incubated 
without lipofection. However, when aptamer was introduced by Oligofectamine 
transfection, the percentage of positive cells was 99%, almost all cells having 
internalised the aptamer. Although the level of uptake without lipofection was 
relatively low, the mechanism of uptake could also be considered in determining the 
function of the internalised aptamer. It has been shown that (Reyes-Reyes et al., 
2010) cancer and non-cancer cells can both internalise a DNA aptamer, AS1411, 
however it can only trigger apoptosis in cancer cells. This might be explained by the 
use of different uptake mechanisms, macropinocytosis in cancer cells and clathrin-
dependent endocytosis in non-cancer cells. It has been shown that hyperstimulation 
of macropinocytosis by continuous uptake of molecules results in a novel form of 
apoptosis in cancer cells (Overmeyer et al., 2008). In addition, molecules entering by 
macropinosomes could escape from these vesicles and function in the cytosol, 
whereas molecules entering by endocytosis e.g. by lipofection would be accumulated 
in the endosomes/lysosomes for degradation unless they manage to escape e.g. by 
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pore formation in the endosomal membrane, molecules with pH-buffering effects and 
the use of fusogenic agents (Varkouhi et al., 2011).  
Flow cytometry experiments were also performed in SiHa cells to test the efficiency 
of 21-2 uptake in the presence/absence of lipofection (Figure 5.12). SiHa cells were 
also able to internalise the aptamer in different conditions. Both Oligofectamine and 
Nanocin transfection introduced aptamers (150 nM) to significantly more cells than 
untransfected (where aptamers were simply incubated with cells) with p values of 
0.0088 and 0.013. When aptamer concentration was dropped to 80 nM, 
Oligofectamine transfection was found to be better than Nanocin transfection (p = 
0.00016). Therefore, Nanocin transfection might require the use of higher 
concentrations of aptamers. In addition, more cells may need to be used to reduce 
the cytotoxic effects of Nanocin in SiHa cells. 
In summary, 21-2 has been shown to be internalised efficiently in primary cells and 
also in the cervical cancer cell line SiHa possibly by macropinocytosis. Therefore, it 
can have a potential for drug delivery, since it is internalised into cells without the 
need for lipofection and, it could be designed to carry cargos such as siRNA, 
nanoparticles or aptamers into the target cells as chimeras.  The HPV16 E7 aptamer 
A2 could be used to create a chimera with 21-2 to facilitate its entry into cancer cells 
and also primary cells which could be useful to target those cells in in vitro skin raft 
systems. However, a drawback may be that engineering such chimeras could also 
diminish the fuction of aptamers.    
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 GENERAL DISCUSSION AND FUTURE 
PROSPECTS 
 
 
Human papillomaviruses are a necessary cause of cervical cancers. Current 
treatment strategies involve surgical removal of the HPV-infected lesions as well as 
the stimulation of the innate immune system to minimise symptoms. Great success 
has been achieved in terms of preventing infection since HPV vaccination was 
introduced. However HPV vaccines are expensive and need to be maintained in a 
stable cold chain, making vaccination in the developing world difficult. These vaccines 
are prophylactic, not therapeutic, therefore will not be effective on people who are 
already infected with HPV16/18 or with HPV types not covered by the vaccine. 
However, there are ongoing clinical trials for the use of therapeutic vaccines (Section 
1.2.6) In this perspective, the generation of novel anti-viral agents targeting HPV 
oncoproteins helps to further elucidate protein-protein interactions in vivo and in vitro 
as well as offering a possible therapeutic approach (1.2.5 and 1.3.5.1).  
 
The work described here employed a library of RNA aptamers identified against 
HPV16 E7 by SELEX (Nicol et al., 2011). A number of aptamers were selected for 
use in this work. They seemed to cause a decrease in E7 levels in addition to the 
induction of apoptosis in cervical cancer cells. Here, delivery mechanisms of 
aptamers and also co-localisation of aptamers with several cellular markers were 
studied. The results suggested the involvement of some potential mechanisms in the 
internalisation of aptamers.  
HPV16 E7 aptamers were used for transfection of HPV16 transformed CaSki cells in 
order to analyse the effects of aptamers on steady state levels of E7 and cellular 
proteins, pRb and p130. In the work described here, HPV16 E7 aptamers, in particular 
A2 was shown to cause a significant decrease in the levels of E7 oncoprotein with an 
accompanying increase in the pRb levels. The N-terminus of E7 is a intrinsically 
disordered region, which may give flexibility and thus multiplicity of interaction 
partners to E7 (Section 1.2.4.2). HPV16 E7 may undergo binding-induced 
conformational change upon target binding. When E7 is liganded or bound, it may 
form more stable structures than unliganded or free E7. It can be hypothesised that 
upon A2-binding, E7 can be destabilised either through disruption of protein-protein 
interactions on the N-terminus, or through induction of a conformational change in E7. 
Future work could involve circular dichroism (CD) spectroscopy to determine whether 
a conformational change in E7 occurs upon A2-binding.  Techniques such as SILAC 
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(stable isotope labelling of amino acids in cell culture) could also be performed to 
analyse whether HPV16 E7 aptamers, in particular A2, can disrupt multiple protein-
protein interactions in cells. Several E7 aptamers were suggested to bind E7 at the 
C-teminus (Nicol et al., 2011). The C-terminus of E7 contains a conserved sequence 
motif, CXXC involved in dimerisation (Section 1.2.4.2). These aptamers may lead to 
a change in the multimerisation/oligomerisation status of E7. Future work could 
involve size exclusion chromatography (SEC), sedimentation equilibrium experiments 
(by analytical ultracentrifugation [AUC]) (Clements et al., 2000, McIntyre et al., 1993) 
or mass spectrometry in order to determine whether the oligomerisation status of E7 
is altered upon aptamer-binding. 
An N-terminal point mutant of GST-E7 was used in an in vitro binding assay, binding 
of an aptamer, termed A2, was reduced and thus A2 was suggested to require 
residues in the N-terminus for binding (Nicol, January 2011). Future work could 
involve characterisation of the minimal binding region of A2 or other E7 aptamers. 
Some information on aptamer-E7 interactions could be obtained e.g. by the use of 
deletion mutants or truncations of E7 in in vitro binding assays and by nuclease 
protection assays to determine the nucleotides of aptamers (especially A2) that are 
required for E7 binding.   
E7 binds hypophosphorylated pRb and mediates its phosphorylation. The resulting 
hyperphosphorylated form of pRb is inactive and cannot function as a tumour 
suppressor. The effects of aptamer, especially of A2 on the level of hypo- or hyper- 
phosphorylated pRb could be tested using phosphorylation specific antibodies. In 
Chapter 4, studies with the use of several inhibitors for proteasomal and lysosomal 
degradation in CaSki cells showed that the pathway of E7 degradation induced by A2 
transfection may possibly be through the 26S proteasome. In order to determine the 
E7 degradation, immunofluorescence experiments were performed using HPV16 
transformed SiHa cells with anti-E7 antibodies and endosomal/lysosomal markers 
e.g. against early and late endosomes as well as a marker against ER in the presence 
or absence of A2 and a control aptamer SF1. Transfection of SiHa cells with A2 
appeared to induce E7 localisation in the ER. It was suggested that this can perturb 
the normal biosynthetic delivery of E7 to the plasma membrane or other organelles. 
It is likely that upon A2 binding, E7 folding or oligomerisation results in its retention in 
ER in an unfolded/aberrant state. However, localisation of aptamer A2 in these cellular 
compartments needs also to be confirmed using fluorescently-labelled A2 in 
immunofluorescence experiments. Labelling A2 with fluorescein maleimide was found 
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to be problematic and inefficient. However, an alternative labelling method can be 
considered for this purpose or A2 can be chemically syntesised with a desired label 
for the use in co-localisation experiments. Furthermore, there are many other 
proteasomal inhibitors that could be used to further analyse the pathway of E7 
degradation. 
There are many alternative methods to study the interactions of E7 with other cellular 
proteins in the presence or absence of aptamers. For example, the mammalian two 
hybrid (M2H) system has been recognised as a powerful assay to study protein-
protein interactions in cells (Luo et al., 1997). This system might be used to verify 
direct interactions of HPV16 E7 with pRb, and related proteins, p130 and p107; and 
the effects of E7 aptamers could be tested in this system. This system consists of 
plasmid constructs encoding the bait protein (e.g. Rb) and a prey protein (E7) fused 
to a DNA binding or a transcription activation domain, respectively. Another construct 
containing reporter genes e.g. chloramphenicol acetyltransferase (CAT) and green 
fluorescence protein (GFP) is included in this system. When the bait and a prey 
protein interacts, DNA binding and activation domains reunion and activate the 
expression of reporter genes that can be measued e.g. by fluoresence microscopy or 
CAT activity assays. An in vitro approach, rabbit reticulocyte lysate systems may also 
be used to study the effects of aptamers on E7 interactions (Belyaeva et al., 2014). 
This system is based on the production of 35S [Methionine]-labelled cellular proteins 
such as pRb, p130 and p107 in rabbit reticulocyte lysates. These radio-labelled 
proteins can subsequently be used in pull-down experiments with affinity tagged E7 
e.g. GST-E7 that is recombinantly expressed in E. coli in the presence or absence of 
HPV16 E7 aptamers. These samples can be analysed on SDS-PAGE followed by 
autoradiography. An alternative approach might be the use of GFP-Trap system 
where GFP tagged E7 is used to pull-down target of interest in the presence or 
absence of aptamer molecules using GFP-Trap beads.  
Inactivation of tumor suppressor function by HPV infection alters the cell cycle 
regulatory  mechanisms and suppresses the induction of apoptosis, causing the 
accumulation of mutations and favouring mutant cells in survival. Although cells 
accumulate mutations over the course of tumor progression which might provide an 
opportunity to survive without the need for E6/E7 expression, constitutive expression 
of E6 and E7 are still required for the viability of cancer cells. For example, E2 
antisense expression or RNAi inhibits E6/E7 expression, resulting in growth inhibition 
of HPV positive cancer cells (Hall and Alexander, 2003). E2 expression in HeLa cells 
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result in senescence and a decrease in telomerase activity, and ability of E7 to 
inactivate the pRb pathway is significant in terms of the maintenance of HeLa cell 
proliferation and elevated levels of telomerase activity (Nishimura et al., 2006). 
Annexin V apoptosis assays showed that the transfection of HPV 16 transformed SiHa 
cells with HPV16 E7 aptamer A2 resulted in apoptosis, possibly due to the 
destabilisation of E7 oncoprotein and the recovery of pRb tumour suppressor 
pathway. Induction of apoptosis by aptamers can also be analysed by DNA 
fragmentation, in situ terminal deoxynucleotidyl transferase-mediated dUTP nick-end 
labeling (TUNEL) analysis and caspase activation assays. These are the first RNA 
aptamers to E7 with apoptotic effects. However, peptide aptamers have been 
previously shown to induce apoptosis in CaSki cells (Nauenburg et al., 2001). Peptide 
aptamers are generated by using the yeast two-hybrid system from a pool of 
molecules containing 10-20 random amino acids presented on a constant protein 
scaffold.  Furthermore, an HPV16 E7 short hairpin RNA (shRNA) was successfully 
used to induce degradation of E6 and E7 and proteins. Silencing of E6 resulted in the 
accumulation of p53 and p21 and that of E7 led to an increase in the 
hypophosphorylated and active species of pRb. These effects of E6 and E7 ceased 
cell proliferation and induced apoptosis in HPV positive but not HPV negative cancer 
cells (Sima et al., 2008). p97 promoter-targeting small interfering RNA (siRNA) has 
also been used to successfully induce E6 and E7 gene silencing of HPV in cervical 
cancer cells as well as xenograft mouse models via an increase and accompanying 
decrease in p53 and p21 levels, respectively (Zhou et al., 2012). RNAi with E7 siRNA 
was seen to be more anti-proliferative when compared to the E6 siRNA in HPV16 
positive cervical cancer cells, indicating that E7 might be more favourable therapeutic 
target for HPV16 positive cervical cancers (Jiang and Milner, 2002). HPV18 E7 siRNA 
was also shown to be more effective in the supression of cell proliferation and 
induction of apoptosis due to to inhibition of both both E6 and E7 transcriptions (Lea 
et al., 2007) . Whereas E6 siRNA was observed having little effect on E7 expression. 
However, use of RNAi technology has some drawback due to unspecific binding of 
siRNAs to non-target mRNAs as well as low efficiency of liposomes in carrying RNA 
molecules in to the nucleus. This could be overcome by using alternative ways of 
delivery such as virus-like particles or lentiviruses encoding for E7 shRNA, which was 
shown to be greatly inhibiting cell proliferation in HPV positive cervical cancer cells 
(Bousarghin et al., 2009). Alternatively, antisense gene expression for E7, cloned in 
a retrovirus, in CaSki cells was also shown to reduce tumourogenicity via reducing 
the level of E7 accompanied by up-regulation and downregulation of pRb and E2F-1, 
respectively (Choo et al., 2000).  
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The pRb family of proteins (pRb, p130 and p107) are involved in cell differentiation, 
growth and apoptosis (Zhang et al., 2006). pRb acts as inhibitor of activating E2F1-3 
promoters, whereas p130 and p107 associate with the repressor promoters E2F5 and 
E2F4 (Section 1.2.4.2). HPV E7 protein binds pRb through LXCXE motif in the CR2 
domain, leading to the release of E2F promoters followed by the activation of E2F-
responsive genes (Section 1.2.4.2). It is suggested that the lack of pRb can cause an 
increase in E2F activity, resulting in the increased levels expression of p107, which 
might possibly be a compensation for the loss of pRb (Sage et al., 2003). It can be 
suggested that p107 may function as a back up when pRb is depleted. Therfore, p107 
expression could also be analysed in cervical cancer cells in the presence or absence 
of aptamers. Effects of aptamers on the activation or inhibition of E2F-responsive 
genes can also be studied by luciferase assays using reporter plasmid constructs 
consisting of wild-type or mutant forms of E2F promoter (e.g. E2F1) region followed 
by a luciferase gene. Such construct was designed during this project and is available 
for future use. 
In Chapter 3, western blot analysis of HeLa cells expressing HPV18 E7 transfected 
with HPV16 E7 aptamers showed that some of the aptamers (in particular A1 and J1) 
may be cross-reacting with HPV18 E7. In this perspective, HPV18 and also low-risk 
HPV11 E7 was succesfully cloned into GST plasmids and their expressions were 
achieved in E. coli. There were several attempts to use these recombinant E7 proteins 
in pull-down assays with pRb in the presence or absence of aptamers. However, this 
system needs to be optimised. Cross-specificity of HPV16 E7 aptamers to HPV11 or 
18 E7 could be analysed by in vitro binding assays as previously described (Nicol et 
al., 2011, Robinson et al., 2006). This method involves the immobilization of GST-E7 
onto GST-coated glutathione beads and incubation with [γ-32P]-ATP radiolabeled-
RNA aptamers. Scintillation counting is then performed to quantitate the amount of 
aptamer bound, and calculation of apparent binding affinity KDapp is as previously 
described (Ellingham et al., 2006, Nicol et al., 2011, Robinson et al., 2006). An 
alternative approach to the scintillation counting may be an electrophoreticmobility 
shift assay (EMSA) where electrophoretic separation of a protein-DNA or protein-RNA 
complexes was performed on an acrylamide or agarose gel. SELEX protocol can also 
be applied for the selection of aptamers against HPV18 E7 due to the fact that 
organotypic raft cultures are well-estabilished for the studies of HPV18 life-cycle. As 
a future prospect, primary keratinocytes transduced with HPV16 can be stratified into 
organotypic raft systems that better represent a skin model. Aptamers can be 
delivered to this systems passively as suggested in Chapter 5 or by e.g. particle-
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mediated RNA transfer (gene gun). W12 cell line represents a model of early HPV16 
infection. This cell line is immortalised by HPV16 and contains around 100 copies of 
HPV DNA as extrachromosomal episomes (Stanley et al., 1989). These cells can be 
used as a model system as they represent early stages of cervical cancer (CIN1).   
The anatomical advantage of cervical cancer gives a great advantage to local 
treatments, such as intratumoral or topical applications of theraupetic agents 
(Sections 1.2.3 and 1.2.5). An example of this was the study where inhibition of 
tumour growth was observed following siRNA microinjection that was combined with 
atelocollagen (Fujii et al., 2006) which is a purified type I collagen obtained by pepsin 
treatment of calf dermis and used in order to enhance cellular uptake and nuclease 
resistance of siRNAs. There are therapeutic HPV E7 vaccines in clinical trials that are 
being administired by lipid based formulations or the use of gene guns into target 
tissues (Section 1.2.5). Therefore, HPV16 E7 targeting aptamer A2 with further 
modifications could also be utilised as potential therapeutic in order to abrogate the 
proliferation of cervical cancer cells by topical application. However, HPV16 E7 
aptamer A2 produced by in vitro transcription was shown to stimulate the production 
of interferon probably by RIG-I activation in section 3.4.2.2. However, de-
phosphorylation of the aptamer seemed to reduce this effect. The similar effect was 
observed when a control aptamer, SF1 was utilised (Belyaeva et al., 2014). Activation 
of RIG-I leads to apoptosis through interferon-dependent and independent pathways 
(Besch et al., 2009, Poeck et al., 2008), providing aptamers potentially with an 
additional anti-tumour activity. This needs to be considered if aptamers will be used 
in clinical trials. As stated above, having 5' immunostimulatory effects, as well as 
sequence specific silencing effects on protein levels, may be advantageous by 
inducing innate immunity especially production of type I IFNs as well as resulting in 
apoptosis of the target cells. This could also be disadvantageous due to possible 
systemic adverse effects when administered intravenously such as by chemotherapy. 
However, specific delivery of aptamers directly into tumours might overcome this 
serious side effects of aptamers. In addition, in vitro transcribed aptamers could be 
replaced by synthetic chemically synthesised aptamers which contains 5' – OH 
instead of 5' triphosphate group. In addition, chemically synthesised RNA may also 
have further advantages over RNA generated by in vitro transcription (Schlee et al., 
2009b). These synthetic RNAs are purer, base composition at the 5` triphosphate can 
easily be modified with preferred nucleosides, adenosine or guanine, additional 
modifications could be performed and biological activity of these synthetic RNAs 
would possibly be higher than in vitro transcribed RNAs. Therefore, these synthetic 
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oligonucleotides might present better theraupetics for future treatments of cancers 
and viral infections.  
Administration of aptamers for extracellular proteins or membrane proteins can be 
mediated intravenously or subcutaneously. These aptamers are of use in drug 
delivery experiments where vectors or nanoparticles are engineered to carry these 
molecules to target specific cell types such as cancer cells (Que-Gewirth and 
Sullenger, 2007). Aptamers can also target the dermis when applied onto skin 
topically. Such an example is that of a modified DNA aptamer to target an extracellular 
upstream mediator of psoriasis, called the LL37 peptide which has been shown to 
transport into the dermis following topical use on mouse murine skin model (Jackson 
and Gilliet, 2013). This modification of the aptamer was performed as previously 
described where they modified antisense oligonucleotides with the use of 5-propynyl-
2'-deoxycytidine-5'-triphosphate, which facilitated the entry of the oligonucleotides 
into psoriatic but not normal skin after topical administration (White et al., 2002). Later 
studies (Dokka et al., 2005) suggested that the possible route of penetration could be 
through hair follicles upon topical application of fluoro-tagged 2'-O-methoxyethyl-
modified oligonucleotides on hairless murine skin by cream-based formulations. In 
Chapter 5, it was shown that model aptamers can be internalised into keratinocytes 
without the need for lipofection. This novel ability of aptamers can be advantageous 
in terms of developing novel potential therapeutics. Reagent-free internalisation of 
aptamer may be passive (in the case of 21-2) or active (47tr) by micropinocytosis or 
receptor-mediated endocytosis, respectively. Although this needs to be verified with 
more experiments such as the use of other inhibitors including cytochalasin D (an 
inhibitor for actin polymerisation) and oligomycin (an inhibitor to ATPase) to determine 
if uptake of aptamers is dependent on actin movement (that is important in 
macropinocytosis) and is also energy-dependent (indicating the receptor-mediated 
uptake), respectively. Another way to inhibit energy-dependent endocytosis of 
molecules is the cold incubation. When the incubation of aptamers 21-2 and 47tr with 
cells was performed in cold (4°C) instead of 37°C, uptake of 21-2 appeared to be 
unaffected while that of 47tr appeared to be blocked, suggesting an energy-
dependent uptake mechanism for the latter. A variety of non-cancer or cancer cell 
types can be tested to determine whether there is any preference for uptake of 21-2 
into one cell type over others. Fluoro-labelled HPV16 E7 aptamer A2 can be used for 
future experiments to study the uptake mechanisms of aptamers in the presence or 
absence of transfection reagents. An alternative to lipofection, nanoparticle-based 
transfection e.g. using Nanocin can be used as apossible delivery reagents for 
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aptamers although the pathway of entry into cells by this method is unknown. Several 
inhibitors for endocytosis and also co-localisation with some endosomal markers can 
be performed to reveal the fate of aptamers following internalisation by Nanocin. If 
they use a different entry mechanism than lipofection, this mode of entry might be 
advantages over lipid-based transfection. Lipofection has some disadvantages as 
molecules can accumulate in endosomes or lysosomes, following the entry, with only 
small proportion of them can manage to escape from these compartments. Aptamers 
that can use different mechanisms for internalisation into cells could be better 
therapeutics. As a future prospect, aptamers such as 21-2 might be used to generate 
chimeric aptamers together with some of HPV16 E7 aptamers, which might facilitate 
the entry of E7 aptamers into cervical cancer cells and tissues.  
This study showed that aptamers could be used as molecular tools in order to 
investigate protein-protein interactions in vitro and in cells. In particular, some of the 
HPV16 E7 aptamers were shown to result in a decrease in E7 levels and in the 
induction of apoptosis in HPV16 transformed cervical cancer cells probably in pRb-
dependent pathways. In the work described here, an aptamer was shown to 
internalise into cells by passive uptake (possibly by macropinocytosis). Therefore, 
aptamers can be potential candidates for the development of novel therapeutics and 
diagnostics. 
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